INTEGRATED MOLECULAR PROFILING FOR ANALYZING AND PREDICTING THERAPEUTIC MECHANISM, RESPONSE, BIOMARKER AND TARGET by JIA JIA








INTEGRATED MOLECULAR PROFILING FOR 
ANALYZING AND PREDICTING THERAPEUTIC 









Jia    Jia 
(B. Sci & M. Sci, Zhejiang University) 
 
 
A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF PHARMACY 
NATIONAL UNIVERSITY OF SINGAPORE 
 
2010 
                                                                                                                                  Acknowledgements 
                                                                                                                                         I   
ACKNOWLEDGEMENTS 
 
I would like to deeply thank Professor Chen Yu Zong, for his constant encouragement and 
advice during the entire period of my postgraduate studies. In particular, he has guided me 
to make my research applicable to the real world problem. This work would not have been 
possible without his kindness in supporting me to shape up the manuscript for publication. 
I am also tremendously benefited from his profound knowledge, expertise in scientific 
research, as well as his enormous support, which will inspire and motivate me to go 
further in my future professional career.   
 
I am also grateful to our BIDD group members for their insight suggestions and 
collaborations in my research work: Dr. Tang Zhiqun, Ms. Ma Xiaohua, Mr. Zhu Feng, 
Ms. Liu Xin, Ms. Shi Zhe, Dr. Cui Juan, Mr. Tu Weimin, Dr. Zhang Hailei, Dr. Lin 
Honghuang, Dr. Liu Xianghui, Dr. Pankaj Kumar, Dr Yap Chun wei, Ms. Wei Xiaona, 
Ms. Huang Lu, Mr. Zhang Jinxian, Mr. Han Bucong, Mr. Tao Lin, Dr. Wang Rong, Dr. 
Yan Kun. I thank them for their valuable support and encouragement in my work. 
 
Finally, I owe my gratitude to my parents for their forever love, constant support, 
understanding, encouragement and strength throughout my life. 
 
 








TABLE OF CONTENTS 
 
1.1 Overview of mechanism and strategies of molecular-targeted therapeutics .................................... 2 
1.1.1 Current progress of molecular-targeted cancer therapeutics ..................................................... 3 
1.1.2 Challenges of targeted cancer therapy, receptor tyrosine kinase as a case study ...................... 5 
1.1.3 Systematic discovery of multicomponent therapies .................................................................. 7 
1.2 Current progress in cancer biomarker discovery ............................................................................ 14 
1.2.1 Introduction to biomarker in cancer diagnosis and prediction ................................................ 14 
1.2.2 Types of cancer biomakers ...................................................................................................... 15 
1.2.3 Approaches of cancer biomarker discovery ............................................................................ 16 
1.2.4 Brief introduction of microarray technology ........................................................................... 20 
1.2.5 The problems of current marker selection methods ................................................................ 29 
1.3 Current progress in tumor antigen discovery ................................................................................. 31 
1.3.1 Overview of tumor vaccine for cancer immunotherapy .......................................................... 31 
1.3.2 Introduction toT cell-defined tumor antigens .......................................................................... 36 
1.3.3 Application of computational methods for MHC-binding peptides and epitopes prediction .. 39 
1.4 Scope and research objective ........................................................................................................... 41 
2.1 Introduction to machine learning methods..................................................................................... 45 
2.1.1 Support Vector Machines ........................................................................................................ 47 
2.1.2 Probabilistic neural network ................................................................................................... 51 
2.1.3 Hierarchical clustering ............................................................................................................ 53 
2.1.4 Parameters optimization and model validation ....................................................................... 55 
2.1.5 Performance evaluation ........................................................................................................... 56 
2.2 Methodology for microarray data processing ................................................................................. 58 
2.2.1 Preprocessing of microarray data ............................................................................................ 58 
2.2.2 Normalization and scaling ....................................................................................................... 59 
2.2.3 Threshold filtering ................................................................................................................... 61 
2.2.4 Missing data estimation........................................................................................................... 62 
2.3 Feature selection procedure ............................................................................................................ 63 
2.3.1 REF based gene selection procedure ....................................................................................... 64 
2.3.2 Recursive feature elimination ................................................................................................. 66 
2.3.3 Random sampling, feature elimination and consistency evaluation ........................................ 67 
2.4 Construction of the feature vector for peptide ................................................................................ 69 
2.4.1 Feature vector for peptide ....................................................................................................... 69 
2.4.2 Scaling of feature vector ......................................................................................................... 70 
3.1 Introduction ..................................................................................................................................... 74 
3.2 Materials and Methods .................................................................................................................... 77 
3.2.1 Mechanism of drug interactions .............................................................................................. 77 
3.2.2 Methods for drug-combination analysis .................................................................................. 78 
3.2.3 Collection of literature-reported drug combinations ............................................................... 78 
3.3 Results and discussion ..................................................................................................................... 79 
3.3.1 Statistics of collected drug combinations and MI profiles ...................................................... 79 
3.3.2 Mechanism underlying the pharmacokinetic and pharmacodynamic drug interactions .......... 80 
3.4 Conclusion ..................................................................................................................................... 102 
4.1 Introduction ................................................................................................................................... 107 
4.2 Materials and Methods .................................................................................................................. 109 
4.2.1 Data collection and preprocessing......................................................................................... 109 
4.2.2 Bypass mechanism of studied tyrosin kinase inhibitors ........................................................ 116 
4.2.3 Drug sensitivity evaluation procedure ................................................................................... 116 
4.3 Results and discussion ................................................................................................................... 119 




4.3.1 Assesment of EGFR-I sensitivity prediction by mutation and amplification profiles ........... 119 
4.3.2 Assessment of integrated molecular profiling for predicting TKIs sensitivity ...................... 121 
4.3.3 The distribution and coexistence of drug sensitive and resistant profiles ............................. 122 
4.4 Summary ........................................................................................................................................ 132 
5.1 Introduction ................................................................................................................................... 133 
5.2 Materials and Methods .................................................................................................................. 136 
5.2.1 Collection of genomic, mutation and expression data ........................................................... 136 
5.2.2 Collection of tumor-specific antigen ..................................................................................... 136 
5.2.3 Computational procedures .................................................................................................... 137 
5.3 Results and Discussion .................................................................................................................. 142 
5.3.1 Performance of collective approach in genome-scaled TSAs identification ......................... 142 
5.4 Conclusion ..................................................................................................................................... 144 
6.1 Introduction ................................................................................................................................... 146 
6.2 Materials and Methods .................................................................................................................. 150 
6.2.1 Lung adenocarcinoma microarray datasets and data preprocess ........................................... 150 
6.2.2 Performance evaluation of survival marker signatures ......................................................... 153 
6.3 Results and discussion ................................................................................................................... 154 
6.3.1 System of the lung adenocarcinoma survival marker selection ............................................ 154 
6.3.2 Consistency analysis of the identified markers ..................................................................... 156 
6.3.3 Disease relevant of identified markers .................................................................................. 161 
6.3.4 The predictive ability of identified markers .......................................................................... 162 
6.3.5 Patient survival analysis using survival markers ................................................................... 168 
6.3.6 Hierarchical clustering analysis of the survival markers ....................................................... 174 
6.4 Summary ........................................................................................................................................ 176 
7.1 Major findings and contributioins ................................................................................................ 178 
7.2 Limitations ..................................................................................................................................... 180 
7.3 Directions for future research ....................................................................................................... 181 





Tailored cancer diagnosis and treatment has been challenged over a century. The 
opportunities as well as the challenges facing disease ―omics‖ are formidable. Taken 
microarray technology as an example, the invention of this technology and its ability to 
simultaneously interrogate thousands of genes has significantly changed the paradigm of 
molecular targeting and classification of human cancers as well as shifting clinical 
prognosis models to a broader prospect. Curretnly, much effort has been done for disease 
mechanism, treatment development and biomarker identification from the perspective of 
different molecular profiling. Particularly promising areas of research include: the 
identification of new targets for therapeutics and the potential for accelerating drug 
development through more effective strategies to evaluate therapeutic effect and toxicity; 
the development of novel biomarkers for disease classification and outcome prediction; 
and delineation of altered gene expression relevant to the course of disease.  
 
The main objective of this dissertation is to investigate the therapeutic mechanism, drug 
efficacy, novel therapeutic targets and biomarkers for cancer prevention and treatment by 
collectively considering the mutational, amplification and microarray gene expression 
profiles. A collected tumor specific antigens prediction approach and a cancer marker 
discovery system have been further developed from microarray data for tumor marker and 
specific antigens prediction. 
 
Combination therapies are now standard in therapeutic areas of multifactorial disease, 
such as cancer, diabetes and infectious disease, which have been proved to enhance the 
efficacy of agents that were initially developed as single-target drugs and reduce counter-
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target activities and toxicities in cancer treatment. Unfortunately, the standard approach of 
combining monotherapies at the clinical stage limits the number of drug pairs that can be 
tested and bypasses the opportunity to find therapeutically relevant interactions between 
novel targets. It is essential to understand the molecular mechanisms underlying the 
successful drug combinations. The knowledge could facilitate the discovery of novel 
efficacious combinations and multi-targeted agents. In this study, we describe an extensive 
investigation of the published literatures on drug combinations for which the combination 
effect has been evaluated by rigorous analysis methods and for which relevant molecular 
interaction profiles of the drugs involved are available. Analysis of the 117 identified 
cases reveals general and specific modes of action of rationale combined drug, and 
highlights the potential value of molecular interaction profiles in the discovery of novel 
multicomponent therapies. 
 
In the second study, a particular focus has been given to investigate the correlation 
between the integrative molecular profiles and the sensitivities of anticancer receptor 
tyrosine kinase inhibitor drugs (TKIs) in lung and breast cancer cell-lines. TKIs elicit 
markedly different response rates in clinical setting. These rates have nowadays been 
linked to mutation and amplification of drug target, activating-mutation of downstream 
signaling genes RAS, BRAF and PIK3CA, and loss-of-function of signaling regulator 
PTEN. Compensatory, alternative and redundant signaling that bypass target inhibition 
also influence drug response. Unlike the traditional cancer diagnostic and prognostic 
indices, which may group molecularly distinct patients into similar clinical classes based 
mainly on the morphology of diseases, we collectively considered the profiles of the 
bypass genes together with the profiles of the drug targets and the relevant downstream 
genes may improve the prediction of clinical response to the relevant drugs. We 
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retrospectively analyzed mutational, amplification and microarray gene expression profiles 
of the drug target and known bypass and downstream drug-resistant genes in non-small 
cell lung cancer (NSCLC) and breast cancer cell-lines sensitive or resistant to TKIs 
including gefitinib, erlotinib, lapatinib, and trastuzumab. Drug sensitivity prediction has 
been potentiated by collective analyzing mutation, amplification and expression profiles of 
target, bypass genes, and drug-resistant downstream signaling and regulatory genes.  
 
Recent progresses in profiling somatic mutations and expressions of human cancer 
genomes, and in predicting T-cell epitopes enable genome-scale tumor-specifi antigen 
(TSA), a class of potential source of disease-targeting molecules, search by collectively 
analyzing these profiles. Such a collective approach has not been explored in spite of the 
availability and usage of individual methods. In this study, genome-scale TSA search was 
conducted by genome-scale search of tumor-specific mutations in differentially over-
expressed genes of specific cancers based on tumor-specific somatic mutation, microarray 
gene expression data, and in silico T-cell recognition analysis. The performance of our 
method was tested against known T-cell defined melanoma and lung cancer TSAs and 
archieved a fairly good perdiction performance. It is suggested that noises in expression 
data of small sample sizes appear to be a major factor for misidentification of known 
TSAs. With improved data quality and analysis methods, the collective approach is 
potentially useful for facilitating genome-scale TSA search. 
 
Cancer markers are useful in following the course of cancer and evaluating which 
therapeutic regimes are most effective for a particular type of cancer, as well as 
determining long-term susceptibility to cancer or recurrence. The case is clear for 
development of biomarkers for early detection and screening tests for diseases such as 
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lung, breast, colon, and ovarian cancer. In addition, diagnostic measurement of cancer 
disease progression is essential to successful disease management. For these reasons, 
development of new and effective biomarkers for cancer detection and diagnosis is crucial 
for efficiouse cancer prevention and treatment. In the last study, a particular focus has 
been given to develop marker discovery system that may benefit early disease diagnosis 
and correct prediction of prognosis. The expression level of such markers presents 
potential therapeutic drug targets and may give suggestions to proper treatment regime. 
We developed a novel gene selection method based on support vector machines (SVMs), 
recursive feature elimination (RFE), multiple random sampling strategies and multi-step 
evaluation of gene-ranking consistency to overcome the unstable and disease irrelevant 
nature of currently biomarker identification approaches. The as-developed program can be 
utilized to derive disease markers which present both good prediction performance and 
high levels of consistency with different microarray dataset combinations. 
The biomarker discovery system has been test in lung adenocarcinoma for survival marker 
discovery by using an 86-sample lung adenocarcinoma dataset. In this case, 21 lung 
adenocarcinoma survival markers were identified with a farily stability across 10 
sampleing-set, suggesting the effectiveness of our system on deriving stable disease 
markers and discovering therapeutic target. 
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Global gene-expression profiling using microarray technologies has improved our 
understanding of the histological heterogeneity of cancer and has been increasingly used 
to discover potential biomarkers for patient classification and promising targets for 
disease prevention and treatment. However, gene expression profile alone may not reflect 
the full story of the cancer due to cancer result from a variety of factors, including 
individual variations in patients and somatic cell genetic differences in tumors, even those 
from the same tissue of origin. The performance and general applicability of published 
biomarkers are highly unstable and have difficulties in generalized cancer discrimination 
because of small numbers of subjects examined and inclusion of heterogeneous tumor 
types. Anti-cancer agents developed to direct at a single altered target frequently show 
reduced efficacies and poor safety and resistance issues. To address these concerns and to 
facilitate a stable marker-selection method, collective approaches have been used for 
analyzing and predicting the drug mechanism, response, novel targets and biomarkers in 
this study. With a focus of efficacious targeted cancer therapy and disease classification 
by molecular indicators, the first section of this chapter introduced the increasing role of 
molecular targeted therapies as well as combination strategies in cancer prevention and 
treatment (Section 1.1). The second section (Section 1.2) of this chapter gives an overview 
of therapeutic molecules, particularly tumor-specific antigen, and cancer biomarkers as 
well. The motivation of this study and outline of the structure of this dissertation are 
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1.1   Overview of mechanism and strategies of molecular-
targeted therapeutics   
Knowing the origin of a disease is the first step in understanding the entire abnormal 
course of disease and helping the treatment of the disease. Sometimes it is very easy to 
determine the cause of certain diseases, such as infectious diseases which are generally 
caused by virus, bacteria or parasites. However, sources of some diseases may not be 
easily identified, especially some multifactorial diseases resulting from an accumulation of 
inherited and environmentally-induced changes or mutations in the genome, such as 
cancer [1-5], diabetes [6,7], cardiovascular disorders [8,9] and obesity [10].  
 
For accurate disease treatment, it is very important to identify genes responsible for 
disease initiation, development and progress. As such, proper treatment regime can be 
applied and the survivability of the patients can be ultimately extended [11]. The 
completion of human genome project [12,13], and the new, economical, and reliable 
methods in functional genomics such as gene expression analysis present the potential for 
disease classification, target identification and drug mechanism study (Figure 1-1). Often, 
the potential disease targets are the  molecules that show significantly different expression 
profiles between healthy people and patients, or among the patients with different progress 
stages/subtypes/outcomes, playing key roles in disease initiation [14] or disease progress 
[15,16]. The disease targets can be used in developing disease targeting molecules such as 
small molecules, antibody, and vaccines based on the protein-small molecule interaction 
and antibody-antigen interaction [17]. 
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An ever-increasing number of molecular-targeted therapeutic agents are nowadays 
approved by US Food and Drug Administration (FDA), which have been summarized in 
Table 1-1 and Table 1-2. For cancer treatment, some promising targeted therapies are 
being studied for use alone, in combination with other targeted therapies, and in 
combination with other cancer treatments, such as radiotherapy and chemotherapy.  
 
Figure 1-1 The discovery and exploitation of cancer genes has the potential to usher in a 
new era of individualized diagnosis and therapy.  
 
 
Notes: The two critical steps in this process are: (1) the successful development of diagnostic, 
prognostic predictive and pharmacodynamic biomarkers; and (2) effective molecularly targeted 
therapeutics. The close integration of the discovery, development, and application of the molecular 
biomarkers and molecular therapeutics is key to future success. The figure is  adapted from [18]. 
 
1.1.1 Current progress of molecular-targeted cancer therapeutics 
The principle of targeted cancer therapy is certainly not new: by focusing on molecular 
and cellular changes that are specific to cancer, targeted cancer therapies may be more 
effective than other types of treatment, including chemotherapy and radiotherapy, and less 
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harmful to normal cells. This kind of targeted cancer therapies give clinicians a better way 
to tailor cancer treatment, especially when a target is present in some but not all tumors of 
a particular type, as is the case for HER2 in breast cancer. Eventually, treatments can be 
individualized based on the unique set of molecular targets produced by the patient‘s 
tumor. Moreover, targeted cancer therapies also hold the promise of being more selective 
for cancer cells than normal cells, thus harming fewer normal cells, reducing side effects, 
and improving quality of life. 
 
The success of Imatinib (Gleevec) in the treatment of chronic myelogenous leukaemia 
(CML) has provided evidence that cancer can be effectively treated by the identification of 
underlying molecular defects. With the progress of genomics and proteomics technologies 
and the campaigns of studying cancer mechanism by these ―omics‖ technology, increasing 
number of gene signatures closely related to cancer initiation and perpetuation have been 
identified, thus provide rich therapeutic candidate for targeted therapies. A new generation 
of drugs, that targeted on the specific molecular targets, such as receptor tyrosin kinases 
(RTKs) and some enzymes, are playing critical roles today in cancer treatment. The 
promising results in trials with RTKs targeted drugs, such as gefitinib (Iressa) and 
trastuzumab (Herceptin) (Table 1-3) have given encouragement results for such 
approaches. In addition, the identified disease genes also greatly stimulated the 
development of antibodies and tumor vaccines that used to activate the both arms of the 
immune system for cancer immunoprevention and treatment.   
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1.1.2 Challenges of targeted cancer therapy, receptor tyrosine kinase as 
a case study 
The ErbB (Erythroblastic Leukemia Viral Oncogene Homolog) family, a class of 
transmembrane RTKs, regulates various signaling pathways that are critical in the 
development and progression of many cancers. It consists of four receptors (ErbB 1-4) 
whose ligands are Neuregulins and EGFs (Epidermal Growth Factors). Upon ligand 
binding, they form homo- and/or heterodimers to activate the downstream signaling 
pathways[19], including phosphatidylinositol-3 kinase (PI3K) and Erk mitogen-activated 
protein kinase (MAPK). Both of these pathways are critical to regulate cell proliferation 
and survival [20]. The key role of ErbB family in regulating signal transduction in the 
context of multiple cellular processes and environments, and the regulatory approval in 
clinical applications makes kinase as a readily accepted druggable protein [16]. In cancer, 
ErbB family members, especially EGFR and ErbB2, are frequently dysregulated through 
gene mutation and gene amplification, resulting in receptor overexpression. For instance, 
EGFR is overexpressed in almost 80% of head and neck cancer whereas overexpression of 
ErbB2 is found in around 30% breast cancer[19].   
 
Over the past few years, these receptors have emerged as promising anticancer targets and 
good prognostic indicators. Many molecular-targeted drugs are developed to target their 
overexpressed proteins. Due to the specific and selective action, the therapeutic effect 
could be highly achieved with much less toxicity, compared to the traditional cytotoxic 
agents. Some successfully marketed drugs are gefitinib (Iressa) for lung cancer, Imatinib 
(Gleevec) for chronic myeloid leukemia and trastuzumab (Herceptin) for breast cancer. 
Table 1-3 summarized the clinical response rate of gefitinib, trastuzumab, and nine other 
kinase inhibitor drugs (cetuximab, erlotinib, canertinib, vandetanib, neratinib, lapatinib, 
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imatinib, nilotinib and dasatinib) in along with targeted cancer (non-small cell lung cancer 
(NSCLC), breast cancer, and acute lymphoblastic leukemia (ALL)), clinical setting (phase 
I/II, II, and III trial), and kinase target or targets of each drug directly responsible for its 
anticancer therapeutic efficacy.  To maintain statistical significance of our analysis and in 
consideration of the typical sizes of the available trial data, only those trials with larger 
than 60 NSCLC, larger than 60 breast cancer and  larger than 40 ALL patients are 
included. It is noticed that these drugs elicit markedly different clinical response rates and 
clinical response rates so far have not been as high as expected, for example, that of 
15~26% ErbB2-positive patients was reported to response trastuzumab single-drug 
treatment (Table 1-3). Thus, agents directed at RTKs, with a few notable exceptions, such 
as imatinib, are frequently showed reduced efficacies, poor safety and resistant problems.  
 
The efficacy of anti-RTK agents is affected by many factors. Diversity in patients‘ 
expression and mutation of a core set of disease-causing genes could be a reason for the 
failure of drug targeted only on ErbB families. Activation of parallel receptors, whose 
pathways could bypass ErbB signaling pathways, also contributes greatly to the resistance 
to ErbB-targeting drugs. Some of the common parallel receptors, which also belong to 
classes of RTKs, are platelet-derived growth factor receptors (PDGFR), vascular 
endothelial growth factor receptors (VEGFR), insulin-like growth factor receptors (IGFR), 
and hepatocyte growth factor receptor (HGFR or c-MET). Besides, activating mutations of 
downstream signaling molecules of PI3K and MAPK pathways, such as Ras, PTEN 
(phosphatase and tensin homolog), PIK3CA (encoding PI3K), have been highly associated 
with drug resistance, too. These are  generally attributed to their ability to activate the 
signaling pathways by themselves [21-23].  Although possible reasons of some drug 
resistance have been postulated [24-33], practical solutions remain limited due to the lack 
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of insights into detailed resistance profiles as well as a systemic analysis for it. To address 
these questions, the drug response rate of 4 well-studied anticancer anti-RTK agents were 
investigated by collectively analyzing the mutation and expression profiles of molecular 
targets, expression of bypass genes, and activating-mutation of downstream signaling 
genes, including RAS, BRAF and PIK3CA, indictaed in many of RTK resistant research 
studies[31,34-47]. 
1.1.3 Systematic discovery of multicomponent therapies 
The progress of systems biology has revealed that human cells and tissues are composed 
of complex, networked systems with redundant, convergent and divergent signaling 
pathways[48-51]. For example, the redundant function of proteins involved in cell-cycle 
regulation[52] has inspired efforts to intervene simultaneously at multiple points in these 
signaling pathways[53]. Drug combinations thus have been used for treating diseases and 
reducing suffering ever since the earliest days of recorded history. The traditional Chinese 
medicines are vivid examples. In some cases, single-target drugs cannot fully correct a 
complex disease condition such as cancer. The poor efficacy of these agents directed 
against individual molecular targets can be attributed to due to network robustness[24-26], 
redundancy[27], crosstalk[28-30], compensatory and neutralizing actions[31,32], and anti-
target and counter-target activities[33]. The limitations of many monotherapies can be 
overcome by attacking the disease system on multiple points. Multicomponent 
therapeutics can be more efficacious and less vulnerable to adaptive resistance because the 
biological system is less able to compensate for the action of two or more drugs 
simultaneously. Several categories of multicomponent therapeutics have been proposed on 
the basis of target relationship. In the first category, the therapeutic effect occurs at 
separate molecular targets that can reside within individual signaling pathways, between 
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pathways within a cell or at separate tissues in the body. In the second category, 
modulation of one target facilitates action at a second target, for example by altering 
compound metabolism, inhibiting efflux pumps or blocking other resistance mechanisms. 
The third relationship is based on a coordinated action at multiple sites on a single target 
or macromolecular complex, which yields the improved therapeutic effect [54].  
 
Attempts have been made during the past century to quantitatively measure the dose-effect 
relationships of each drug alone and its combinations. The concepts of synergy, 
additivism, and antagonism have been explored extensively, particularly in the fields of 
pharmacology and toxicology [55-57]. Traditionally, combinations can be efficiently 
discovered by dose–response matrix screening and systematically analyzing for drug 
synergies in various cell-based models of disease [58]. The cell-based phenotypic assays 
are employed because they maintain reasonable experimental efficiency while preserving 
disease-relevant molecular-pathway interactions [58]. In vivo screening using a whole 
organism model such as the zebrafish[59] could identify multi-target therapeutics that 
integrates their effect at the level of the organism. Often, limited combination testing 
samples can be used in these systems and is unlikely to have resulted in the selection of 
optimal combinations among the very large number of possibilities.   
 
The deliberate mixing of drugs in a clinical setting requires an understanding of the 
mechanism of action of each drug class. [58]. Tremendous progress has been made over 
the past decade in the development and refinement of genomic and proteomic technologies 
and lead to uncover many novel functional pathways, therapeutic targets, and molecular 
interaction (MI) profiles between disease targets and therapeutic molecules. Despite of the 
importance of these progress towards the system-oriented drug combinations, knowledge 
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of disease biology, drug mechanism or intuition are still required to guide a large, agnostic 
surveys of molecular mechanisms that can combine to produce synergistic combination 
effects. Knowledge of the molecular mechanisms of currently explored multicomponent 
therapies is a particular crucial starting point for investigating and developing rational 
drug combinations and multi-targeting agents. In this study, some key characteristics of 
the modes of multicomponent therapies have been discussed by using the knowledge of 
molecular interaction profiles of individual drugs, disease network crosstalks and 
regulations. The identified modes of actions of drug combinations reveal some important 
categories of multicomponents therapeutics of current successful drug-combinations and 
multi-targeting agents. Rational  multicomponents therapeutics thus can be realized from 
different perspectives, such as selectively modulating the elements of counter-target and 
toxicity activities[60-63].  
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Table 1-1 US FDA-approved molecule targeting drugs (kinase inhibitor) between 2001 to 2010 [64,65]. 
 











kit, and PDGFR 
Renal cell carcinoma 
Advanced renal cell 
carcinoma 
GlaxoSmithKline 







































CID: 216239 Multikinase inhibitor 
VEGFR, PDGFR, c-
KIT 
Renal Cell Carcinoma 










Non-small cell lung cancer 
(NSCLC) 
Treatment of advanced 
refractory metastatic 




















PDGF, SCF, c-kit, 
Positive inoperable and/or 
metastatic malignant 














Chronic myeloid leukemia 
(CML) 
Oral therapy for the 





                                                                                                    









Type of Antibody  Isotype Kd (nM) FDA-Approved Indication(s)  Company  Reference 
2006 
Vectibix (panitumumab) EGFR Human antibody  IgG2, kappa 0.05 Treatment of colorectal cancer Amgen 
[64,66,67] 
 
Herceptin* (trastuzumab) ERBB2 
Humanized 
antibody 
 IgG1  0.1 
A second- or third-line therapy for 
patients with metastatic breast cancer 
Genentech 
[64,68,69] 






treat the "wet" type of age-related 
macular degeneration (ARMD), a 








Treatment of metastatic carcinoma of the 
colon or rectum 
Genentech 
[64,71,72] 
Erbitux (cetuximab)  EGFR 
Chimeric 
antibody 
IgG1, kappa 0.2 
Treatment of EGFR-expressing 




2002 Humira (adalimumab)  TNF-alpha  Human antibody  IgG1, kappa 0.1 
For treatment of adults with rheumatoid 





Remicade (infliximab)  TNF-alpha  
Chimeric 
antibody 
IgG1, kappa 0.1 
For treatment of rheumatoid arthritis, 
Crohn‘s disease, ankylosing spondylitis, 













*First approved October 1998, used extended 2006 
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Table 1-3 Clinical response rates, targeted cancer in clinical test, clinical test setting, and kinase target / targets of 11 anticancer kinase inhibitor 
drugs approved or in clinical trial for the treatment of non–small cell lung cancer (NSCLC), breast cancer, and acute lymphoblastic leukemia 
(ALL) 
Drug  
Kinase Target / Targets Directly 
Responsible for Anticancer Effect (Potency) 





Clinical Test Setting  Clinical 
Response 
Rate 
Reference of Clinical Test in 





Cetuximab   EGFR (Kd  0.39nM) [19216623] 
NSCLC Phase II 60 Not found 3.3% 16472704 
NSCLC Phase II 66 




EGFR (IC50 33nM), HER4 (IC50 476nM) 
[9578319, 12384534, 18089823] 
NSCLC Phase II 210 
Advanced NSCLC received 1 or 2 
chemotherapy, at least one with platinum 
18.4% 12748244 
NSCLC Phase II 216 
Locally advanced or metastatic NSCLC 
failed 2 or more chemotherapy with 
platinum, docetaxel  
8% 
Proc Am Soc Clin Oncol 21: 
2002 (abstr 1166) 
NSCLC Phase II 100 
Chemotherapy naïve stage IIIB/IV 




Phase II 63 




EGFR (IC50 1nM), HER4 (IC50 230-
790nM)[15711537, 18183025, 18089823] 
NSCLC Phase II 1,949 2nd/3rd-line advanced NSCLC 12% 
J Clin Oncol 27: 15s, 2009 
(suppl abstr 8001) 
NSCLC Phase III 731 
Stage IIIB or IV NSCLC received 1 or 2 
chemotherapy  
8.9% 16014882 
NSCLC Phase II 66 Chemotherapy-naïve NSCLC aged ≥70 10% 17228019 
Canertinib 
EGFR (IC50 0.8nM), HER2 (IC50 19nM), 
HER4 (IC50 4~7nM)  [12138393] 
NSCLC Phase II 166 
Advanced-stage NSCLC failed or 





Phase II 194 
Progressive or recurrent metastatic breast 
cancer expressed 1 or more ErbB 
7.3% 19294387 
Vandetanib 
EGFR (IC50 500nM), 
VEGFR2 (IC50 40nM) ,  
RET (IC50 100nM), HER4 (IC50 480nM), 
SRC (IC50 70nM) [12183421, 12499271, 
18183025] 
NSCLC Phase II 83 
Locally advanced or metastatic stage 
IIIB/IV NSCLC failed platinum-based 
chemotherapy 
8% 
J Clin Oncol 24, No. 18S 
(Suppl, 2006: 7000 
NSCLC Phase II 73 
NSCLC histologies and pretreated CNS 
metastases 
7% 18936474 
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Trastuzumab HER2 (Kd  0.1nM) [19216623] 
Breast 
Cancer 
Phase II 222 





Phase II 114 








Phase II 124 





Phase II 124 




HER2 (IC50 7nM), EGFR (IC50 0.6-8.9nM), 
HER4 (IC50 54nM) [18183025] 
Breast 
Cancer  
Phase II 138 
First-line ErbB2-amplified locally 




Phase II 78 
Stage IIIB/IV HER2+ advanced or 





Phase II 126 
Relapsed or refractory HER2+ 




Phase II 141 First-line HER2+ metastatic breast cancer 22.2% 19525314 
Imatinib 
ABL1 (IC50 12nM), c-KIT (IC50 14nM), 
PDGFRB (IC50 14nM), SRC (IC50 352nM) 
[18183025, 19890374, 16105974] 
ALL Phase II 48 
Ph+ALL without response or relapse to 
chemotherapy or SCT 
19% 12200353 
ALL  Phase II 56 




ABL1 (IC50 56nM), PDGFR (IC50 22nM), c-
KIT (IC50 18nM) [19922818] 
ALL  Phase II 41 
Ph+ALL resistant to imatinib or 
intolerant/ relapse to chemotherapy or 
SCT 
24% Ottmann et al(2007c) 
Dasatinib 
ABL1 (IC50 0.53nM), SRC (IC50 0.21nM), 
FGR (IC50 0.5nM), FYN (IC50 0.7nM), HCK 
(IC50 0.35nM), LYN (IC50 0.57nM), 
PDGFRB (IC50 0.63nM), PDGFRA (IC50 
0.45nM), c-KIT (IC50 0.62nM) 
[18183025,19039322] 
ALL  Phase II 46 
Ph+ALL resistant to imatinib or 
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1.2 Current progress in cancer biomarker discovery  
1.2.1 Introduction to biomarker in cancer diagnosis and prediction 
Generally tumors are differentiated according to their gross morphological appearance of 
the cells and the surrounding tissues. However, such a differentiation criterion has 
limitations. First, it relies on a subjective review of the tissue, which depends on the 
knowledge and experience of a pathologist, which may not be consistent or reproducible 
[73,74]. Second, this method provides discrete, rather than continuous classification of 
disease into broad groups with limited ability to determine the treatment regime of 
individual patients[75]. Third, disease with identical pathology may have different origins 
and respond differently to treatment [76]. Last but not the least, current pathology reports 
offer little information about the potential treatment regime which a disease will respond 
to. The accurate diagnosis and differentiation of tumor subtypes remains a challenge and 
the efforts to combat cancer remain extremely disappointing. One main reason for the lack 
of desired success in cancer diagnosis and differentiation is that in many cases, cancer is 
diagnosed too late and treated with improper regimens. Therefore, factors that can 
accurately predict response/toxicity to systemic treatments are urgently needed.   
 
Fortunately, disease differentiation based on molecular profile of diseases can overcome 
those limitations [5,77-80]. Spectacular advances in molecular medicine, genomics, and 
proteomics are nowadays leading to the search for new biomarkers in cancer research. 
Microarray technology, for example, has become a very important component of disease 
molecular differentiation. The gene expression profiles can be used to identify markers 
which are closely associated with early detection/differentiation of disease, or disease 
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behavior (disease progression, response to therapy), and could serve as disease targets for 
drug design [81]. 
1.2.2 Types of cancer biomakers 
A cancer biomarker is a substance that is objectively measured and evaluated as an 
indicator of pathogenic processes or pharmacological response to a therapeutic 
intervention in oncology[82]. Broadly speaking, cancer biomarkers can be divided into 
three categories[83] based on the recent advances in genomic and genetic research:  
 
(a) Diagnostic (screening) biomarkers are used to detect and identify a given type of 
cancer in an individual. This type of biomarkers is expected to possess high levels of 
diagnostic sensitivity and specificity, especially if it is used in large-screening trials; 
 
(b) Prognostic biomarkers are commonly used in clinical outcome prediction once the 
disease status has been established, independent of the therapy that is used. They are 
expected to predict the likely course of the disease, reflecting the metastatic, recurrence 
potential and/or growth rate of the tumor and thus they have an important influence on the 
aggressiveness of the therapy[84]. Prognostic biomarkers can be further divided into 
biological progression markers and risk biomarkers[84]. Biological progression markers 
are measures of tumor burden and are commonly circulating cellular proteins that are 
associated with tumor progression. Among the most commonly used of these ―tumor 
markers‖ are CA-125 for ovarian cancer and prostate-specific antigen (PSA) for prostate 
cancer [85-87]. Risk biomarkers are usually implicated in the mechanisms of disease 
causality or neoplastic progression, and are increasingly used in drug development to 
identify populations likely to be responsive to a given drug treatment. The foremost 
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example of this is ERBB2/HER2 gene amplification in 25% of patients with invasive 
breast cancer, which correlates with inferior patient survival [88];  
 
(c) Predictive biomarkers or pharmacodynamic biomarkers serve to predict the likely 
clinical response to a specific treatment that are most relevant for monitoring effects of a 
drug or other intervention, and classifying individuals as ―responders‖ or ―non-
responders‖ by using molecular, cellular, histopathological, and imaging parameters 
[83,84].  Such predictive classification is of a major importance in designing clinical drug 
trails to define an intended use for the drug under investigation. It is a indicator of drug 
effect, they may not necessarily correlate with or predict a therapeutic impact on the 
disease[84]. Examples of typical pharmacodynamic biomarkers include changes in 
proliferation using Ki67 expression, apoptosis using the TUNNEL assay, alterations in 
gene expression profiles, and functional or molecular imaging changes[89].  
 
Although prognostic and predictive biomarkers have different focus, some factors, such as 
EGFR mutations, are used as both prognostic and predictive in clinical studies[90]. 
 
1.2.3 Approaches of cancer biomarker discovery 
1.2.3.1 Traditional gene discovery method 
The early approaches to discover and identify cancer biomarkers were mainly based on 
preliminary clinical or pathological observations. Two methods, candidate gene approach 
and positional cloning approach, have traditionally been used to discover physiologically 
and pathologically natural history markers markers underlying human diseases. Candidate 
gene method is based on prior biochemical knowledge about the genes, such as putative 
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functional protein domain of genes and tissues in which genes are expressed [91,92].  Li-
Fraumeni syndrome [93], hereditary prostate cancer risk [92], metastasis of hepatocellular 
carcinoma [94], and breast cancer risk [95] were discovered in this manner. However very 
limited well-characterized genes are currently available [91], and most genes cannot be 
analyzed in this manner due to the limitation of biochemical knowledge.  
 
In contrast to candidate gene method, positional cloning identifies genes without any prior 
knowledge about gene function[8]. This method is performed in patients and their family 
members using DNA polymorphisms. Alleles of markers that are in close proximity to the 
chromosome location of the disease genes can be determined by genetic linkage analysis, 
and critical region can be defined by haplotype analysis. The candidate genes residing in 
the critical regions can be identified [8,91]. This method was applied in identifying genes 
related with asthma [96], cardiovascular disorders [8,9], and diabetes mellitus [7]. 
However, the nature of positional cloning limits its resolution to relatively large regions of 
the genome [91]. The candidate genes within a certain critical region need to be filtered 
from the relatively large regions of the genome by identifying mutations in genes that 
segregate with the disease [91]. 
 
These traditional approaches lead to the development of some most reliable and validated 
markers in daily clinic, which include carcinoembryonic antigen for a variety of cancers, 
such as calcitonine for medulary thyroid carcinoma,prostate-specific antigen for prostate 
carcinoma, thyroglobulin for papillary or follicular thyroid carcinoma, human chorionic 
gonadotropin or alpha-fetoprotein for germ cell tumors, CA-125 for ovarian carcinoma, 
CA 15-3 for breast carcinoma, and SCC for squamous cell carcinoma of the cervix (Table 
1-4) [97]. The optimum management of patients with several types of malignancy also 
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requires the use of tumor biomarkers correlating with clinical response to a specific 
treatment and most relevant for monitoring drug activity. The foremost example of these 
biomarkers includes mutations of EGFR and K-ras for Non-small cell lung cancer and 
Colorectal respectively(Table 1-4)[97]. 
Table 1-4 Tumor markers used in clinical practice. Simplifed list of predictive tumor markers in 
breast and other solid tumors  [97]  
Cancer type Marker(s) Main use(s) Clinical scenario  
Colorectal  CEA Prognosis, postoperative 
sruvelliance, monitoring therapy 
 
Germ cell AFP, HCG, LDH 
(prognosis only) 
Prognosis, postoperative 
surveillance, monitoring therapy 
 
Trophoblastic HCG Prognosis, postoperative 
surveillance, monitoring therapy 
 
Ovarian  CA-125 Monitoring therapy, differential 
diagnosis of benign and malignant 
masses in postmenopausal women 
 
Prostate  PSA Screening, prognosis, postoperative 
surveillance, monitoring therapy 
 
Breast ER, PR Predicting response to hormone 
therapy, prognosis 
Endocrine agents 
 HER-2  Predicting response to trastuzumab 
and lapatinib, prognosis 
Anti-HER2 agnets 
 uPA, PAI-1 Prognoiss in node-negative patients Chemotherapy 
 CA15-3, CEA postoperative surveillance, 
monitoring therapy 
 




Thyroid(differentiated) Thyroglobulin Postoperative surveillance, 
monitoring therapy 
 
Colorectal  K-ras mutations  Getuximab 
Non-small cell lung cancer EGFR mutations  Gefitinib, erlotinib 
Gastrointestinal stomal tumors C-kit or PDGFRA 
mutations 
 Imatinib mesulate 
Abbreviations: CEA,carcinoembryonic antigen; AFP, alpha-fetoprotein; HGC, human choriogonadotrophin; 
LDH, lactate dehydrogenase; PSA, prostate-specific antigen; ER, estrogen receptor; PR, progesterone 
receptor; uPA, urokinase plasminogen activator; PAI, plasminogen activator inhibitor.  
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1.2.3.2 New approaches of cancer biomarker discovery  
Currently, there are a number of newly emerged platforms leading to the search for new 
biomarkers in cancer research. On the proteomic side, we have a number of emerging 
technologies that are applied in the area of biomarkers discovery, including surface 
enhanced laser desorption ionization (SELDI) [98,99], mass sepectrometry combined with 
two-dimensional liquid chromatography [100-102] or two-dimensional gel electrophoresis 
[103-106], protein microarrays [107-109], and imaging mass spectrometry[110-112]. On 
the genomic side, there are equally powerful platforms for biomarkers discovery, which 
use polymerase chain reaction (PCR) [113,114], serial analysis of gene expression 
(SAGE) [115], and DNA microarrays [4,5,116].  These technique is widely used in cancer 
research for the identification of cancer biomarkers, and provide new insights into 
tumorigenesis, tumor progression and invasiveness [4,5,117-120]. 
 
Among these well developed techniques, DNA microarrays has emerged as being the most 
clinically useful[121]. Computational analysis of microarray data can be used to identify 
certain sets of cancer-associated marker genes based on gene expression patterns. 
Furthermore, gene expression profiling provides high levels of specificity and sensitivity 
in cancer process where classical histo- or immunopathological approaches are 
unsatisfactory. Currently, powerful microarray technology has provided several new 
molecular classifications[4,117,122,123] of different solid tumors but also new prognostic 
and predictive tools in breast cancer [97], colorectal tumors [124], prostate cancer[125], 
non-Hodgkin‘s lymphoma [126], acute myeloid leukemia [127]. In breast cancer, 
multigene predictors of response to chemotherapy, endocrine therapy, or targeted agents 
are in earlier stages of development [97]. Two profiles, in particular, have undergone 
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detailed studies in this malignancy: MammaPrint
®
 and Oncotype DX
®
.  Similar multigene 
signatures are under development in other solid tumors[97].  
1.2.4 Brief introduction of microarray technology 
1.2.4.1 Introduction to microarray experiments 
Microarray technology, also known as DNA chip, gene ship or biochip, is one of the 
indispensable tools in monitoring genome wide expression levels of genes in a given 
organism. Microarrays measure gene expression in many ways, one of which is to 
compare expression of a set of genes from cells maintained in a particular condition A 
(such as disease status) with the same set of genes from reference cells maintained under 
conditions B (such as normal status).  
 
Figure 1-2 shows a typical procedure of microarray experiments [128,129]. A microarray 
is a glass substrate surface on which DNA molecules are fixed in an orderly manner at 
specific locations called spots (or features). A microarray may contain thousands of spots, 
and each spot may contain a few million copies of identical DNA molecules (probes) that 
uniquely correspond to a gene. The DNA in a spot may either be genomic DNA [130], or 
synthesized oligo-nucleotide strands that correspond to a gene [131-133]. This microarray 
can be made by the experimenters themselves (such as cDNA array) or purchased from 
some suppliers (such as Affymetrix GeneChip). The actual microarray experiment starts 
from the RNA extraction from cells. These RNA molecules are reverse transcribed into 
cDNA, labeled with fluorescent reporter molecules, and hybridized to the probes 
formatted on the microarray slides. At this step, any cDNA sequence in the sample will 
hybridize to specific spots on the glass slide containing its complementary sequence. The 
amount of cDNA bound to a spot will be directly proportional to the initial number of 
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RNA molecules present for that gene in both samples. Following, an instrument is used to 
read the reporter molecules and create microarray image. In this image, each spot, which 
corresponds to a gene, has an associated fluorescence value, representing the relative 
expression level of that gene. Then the obtained image is processed, transformed and 
normalized. And the analysis, such as differentially expressed gene identification, 
classification of disease/normal status, and pathway analysis, can be conducted. 
 




Microarray making Hybridization  
+ 
mRNA reverse transcription 
Fluorescentlabeling 
Sample A Sample B 
RNA extraction 
RNA sample A RNA sample B 
Microarray hybridization 
Microscope glass slides 
DNA molecules 
amplified by PCR 
Spotting 
microarray 




Classification Other analyses (e.g. 
pathway analysis) 
Cy3 labeled sample A 
(green) 
Cy5 labeled sample B 
(red) 
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1.2.4.2 Public repository for microarray data 
Reword to the variety of journals and funding agencies which have established and 
enforced microarray data submission standards, currently, a wealth of microarray data is 
now available in different databases such as the Stanford Microarray Database (SMD) 
[134], Gene Expression Omnibus (GEO) [135], and Array Express (EBI) [136]. Table 1-5 
gives a list of public available microarray databases. Many of those databases require a 
minimum information about a microarray experiment (MIAME)-compliant manner in 
order to interpret the experiment results unambiguously and potentially be able to 
reproduce the experiment [137]. As a public resource, these expression databases are 
valuable substrates for statistical analysis, which can detect gene properties that are more 
subtle than simple tissue-specific expression patterns. 
1.2.4.3 Statistical analysis of microarray data 
Since microarray contains the expression level of several thousands of genes, it requires 
sophisticated statistical analysis to extract useful information such as drug responsive 
markers. Theoretically, one would compare a group of samples of different conditions and 
identify good candidate genes by analysis of the gene expression pattern. However, a 
typical microarray data set is extremely sparse compared to traditional classification data 
sets[138]. Microarray data set may also contain some noises arising from measurement 
variability and biological differences [139,140]. The gene-gene interaction also affects the 
gene-expression level. Furthermore, the high dimensional microarray data can lead to 
some mathematical problems such as the curse of dimensionality and singularity problems 
in matrix computations, causing data analysis difficult. Therefore, choosing a suitable 
statistical method for gene selection is very important. 
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Table 1-5 A  list of public available microarray databases 




A public repository for 


















A relational database 
containing yeast and E. coli 








A database for gene expression 
profile from 91 normal human 
and mouse samples across a 
diverse array of tissues, 










An extensive and easily 
searchable database of gene 











containing tens of millions of 
expression profiles 







Information and microarray 
expression data for genes 
involved in mitosis and 
meiosis, gamete formation and 
germ line development across 
species 
Biozentrum and 








A comprehensive database to 
understand the expression of 
human genes in normal human 
tissues 







A web-accessible archive of 
DNA microarray data 
Medical University 






A database of expression 
profile data from the RIKEN 







Expression profiles obtained 
by the Rice Microarray Project 
and other research groups 








A public gene expression 
database designed to hold data 













A gene expression database of 
Saccharomyces genome 
Stanford University [151] 








Raw and normalized data from 
microarray experiments, as 
well as their corresponding 
image files 





A microarray database for 
large-scale gene expression 
analysis. 
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The statistical methods in microarray data analysis can be classified into two groups: 
unsupervised learning methods and supervised learning methods. Unsupervised analysis of 
microarray data aims to group relative genes without knowledge of the clinical features of 
each sample [154]. A commonly-used unsupervised method is hierarchical clustering 
method. This method groups genes together on the basis of shared expression similarity 
across different conditions, under the assumption that genes are likely to share the same 
function if they exhibit similar expression profiles [155-158]. Hierarchical clustering 
creates phylogenetics trees to reflect higher-order relationship between genes with similar 
expression patterns by either merging smaller clusters into larger ones, or by splitting 
larger clusters into smaller ones. A dendogram is constructed, in which the branch lengths 
among genes also reflect the degree of similarity of expression [159,160]. By cutting the 
dendogram at a desired level, a clustering of the data items into the disjoint groups can be 
obtained. Hierarchical clustering of gene expression profiles in rheumatoid synovium 
identified 121 genes associated with Rheumatoid arthritis I and 39 genes associated with 
Rheumatoid arthritis II [161]. Unsupervised methods have some merits such as good 
implementations available online and the possibility of obtaining biological meaningful 
results, but they also possess some limitations. First, unsupervised methods require no 
prior knowledge and are based on the understanding of the whole data set, making the 
clusters difficult to be maintained and analyzed. Second, genes are grouped based on the 
similarity which can be affected by input data with poor similarity measures. Third, some 
of the unsupervised methods require the predefinition of one or more user-defined 
parameters that are hard to be estimated (e.g. the number of clusters). Changing these 
parameters often have a strong impact on the final results [162].  
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In contrast to the unsupervised methods, supervised methods require a priori knowledge of 
the samples. Supervised methods generate a signature which contains genes associated 
with the clinical response variable. The number of significant genes is determined by the 
choice of significance level. Support vector machines (SVM) [163] and artificial neural 
networks (ANN) [164] are two important supervised methods. Both methods can be 
trained to recognize and characterize complex pattern by adjusting the parameters of the 
models fitting the data by a process of error (for example, mis-classification) minimization 
through learning from experience (using training samples). SVM separates one class from 
the other in a set of binary training data with the hyperplane that is maximally distant from 
the training examples. This method has been used to rank the genes according to their 
contribution to defining the decision hyperplane, which is according to their importance in 
classifying the samples. Ramaswamy et al. used this method to identify genes related to 
multiple common adult malignancies [5]. ANN consists of a set of layers of perceptrons to 
model the structure and behavior of neutrons in the human brain. ANN ranks the genes 
according to how sensitive the output is with respect to each gene‘s expression level. Khan 
et al identified genes expressed in rhabdomyosarcoma from such strategy [118].   
 
In classification of microarray datasets, it has been found that supervised machine learning 
methods generally yield better results [165], particularly for smaller sample sizes [140]. In 
particular, SVM consistently shows outstanding performance, is less penalized by sample 
redundancy, and has lower risk for over-fitting [166,167]. Furthermore, some studies 
demonstrated that SVM-based prediction system was consistently superior to other 
supervised learning methods in microarray data analysis [168-170]. As such, SVM for 
identifying marker genes related to the survival and death lung cancer patients from 
microarray data analysis were used in this study. The lung cancer patients discrepancy 
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capability of identified disease markers were futher evaluated and compared by supervised 
methods including SVM and Probabilstic Neural Network, which is an extension of ANN; 
whereas the unsupervised approach, hierarchical clustering, were used to generate clusters 
of patients bearing the different survivalbilities.  
1.2.4.4 Feature selection in microarray data analysis 
No matter whether the supervised or unsupervised methods are used, one critical problem 
encountered in both methods is feature selection, which has become a crucial challenge of 
microarray data analysis. The challenge comes from the presence of thousands of genes 
and only a few dozens of samples in currently available data. From the mathematical view, 
thousands of genes are thousands of dimensions. Such a large number of dimensions leads 
microarray data analysis to problems such as the curse of dimensionality [171,172] and 
singularity problems in matrix computations. Therefore, there is a need of robust 
techniques capable of selecting the subsets of genes relevant to a particular problem from 
the entire set of microarray data both for the disease classification and for the disease 
target discovery. 
 
The goal of gene selection from microarray data is to search through the space of gene 
subsets in order to identify the optimal or near-optimal one with respect to the 
performance measure of the classifier. Many gene selection methods have been developed, 
and they generally fall into two categories: the filter method and the wrapper method 
[173]. Figure 1-3 shows how these two methods work.  
 
In brief, the filter method selects genes independent of the learning algorithms [174-176]. 
It evaluates the goodness of the genes from simple statistics computed from the empirical 
distribution with the class label [177]. Filter method has some pre-defined criteria. Mutual 
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information and statistical testing (e.g. T-test and F-test) are two typical examples of filter 
method [4,174,178-182]. Filter method can be easily understood and implemented, and 
needs little computational time. But the pitfall of this method is that it is based on the 
assumption that genes are not connected to each other, which is not true in real biological 
process.  
 
Figure 1-3 Filter method versus wrapper method for feature selection 
 
 
Wrapper method generates genes from the evaluation of a learning algorithm. It is 
conducted in the space of genes, evaluating the goodness of each gene or gene subsets by 
such criteria as cross-validation error rate or accuracy from the validation dataset [183]. 
The wrapper method is very popular among machine learning methods for gene discovery 
[173,184,185]. Although the wrapper method needs extensive computational resources 
and time, it considers the gene-gene interaction and its accuracy is normally higher than 
 
 
The filter method for feature selection 
Training dataset: 
All features 
Feature subset selection 
Learning algorithm 






Feature subset generation 
Training dataset and test dataset: 
Final performance evaluation 
Training dataset and test dataset: 
Performance evaluation 
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the filter method [173,184,185]. Recursive feature elimination (RFE) is a good example of 
the wrapper method for disease gene discovery. The RFE method uses the prediction 
accuracy from SVM to determine the goodness of a selected subset. This thesis will 
employ RFE for disease gene discovery from microarray data.  
 
1.2.5 The problems of current marker selection methods 
The methodology of SVM and RFE will be discussed in Chapter 2 in details. Here, some 
problems encountered in current marker discovery from microarray data analysis are 
discussed. One problem is to specify the number of genes for differentiating disease. The 
number of derived colon cancer genes and leukemia genes ranges from 1 to 200 [4,186-
191]. 50 genes were arbitrarily chosen for differentiating AML from ALL by Golub et al, 
since they supposed that 50 genes might reflect the difference between AML and ALL [4]. 
In most cases, the gene number was decided by the classification performance of different 
gene combinations. The gene combination which produced the highest classification 
accuracy constituted the gene signature. This strategy might produce small sets of genes 
(one or two genes) that formed accurate classifier [189-191]. For example, Slonim et al 
reported that the classifier consisting of one gene (HOXA9) outperformed all of other 
classifiers consisting of other gene combinations for recurrence prediction in AML 
patients [191]. Li and Yang showed that one gene (Zyxin) constituted the best classifiers 
for AML/ALL differentiation [189]. Nevertheless these results were only obtained and 
tested of one dataset. Considering that the number of genes should correlate with the 
disease situation, the selected genes should be large enough to be robust against noise and 
small enough to be readily applied in clinical settings. Therefore, it is not appropriate to 
use the arbitrary gene number. Similarly, to use just one dataset to decide the optimal gene 
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number may not be satisfactory, because the optimal gene number varies with the different 
sample sizes and sample combinations [139,192,193].  
 
Another problem in gene discovery is that gene signatures are highly unstable and strongly 
depended on the selection of patients in the training sets [4,118,139,140,194-197], despite 
the use of sophisticated class differentiation and gene selection methods by various 
groups. The unstable signatures were observed in most microarray datasets including 
colon cancer, lung adenocarcinoma, non-Hodgkin lymphoma, acute lymphocytic 
leukemia, acute myeloid leukemia, breast cancer, medulloblastoma, and hepatocellular 
carcinoma [139,159,168,173,176,194,198-201]. While these signatures display high 
predictive accuracies, the highly unstable and patient-dependent nature of these signatures 
diminishes their application potential for diagnosis and prognosis [139]. Moreover, the 
complex and heterogenic nature of disease such as cancer may not be adequately described 
by the few cancer-related genes in some of these signatures. The unstable nature of these 
signatures and their lack of disease-relevant genes also limit their potential for target 
discovery. The instability of derived signatures is likely caused by the noises in the 
microarray data arising from such factors as the precision of measured absolute expression 
levels, capability for detecting low abundance genes, quality of design and probes, 
annotation accuracy and coverage, and biological differences of expression profiles 
[140,202]. Apart from enhancing the quality of measurement and annotation, strategies for 
improving signature selection have also been proposed. These strategies include the use of 
multiple random validation [139], large sample size [203], known mechanisms [204], and 
robust signature-selection methods which is insensitive to noises [140,205,206]. 
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This thesis explored a new gene signature selection method aiming to reduce the chances 
of erroneous elimination of predictor-genes due to the noises contained in microarray 
dataset. Multiple random sampling and gene-ranking consistency evaluation procedures 
were incorporated into RFE gene signature selection method. The consistent genes 
obtained from the multiple random sampling method may give us a better understanding 
to the disease initiation and progress, and may provide potential disease targets. 
 
1.3 Current progress in tumor antigen discovery 
1.3.1 Overview of tumor vaccine for cancer immunotherapy 
The major role of the immune system is to destroy cells expressing non-self or mutation 
proteins, which is carried by cytotoxic T lymphocytes (CTLs) by recognizing short 
peptides in association with major histocompatibility complex (MHC) class I molecules. 
Tumors have been known to express aberrant levels of mutated or modified forms of 
proteins that are associated with malignant growth. Such proteins can be immunogenic and 
stimulate cellular and humoral immune responses[207-209]. Inducing T-cell immunity by 
peptide vaccines derived from these alternated proteins holds great potential of effectively 
destroying cells carrying viral invaders (by recognizing the antigenic viral peptides) or 
against tumor cells (by recognizing peptides from tumor antigens) [210].  
 
The interests in peptide-based cancer vaccines have been steadily growing since it has 
been indeed shown that peptide immunization can elicit specific CTL responses and 
confer protective immunity against tumor cells. Furthermore, the identification of tumor-
associated and -specific T cell epitopes has contributed significantly to the understanding 
of the interrelationship of tumor and immune system and is instrumental in the 
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development of attractive biomarkers and therapeutic vaccines to treat patients [211]. The 
discovery and identification of tumor antigens, which now number in the hundreds (Table 
1-6 ) [212]; however, very few of tumor antigens have been successfully identified and the 
immune response they provoke in cancer treatment [212,213]. The main reason is that 
tumors cancer escape an immune response in many ways[214]. Moreover, Tumors are 
generally genetically unstable, and they can lose their antigens by mutation. Some tumors 
even lose expression of a particular MHC molecule, totally blocking antigen 
presentation[215]. There is a need to search for new cancer immunotherapies, such as 
cancer vaccines, from more diverse sources [216-219] that takes into consideration not 
only tumor-specific mutations and MHC-binding but also the expression profiles of the 
antigens, processing and transport of the epitopes, and availability of T-cell repertoire in 
specific tumors [220]. 
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Table 1-6 Selected cancer vaccines in early and late stages of clinical trials [212] 
Product Composition  Company (location) Product  Description  Indication Trial phase 
  
Antigen Express (Worcester, MA, 
USA; a subsid-iary of Generex 
Biotechnology, Toronto)  
Her-2/neu breast 
cancer vaccine  
Her-2/neu epitope peptide con-jugated at N terminus 
to the C terminus of the key moiety of the MHC class 
II¡Vassociated invari-ant chain (Ii protein) containing 
a four¡Vamino-acid (LRMK) modi-fication  Breast cancer  Phase 2  
  Apthera (Scottsdale, AZ, USA)  NeuVax  
Immunopeptide (E25) from Her-2/neu administered 
together with GM-CSF  Early-stage breast cancer  Phase 1/ 2  
  
Argos Therapeutics (Durham, NC, 
USA)  AGS-003  
Autologous dendritic cells loaded with total RNA from 
resected tumors  Renal cancer  Phase 2  
  
Immunocellular Therapeutics (Los 
Angeles, CA, USA)  ICT-107  
Autologous dendritic cells treated with tumor-specific 
peptides from 6 antigens expressed on glioblastomas  Brain cancer  Phase 1  
  
Immunotope (Doylestown, PA, 
USA)  IMT-1012  
Peptide vaccine containing 12 tumor-associated 
peptides discovered through proteom-ics, including A-
kinase anchor protein 9, midasin (MIDAS-containing 
protein RAD50), talin 1, vinculin vimentin and cen-
trosome-associated protein 350  Advanced ovarian and breast cancer  Phase 1  
  Pevion Biotech (Bern, Switzerland)  Pevi-Pro  
Influenza virosomes expressing three Her2/neu 
epitopes  Breast cancer  Phase 1  
  Vaxon Biotech (Paris)  Vx-001  
A peptide vaccine comprising the cryptic peptide 
human telomerase reverse tran-scriptase (TERT572) 
and its HLA-A*0201-restricted modified variant 
(TERT572Y)  NSCLC  Phase 1  
Whole-cell-based autologous cells 
(personalized) Avax Technologies (Philadelphia)  M-Vax  
Autologous cell vaccine in which patient tumor cells 
are treated with the hapten dinitrophenyl  
Metastatic melanoma with at least one 
tumor to create vaccine  Phase 3  
Whole-cell-based autologous cells 
(personalized) Dendreon  Provenge  
Autologous dendritic cells exposed ex vivo to fusion 
protein combining prostate alkaline phosphatase and 
GM-CSF  
Asymptomatic, metastatic hor-mone-
refractory prostate cancer  Phase 3  
Whole-cell-based autologous cells 
(personalized) Geron (Menlo Park, CA, USA)  GRNVAC1  
Autologous dendritic cells trans-fected with mRNA 
for human telomerase and a portion of lysosome-
associated membrane protein (enhances antigen pre-
sentation)  AML in remission  Phase 2  
Whole-cell-based autologous cells 




Autologous interferon-£^ -activated macrophages 
(monocyte-derived activated NK cells). Autologous 
dendritic cell vaccine loaded ex vivo with tumor 
antigens derived from resected tumor  
Superficial bladder cancer Melanoma 
with M1a or M1b stage disease and/or 
in-transit lesions; stage III and IV 
melanoma Colorectal cancer  
Phase 2/3 Phase 2 Phase 
1/2  
Whole-cell-based autologous cells 
(personalized) 
Introgen Therapeutics (Austin, TX, 
USA)  INGN 225  
Dendritic cells treated with an adenovector carrying 
the human p53 gene  Advanced metastatic SCLC Breast  Phase 2  
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Whole-cell-based autologous cells 
(personalized) MolMed (Milan)  M3TK  
T cells bioengineered to express MAGE 3 tumor 
antigen  Metastatic melanoma  
Phase 2 (enrollment 
halted)  
Whole-cell-based autologous cells 
(personalized) 
Northwest Biotherapeutics 
(Bethesda, MD, USA)  
DC-Vax Prostate 
DC-Vax Brain  
Dendritic cells loaded with recombinant prostate-
specific membrane antigen (PSMA) Dendritic cells 
loaded with tumor extract  
Hormone-dependent, nonmeta-static 
prostate cancer Newly diagnosed 
glioblastoma multiforma requiring 
surgery, radiation and chemotherapy  Phase 3 Phase 2  
Whole-cell-based autologous cells 
(personalized) Prima Biomed (Sydney, Australia)  CVac  
Dendritic cells primed with a mucin-1 and a mannan-
fusion protein adjuvant  Late-stage ovarian cancer  Phase 2  
Whole-cell-based autologous cells 
(personalized) Cell Genesys  
GVAX 
pancreatic 
GVAX leukemia  
Two allogeneic cultured cancer lines, irradiated and 
bioengi-neered to secrete GM-CSF. One allogeneic 
leukemia cell line irradiated and bioengineered to 
secrete GM-CSF  
Metastatic pancreatic cancer Newly 
diagnosed AML, chronic CML and 
myelodysplastic syndrome  Phase 2 Phase 2  
Whole-cell-based autologous cells 
(personalized) NovaRx (San Diego)  Lucanix  
Four non-small cell lung cancer cell lines carrying 
antisense oli-gonucleotides against transform-ing 
growth factor £]-2  Advanced NSCLC  Phase 3  
Whole-cell-based allogeneic 
tumor cells (off-the-shelf) Company (location)  Product  Description  Indication  Trial phase  
Whole-cell-based allogeneic 
tumor cells (off-the-shelf) Onyvax (London)  
Onyvax-P 
protein  
Three human cell lines repre-senting different stages 
of pros-tate cancer  Hormone-resistant prostate cancer  Phase 2  
Unique-antigen-based 
(personalized): purified peptide  Antigenics  
HSPPC-96 
Oncophage  
Heat shock protein vaccine puri-fied from autologous 
tumor cells  
Recurrent glioma Resected renal-cell 
carcinoma (RCC)  
Phase 2 (investigator-
initiated trial)  
Phase 3 (completed)  
Unique-antigen-based 
(personalized): purified peptide  Biovest International  BiovaxID  
Tumor-specific idiotype conju-gated to keyhole limpet 
hemo-cyanin, plus GM-CSF  
Mantle cell lymphoma Indolent 
follicular B-cell non-Hodgkin¡¦s 
lymphoma  Phase 2 Phase 3  
Shared antigen (off-the-shelf): 
purified protein or peptide  Apthera (Scottsdale, AZ, USA)  NeuVax  
Immunogenic peptide derived from the Her-2/neu 
protein plus GM-CSF  
Early-stage Her-2-positive breast 
cancer  Phase 2/3  
Shared antigen (off-the-shelf): 
purified protein or peptide  CellDex  CDX-110  A 14-amino-acid segment of a mutated EGFR  Glioblastoma multiforme  Phase 2/3  
Shared antigen (off-the-shelf): 
purified protein or peptide  




Modified fragment of the Melan-A/MART-1 protein 
coupled to the carrier QbG10  Advanced-stage melanoma  Phase 2  
Shared antigen (off-the-shelf): 




Peptide vaccine containing Ii-Key modified Her-2/neu 
pro-tein fragment  Node-negative breast cancer  Phase 2  
Shared antigen (off-the-shelf): 
purified protein or peptide  
GlaxoSmithKline Biologicals 






Liposomally packaged cancer vaccine against MAGE-
3 antigen  
Metastatic MAGE-A3-positive 
melanoma NSCLC following surgery  Phase 3 Phase 3  
Shared antigen (off-the-shelf): 
purified protein or peptide  IDM Pharma  IDM-2101  
Nine CTL epitopes from four tumor-associated 
antigens, including two proprietary native epitopes and NSCLC  Phase 2  
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seven modified epitopes and one universal epitope (a 
source of T-cell help)  
Shared antigen (off-the-shelf): 
purified protein or peptide  
Immatics Biotechnologies 
(Tuebingen, Germany)  
IMA901 
IMA910  
Peptide vaccine comprising multiple fully synthetic 
tumor-associated peptides  Renal cancer Colorectal cancer  Phase 2 Phase 1/2  
Shared antigen (off-the-shelf): 
purified protein or peptide  
Norwood Immunology (Chelsea 
Heights, Australia)  
Melanoma 
cancer vaccine  Melanoma-specific peptides gp100 and MAGE-3  Melanoma  Phase 2  
Shared antigen (off-the-shelf): 
purified protein or peptide  Oncothyreon  Stimuvax  
Liposomal vaccine containing a synthetic 25¡Vamino-
acid-peptide sequence from MUC-1  Stage lll NSCLC  Phase 3  
Shared antigen (off-the-shelf): 
purified protein or peptide  Pharmexa (Hoersholm, Denmark)  GV1001  
Recombinant protein vaccine tar-geting human 
telomerase reverse transcriptase, plus GM-CSF  Pancreatic Liver Lung  Phase 3 Phase 2 Phase 2  
Antigenics   OncoPhage  
Heat shock protein vaccine puri-fied from autologous 
tumor cells  Renal cell carcinoma  
Approved in Russia 
Granted fast track status 
by US FDA  
Biovest International   BiovaxID  
Tumor-specific idiotype conju-gated to keyhole limpet 
hemocya-nin, plus GM-CSF  Various B-cell¡Vrelated cancers  
Compassionate use in 
France, Germany, Italy, 
Greece, Spain and the 
UK. Granted fast track 
status by US FDA  
Corixa (acquired by GSK in 
2005)   Melacrine  
Lysate from two melanoma cell lines, Detox adjuvant 
(proprietary) with monophosphoryl lipid A and 
mycobacterial cell wall skeleton   Melanoma Approved in Canada  
CreaGene (Seoul)   CreaVaxRCC  
Autologous monocytes treated with GM-CSF and IL-4 
to create immature dendritic cells acti-vated with 
tumor extracts plus cytokines  Metastatic renal cell carcinoma  Approved in Korea  
Genoa Biotechnologia (Brazil)   Hybricell  
Autologous monocytes treated with cytokines and 
converted to dendritic cells that are fused with patient-
derived tumor cells  Various cancers  Approved in Brazil  
Vaccinogen (Frederick, MD, 
USA)   OncoVax  
Metabolically active, irradiated, autologous tumor 
cells with BCG  Colon cancer  
Approved in Europe, 
available in Switzerland 
Granted Fast Track 
status by FDA  
Mologen (Berlin)   dSlim/Midge  
Genetically modified allogeneic (human) tumor cells 
for the expression of IL-7, GM-CSF, CD80 and 
CD154, in fixed combination with a DNA-based 
double stem loop immunomodulator (dSLIM).  Kidney cancer  
Orphan drug status 
granted by EMEA in 
2006  
Center of Molecular Immunology 
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1.3.2 Introduction toT cell-defined tumor antigens  
As discussed previously, the most dominant mechanism of immune response to foreign or 
self protein antigens is the activation of T-cells by the recognition of T-cell receptors of 
specific peptides degraded from these proteins and transported to the surface of antigen 
presenting cells [221]. Theoretically, every sub-sequence along the protein could be 
antigenic. However, T cell immunity is limited to a small number of immunodominant 
peptides [210]. Such recognition requires the binding of antigen-peptides to major 
histocompatibility complex (MHC) molecules. Peptide epitopes recognized by T-cells are 
potential tools for diagnosis and vaccines for immunotherapy of infectious, autoimmune, 
and cancer diseases [222]. Currently, reverse immunogenetic approaches attempt to 
optimize the selection of candidate epitopes, and thus minimize the experimental effort 
needed to identify new epitopes [223]. When predicting cytotoxic T cell epitopes, the main 
focus has been on the highly specific MHC binding event [223]. 
1.3.2.1 The role of MHC-peptides biding in T-cell epitopes pathway 
The MHC pathway of antigen processing and presentation is highly complex and involve 
many steps that select the peptides to be presented on the cell surface. The first step in this 
pathway is the digestion of native proteins. Peptides (epitopes) are initially generated in 
this step by proteasome, a multi-subunit protease that is responsible for the majority of 
intra-cellular protein degradation and representing about 1% of total cellular proteins 
[224]. It shows some degree of specificity, as some sites in the proteins are preferentially 
cleaved [225]. Furthermore, those peptides having escaped from proteolytic attack of 
various cytosolic proteases are transported into the endoplasmic reticulum (ER) by TAP.   
Within the ER, peptides may undergo N-terminal trimming, whereas their C terminus is 
kept intact [226,227]. The ER aminopeptidase associated with Ag processing responsible 
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for this trimming was recently identified [228-230]. Peptides with correct sizes and proper 
amino acid sequence motifs bind to MHC, and the receptor-peptide complexes are 
transferred via the Golgi to the cell surface. The MHC binding is the most essential and 
selective step since only a minor fraction of the peptide repertoire will bind to a given 
MHC molecule [231]. Peptides in the ER with less efficient MHC binding are either 
degraded there or exported for rapid degradation in the cytosol [232]. For several areas in 
immunology, including the identification of CTL epitopes and vaccine design, reliable 
prediction of MHC binders is important [233]. 
1.3.2.2 Types of tumor antigens 
Broadly speaking, tumor antigens can be classified into unique antigens and shared 
antigens based on their pattern of expression  [234-237]. Examples of these two groups of 
antigens are listed in Table 1-7. Unique antigens result from point mutations in genes that 
are expressed ubiquitously and some of these mutations may be implicated in tumoral 
transformation by affecting the coding region of the gene [235]. Such tumor-specific 
antigens (TSAs), which are unique to the tumor of an individual patient or restricted to 
very few patients, play an important role in the natural anti-tumor immune response of 
individual patients.  
 
On the other hand, shared antigens are present on many independent tumors and may also 
be expressed by normal tissues. Such tumor-associated antigens (TAAs) can be further 
divided into three groups [237]. One group corresponds to peptides encoded by "cancer-
germline" genes, such as MAGE, which are expressed in many tumors but not in normal 
tissues. The only normal cells in which significant expression of such genes has been 
detected are placental trophoblasts and testicular germ cells. Because these cells do not 
express MHC class I molecules, gene expression should not result in the expression of the 
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antigenic peptides and such antigens can therefore be considered as strictly tumor-specific. 
The genes encoding such antigens have also been referred to as "cancer-testis" (CT) genes.  
A second group of shared tumor antigens, named differentiation antigens, are also 
expressed in the normal tissue of origin of the malignancy. The paradigm is tyrosinase, 
which is expressed in normal melanocytes and in most melanomas. Antigens of this group 
are not tumor-specific, and their use as targets for cancer immunotherapy may result in 
autoimmunity towards the corresponding normal tissue. More serious concerns about 
autoimmune side effects apply to carcinoembryonic antigen (CEA), an oncofetal protein 
expressed in normal colon epithelium and in most gut carcinomas. Autoimmune toxicity 
should not be an issue, however, in situations where the tissue expressing the antigen is 
dispensable or even rejected by the surgeon in the course of cancer therapy, as would be 
the case for prostate specific antigen (PSA). The last group of shared antigens refers 
antigens that are expressed in a wide variety of normal tissues and overexpressed in 
tumors. Full list of T-cell defined TSAs and TAAs are available at Cancer Immunity 
database (http://www.cancerimmunity.org/ peptidedatabase/Tcellepitopes.htm).  
Table 1-7 Examples of tumor-specific antigens and shared antigens (Source: GSK) 
Expressed in cancer only  
 MAGE-3  
 NY-ESO-1  
 TRAG-3  
Expressed in some normal tissues 
 WT-1  
 PRAME  
 SURVIVIN-2B  
Overexpressed in cancer  
 Her-2  
 MUC-1  
 Survivin  
Mutated, unique  
 p53   
 a-actinin-4  
 Malic enzymes  
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1.3.3 Application of computational methods for MHC-binding peptides 
and epitopes prediction   
To facilitate the discovery of T-cell epitopes, computational methods for predicting MHC-
binding peptides [238-244] and T-cell epitopes [223,242,245-249] have been developed. 
These methods predict MHC-binding peptides and T-cell epitopes by using binding motifs 
[240,241,244], quantitative matrices of structure-affinity relationships [242], structure-
based methods [239], and statistical learning methods such as ANN [238,246] and SVM 
[246,250]. These methods achieve impressive prediction accuracies of 70%~90% for the 
binders and 40%~80% for the non-binders of selected MHC alleles [238-244]. T-cell 
epitope prediction accuracy has been further improved by integrating MHC-binding 
peptide prediction with proteasomal cleavage and TAP transport [223,231,247-249,251]. 
 
The application range and accuracy of in silico T-cell epitope prediction approaches can 
be affected by several factors. Most prediction systems have been developed for peptides 
of a few fixed lengths, 8, 9 and 10mers for MHC Class I and 9, 13 and 15mers for MHC 
Class II alleles, with the majority of these focusing on 9mers only [238-244]. While the 
longer peptides have been studied by using all of their constituent sequential segments of 
fixed lengths [238], this introduces some non-binder segments as binders. Some binders of 
longer lengths form mini-hairpin-like structure with the central section unattached and the 
two ends attached to the binding groove [252]. By fixing a shorter length, these peptides 
may not be adequately represented. Moreover, most studies have used a relatively small 
number of non-binders to train the respective prediction system, typically no more than 
100 peptides [238-244], which may not be enough to cover the vast sequence space of 20
n
 
possible sequences for an n-mers peptide. This inadequate representation of non-binders 
likely leads to a higher false binder rate. Some of the methods use sequence 
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straightforwardly for representing peptides, instead of their structural and physicochemical 
properties [243]. Consequently, the derived prediction systems tend to be less effective for 
peptides non-homologous to the known binders. Moreover, most studies cover a limited 
number of MHC alleles partly due to the lack of statistically significant number of known 
peptides in commonly studied length ranges. 
 
These problems may be partially alleviated if the prediction algorithm is based on peptides 
of flexible lengths and sequence-derived structural and physicochemical properties, and 
the training is conducted by using a sufficiently diverse set of non-binders. A suitable 
method for accommodating these features is support vector machines [253]. SVM has 
shown promising capability for predicting proteins of varying lengths that belong to a 
specific functional class from sequence-derived structural and physicochemical properties 
[254,255]. Improved performance has been archieved while predicting novel proteins non-
homologous to other proteins [255,256]. MHC-binding peptides also possess similar 
characteristics in that they also share some structural and physicochemical features to 
facilitate MHC binding [257-259]. Therefore, SVM is expected to be equally applicable 
for predicting MHC-binding peptides.  
Based on this assumption, our research group developed a SVM prediction system (MHC-
BPS) of 18 MHC Class I and 12 Class II alleles by using 4208~3252 binders and 
234333~168793 non-binders, and evaluated by an independent set of 545~476 binders and 
110564~84430 non-binders[260]. The comparison between MHC-BPS and other popular 
computational methods such as MHCBN, BIAS and AFIPHITH suggested that this tool 
works more efficiently than other well-known methods for the same HIV test dataset with 
improved sensitivity and specificity.  Currently the reported sensitivities (true hit rates) of 
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three T-cell recognition software NetChop3.0, NetCTL1.2, and MHC-BPS (for the studied 
alleles in this work) are 81%, 98.5%, and 75–93.8%, and the reported specificities (true 
non-hit rates) are 48%, 32%, and 96.2–99.8% respectively [231,261,262]. In this work, 
MHC-BPS was therefore used to facilitate the in silico prediction of T-cell recognistion of 
newly derivied tumor antigens.  
1.4 Scope and research objective 
The main purpose of this study is to explore the usefulness of cancer molecular profiling 
toward ―personalized‖ cancer therapies. Collected molecular profiling is used to analyze 
the general and specific mode of actions of combination treatment and prediction, to 
evaluate the efficacy of molecular-targeted cancer therapy, and to design bioinformatics 
tools for tumor biomarker and antigens discovery. 
There are three main objectives of this work. The first objective of this study is to 
understand the mechanism that underlies the rational combination disease treatment 
(Chapter 3).  Due to the lower response rate observed in a single molecular targeted 
therapy, systems-oriented drug design, such as development of multi-component therapies, 
has been increasingly emphasized as a potentially more productive strategy in multi-
factorial diseases treatment. Understanding the molecular mechanisms underlying 
synergistic, potentiative and antagonistic effects of drug combinations is crucial to 
discover of novel efficacious combinations and multi-targeted agents from systemically 
perspective. Analysis of 117 selected drug combinations revealed 7 general and specific 
modes of action from the cases of synergistic, potentiative, additive, antagonistic and 
reductive combinations. It is suggested that knowledge of MI profiles of individual drugs, 
network crosstalk and regulation, and modes of actions of drug combinations are useful 
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starting points for investigating the effects of drug combinations. The molecular clues 
derived from the pharmacodynamic, toxicological and pharmacokinetic effects should be 
highlighted in the discovery of novel multicomponent therapies.  
 
The second objective of this study, as shown in Chapter 4, is to study the drug efficacy of 
anticancer tyrosine kinase inhibitors by using genetic and expression profiles of target and 
bypass gene in selected cancer types. In this chapter, we retrospectively analyzed 
mutation, amplification and gene expression profiles of targets and known bypass genes of 
4 well studied anti-cancer drugs, namely gefitinib, erlotinib, lapatinib, and trastuzumab. 
The clinical relevance of the correlation analysis against cell-line data was evaluated by 
comparing the levels of correlation between the individual profiles and the 
sensitive/resistant cell-lines with the reported level of correlations. The study suggested 
that the individual-profile tends to show good performance for sensitivity prediction and it 
is capable of predicting EGFR inhibitors sensitivity from NSCLC cell-lines at 
performance levels that reflect the sensitivity of real patients. Comparing to the individual 
profiles, the collective profiles showed a more balanced and improved correlation with 
sensitive and resistant cell-lines. This study suggests that an accurate patient 
differentiation, better safety profile, improved response rate and personalized treatment 
can be achieved by system-oriented molecular profiling approaches. Moerover, this study 
also indicates that disease molecular profiles are useful sources of discover new diagnostic 
and effective therapeutic targets with targeted disease population. In Chapter 5, we applied 
the similar strategy of genome-scale tumor-specific antigens (TSAs) search by collectively 
considering the tumor-specific mutations in differentially over-expressed genes in specific 
cancers. Virtual T-cell recognition analysis, including proteasomal cleavage, TAP 
mediated transport and MHC-I binding affinity prediction, were performed to ensure the 
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tumorgenic and epitopable of identified peptides. While the results show fair agreement in 
identifying know TSAs from melanoma and lung cancer, the known TSA hit rates (1.9% 
and 0.8%) are enriched by 29-fold and 35-fold over those of mutation analysis. The 
numbers of predicted TSAs are within the testing range of typical screening campaigns. 
 
The third objective of this study is to design bioinformatics tools for cancer biomarker 
discovery from microarray data. A cancer biomarker discovery system is developed by 
using gene selection strategies from microarray data. This system aims to identify stable 
and cancer relevant biomarkers with good prediction performance for disease diagnosis 
and differentiation. The strategies include the incorporation of multiple random sampling 
methods and the evaluation of gene-consistency into RFE gene selection procedure. The 
stable gene signatures may help us understand the mechanism of disease initiation and 
process, and may provide an insight for diagnosing disease, predicting disease types, 
prognosis of the outcome of a specific therapeutic strategy, and drug resistance before 
drug treatment. In Chapter 6, survival marker selection from lung cancer is used as a case 
study to evaluate the performance of the system. The stable gene signatures provide the 
biologists an opportunity to further investigate the role of derived genes in the initiation 
and progress of a disease, and give suggestions about potential disease targets for 
therapeutic molecule design.  
 
This thesis is divided into 7 chapters. Chapter 1 provides the background, current progress, 
and challenges of molecular-targeted therapy and cancer biomarker discovery. Chapter 2 
describes the methodology of this study. Methods for machine learning approach, 
especially the support vector machine, and microarray data analysis are described in detail.  
The rationale of current combination therapy is discussed in Chapter 3. Chapter 4 and 
Chapter 5 present the application of integrated molecular profiling for drug sensitivity and 
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novel target identification. The development and application of bioinformatics tools for 
cancer biomarker discovery is described in Chapter 6. Chapter 7 presents the conclusion 
and future work.  
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2 Methodology 
In this Chapter, a specific introduction of machine learning algorithms related to this 
study is described in the first Section of this chapter (Section 2.1), which includes Support 
vector machines, Probabilistic neural network, and Hierarchical clustering. Strategies of 
microarray data processing used for drug sensitivity, cancer biomarker, and tumor-
specific antigen are presented in section 2.2. Other important methodologies used for 
biomarker discovery are further introduced in Section 2.3. The last section introduces the 
methodologies are required for tumor-specific antigen prediction. 
2.1    Introduction to machine learning methods 
Machine learning is the study of computer algorithms capable of learning to improve their 
performance automatically through experiences [263]. The goal of machine learning is to 
extract useful information from data by building good probabilistic modes, which should 
be simple enough to be understood by human [264]. Machine learning is closely related to 
statistics and pattern recognition, since they all study the analysis of data. However, unlike 
statistics and pattern recognition, machine learning is primarily concerned with the 
algorithmic complexity of computational implementations [265]. These methods for 
classification employ computational and statistical methods to construct mathematical 
models from training samples which is used to classify independent test sample. The 
training samples are represented by vectors which can binary, categorical or continuous.  
Over the past 50 years, a variety of machine learning methods have been developed for 
solving real-life problems, for examples, Decision Tree (DT), Hidden Markov Model 
(HMM), Artificial Neural Networks (ANN), Support Vector Machines (SVM), and Self 
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organized map (SOM). All these methods could be classified along the distinction between 
supervised and unsupervised learning. In supervised learning, a classification system is 
given some inputs along with their answers. The purpose of the learning process is to 
specify a relationship between the sample vector input and the answers. Algorithms under 
this category such as decision trees, neural networks and support vector machines were 
widely applied in the field of pattern recognition. On the contrary, answer set would not be 
given to unsupervised learning approach, so it is basically left on its own to classify its 
inputs. Well-known clustering methods and self-organized maps are implemented in the 
unsupervised manner. Websites for the freely downloadable codes of some methods are 
given in Table 2-1. In the following section, three machine learning algorithms will be 
introduced, including support vector machines, neural network and hierarchical clustering. 
The specific properties of each method will be discussed briefly.  







k Nearest Neighbor  http://www.cs.cmu.edu/~zhuxj/courseproject/knndemo/KNN.html 



















NeuralWorks Predict http://www.neuralware.com/products.jsp 
NeuroShell Predictor http://www.mbaware.com/neurpred.html 
SVM 
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SVM light http://svmlight.joachims.org/ 
LIBSVM http://www.csie.ntu.edu.tw/~cjlin/libsvm/ 
mySVM http://www-ai.cs.uni-dortmund.de/SOFTWARE/MYSVM/index.html 




GIST SVM Server http://svm.sdsc.edu/svm-intro.html 
 
2.1.1 Support Vector Machines 
 
Support vector machines (SVM), a new machine learning method proposed by Vapnik in 
1995 [163,266,267], is a supervised classification algorithm that provides state-of-the art 
performance in a variety of applications, including image classification and object 
detection [268,269], text categorization [270], prediction of protein solvent accessibility 
[271], microarray data analysis [169,170,187,200], protein fold recognition [272], protein 
secondary structure prediction [273], prediction of protein-protein interaction [274] and 
protein functional class classification [254].  
Based on the structural risk minimization principle of statistical learning theory[275,276], 
SVM has shown outstanding classification performance due to the system can be less 
penalized by sample redundancy and has lower risk for over-fitting[277,278]. In linearly 
separable cases, SVM constructs a hyper-plane to separate two different groups of feature 
vectors with a maximum margin. For the cases of biomarker identification from cancer 
patients and healthy people, a feature vector is represented by ix , with gene expression 
descriptors of a patient as its components. The hyperplane is constructed by finding 
another vector w  and a parameter b  that minimizes 
2
w and satisfies the following 
conditions: 
 1,  for 1i ib y     w x  Class 1 (active)   (1) 
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 1,  for 1i ib y     w x  Class 2 (inactive)   (2) 
where yi is the class index, w is a vector normal to the hyperplane, /b w  is the 
perpendicular distance from the hyperplane to the origin and 
2
w  is the Euclidean norm 
of w. Base on w and b, a given vector x can be classified by 
 f(x) = [( ) ]sign b w x                                                                                  (3) 
 
A positive or negative f(x) value indicates that the vector x belongs to the cancer patient or 
healthy people respectively.  
In nonlinearly separable cases, which frequently occur in classifying gene expression 
profile of high dimension, non-linear SVM projects both positive and negative examples 
into a higher-dimensional feature space using a kernel function K(xi, xj) and then separates 
them in that space.  
An example of a kernel function is the Gaussian radian basis kernel (RBF), which has 
been extensively used and consistently shown better performance than other kernel 
functions in a number of classification studies [271-274,279-281]  
2 2/ 2




x x         (4) 
 
After project the examples into higher-dimensional feature space, the linear SVM 
procedure is then applied to the feature vectors in this feature space with the following 
decision function:  
0
1




f sign y K b

 x x x        (5)  
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Where the coefficients i
0







i i j i j i j
i i j
y y K 
  
  x x        (6) 
Under conditions:  
1






          (7) 
 
A positive or negative value from Eq. (3) or Eq. (5) indicates that the vector x belongs to 
the positive or negative group respectively.  
RBF kernel was chosen to construct the SVM model in cancer biomarker and tumor 
antigen discovery in this study. In practice, RBF kernel is the most widely used kernel 
function due to three reasons. First, linear kernel and sigmoid kernel can be treated as 
special cases since RBF kernel in certain parameters has the same performance as the 
linear kernel [282] or sigmoid kernel [283]. Second, comparing with polynomial kernel, 
RBF kernel has few parameters which influence the complexity of model selection. Third, 
RBF function has less computational cost compared with polynomial kernels in which 
kernel values may go to infinity or zero while the degree is large. Based on these reasons, 
we mainly applied RBF kernel SVM model in this study. We further choosed hard margin 
SVM and scanned  from 1 to 200 for the best discrepancy model for survival and death 
lung cancer patient. An integrated SVM software, LibSVM[284], was chosen to do the 
machine learning in this work.  
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Figure 2-1   Margins and hyperplanes of a 2D SVM model 
  
 
Linear SVM is the simplest form of SVM, in which the data represented as a p-dimensional vector (a list of 
p numbers) can be separated by a p-1 dimensional hyperplane. On each side of this p-1 hyperplane, two 
parallel hyperplanes can be constructed (Figure 2-1). The separating hyperplane is the one that maximizes 
the distance between these two parallel hyperplanes. Many linear hyperplanes (also called classifiers) can 
separate the data. However, only one can achieve the maximum separation. Under the assumption that the 
larger the margin or distance between these two parallel hyperplanes, the better of the generalization error of 
the classifier will be [285], the maximum separating hyperplane (also known as maximum-margin 
hyperplane) is clearly of interest.  
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2.1.2 Probabilistic neural network  
Artificial neural network (ANN) is a statistical learning method inspired by the biological 
nervous system, which employs a multilayered network and uses its connected structures 
for pattern recognition and classification [286,287](Figure 2-2). Neural networks perform 
impressively in various applications such as pattern reorganization, association, and 
transformation to modeling in process control or expert system. It is suitable for both 
discrete and continuous data (especially better for the continuous domain). Probabilistic 
Neural Networks (PNN) is an improved form of ANN that classifies objects based on 
Bayes‘ optimal decision rule[288]: 
         ( ) ( )i i i j j jh c f h c fx x         (8) 
where hi and hj are the prior probabilities, ci and cj are the costs of misclassification and 
fi(x) and fj(x) are the probability density function for class i and j respectively.  
A compound x is classified into class i if the product of all the three terms is greater for 
class i than for any other class j (not equal to i). In most applications, the prior 
probabilities and costs of misclassifications are treated as being equal. The probability 
density function for each class for a univariate case can be estimated by using the Parzen‘s 
nonparametric estimator[289]. 
           
1
1









x        (9) 
where n is the sample size,  is a scaling parameter which defines the width of the bell 
curve that surrounds each sample point, W(d) is a weight function which has its largest 
value at d = 0 and (x – xi) is the distance between the unknown vector and a vector in the 
training set. The Parzen‘s nonparametric estimator was later expanded by Cacoullos[290] 
for the multivariate case. 
Chapter 2: Methodology 
                                                                                                                                 52 











g x x W
n   

      (10)   
The Gaussian function is frequently used as the weight function because it is well 
behaved, easily calculated and satisfies the conditions required by Parzen‘s estimator. 
Thus the probability density function for the multivariate case becomes 












    
 
 x         (11) 
In this work, PNN was used to evaluation the classification performance of identified 
cancer biomarkers, and the programme is developed by our research group. 
 

















The network architectures of PNN are determined by the number of input samples and descriptors in the 
training set. There are 4 layers in a PNN. The input layer provides input values to all neurons in the pattern 
layer and has as many neurons as the number of descriptors in the training set. The number of pattern 
neurons is determined by the total number of samples in the training set. Each pattern neuron computes a 
distance measure between the input and the training case represented by that neuron and then subjects the 
distance measure to the Parzen‘s nonparameteric estimator. The summation layer has a neuron for each class 
and the neurons sum all the pattern neurons‘ output corresponding to members of that summation neuron‘s 
class to obtain the estimated probability density function for that class. The single neuron in the output layer 
then estimates the class of the unknown sample x by comparing all the probability density function from the 
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2.1.3 Hierarchical clustering 
Cluster analysis, which is one of the famous pattern recognition tools and has hierarchical 
and non-hierarchical methods, contributes to the objectivity in this sense. Instead of 
relying on any expertise or personal interpretations, clustering methods provide a 
mathematical approach with the multivariate data set. 
 
Hierarchical clustering is often portrayed as the better quality clustering approach, but is 
limited because of its quadratic time complexity[291,292]. Its quality may be observed if 
an appropriate distance metric can be defined to obtain the similarity, in this case a 
distance matrix.  Some of the best known distances metric for distance measures are 
Minkowski Metric, Euclidean Metric, Manhattan Metric, and Mahalanobis Distance. 
Minkowski metric is a more general form where some others can be extracted from. 
' 1/
1
( , ') ( | | )
d q q
k kk
d x x x x

                                                                (12) 
where ( , ')d x x  is the distance between x  and 'x . 
 
The Euclidean metric is a particular case of Minkowski metric. In this case we have the 




( , ') ( | | )
d
k kk
d x x x x

                                                                  (13) 





( , ') | |k kkd x x x x


                                                                         (14) 
It is also known as taxicab distance. 
Mahalanobis distance is 
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1
( , ') ( ') ( ')td x x x x x x

                                                                (15) 
where  is the inverse of the covariance matrix [293] 
 
There are two major types of hierarchical techniques: divisive and agglomerative. 
Agglomerative hierarchical techniques are used more commonly in microarray data 
analysis. The idea behind this set of techniques is to start with each cluster comprising of 
exactly one object and then progressively agglomerating (combining) the two nearest 
clusters until there is just one cluster left consisting of all the objects. Nearness of clusters 
is based on a measure of distance between clusters. All agglomerative methods require as 
input a distance measure between all the objects that are to be clustered. This measure of 
distance between objects is mapped into a metric for the distance between clusters (sets of 
objects) metrics for the distance between two clusters. The only difference between the 
various agglomerative techniques is the way in which this inter-cluster distance metric is 
defined[292]. Three graphical tools are often used to measure inter-clusters distances. 
These graphical methods are single linkage (distance between any two clusters is the 
minimum distance between two points such that one of the points is in each of the 
clusters.), complete linkage(distance between any two clusters is the minimum distance 
between two points such that one of the points is in each of the clusters) and average 
linkage methods (distance between any two clusters is the average distance between two 
points such that each pair has a point in both clusters)[294]. 
 
In this work, the hierarchical clustering  was carried out by using a software, Cluster, 
developed by EisenLab, which provides variety of types of cluster analysis and data 
processing on large microarray datasets [160].  
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Agglomerative clustering starts from leaf which keeps on adding together untill it reaches to root. 
The Single Linkage method firstly determines and stores the distance between each pair of 
clusters. (Initially, each point is considered a cluster by itself) Also, for each cluster determine its 
nearest neighbor. The pair of clusters with the smallest distance between them can be determined 
and agglomerated. Finally, the system updates the pairwise distances and the new nearest 
neighbors. This process is repeated till only one cluster is left.   
 
2.1.4 Parameters optimization and model validation 
To each machine learning method, parameters that represent the best prediction 
performance must be optimized by using training data sets. In this work SVM is trained by 
using a Gaussian RBF function which has an adjustable parameter σ. The range of σ is 
estimated from the recommedate values of LibSVM, where σ=sqrt( number of features) 
[295].  
For PNN, the only parameter to be optimized is a scaling parameter σ. Optimization of the 
parameter for each of these methods is conducted by scanning the parameter through a 
range of values. The set of parameters that produces the best prediction performance 
model can be determined by using test data sets or cross-validation methods, such as 5-
fold cross-validation or leave-one-out cross-validation (LOOCV). Finally, an independent 
data can be used to further validate the generalization capability of selected models.  
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Overfitting, a major concern in machine learning, is recognized as a violation of Occam‘s 
razor[296]. In the process of overfitting, the performance on the training samples still 
increases, whereas the performance on the test data worsens. Overfitting occurs, for 
example, because the model is too complicated, or irrelevant descriptors are used, or the 
training sample is too small or its dimension is too high, and the learning process is too 
long [297]. It is somewhat suspicious that a learning method, without any mechanism to 
reduce the risk of overfitting, can achieve a robust performance. Various regularization 
methods such as penalization, selection and shrinkage can be employed to reduce the risk 
of overfitting [298]. In real life application, a simply but frequently used method of 
overfitting evaluation and prevention is to compare the prediction accuracies determined 
by using cross validation methods with those determined by using independent validation 
sets[297]. It is suggested that a model that is not overfitted should not have large 
differences in the estimation of its predictive capability between cross-validation methods 
and independent validation sets.  
 
Microarray data are typically small size sample with high dimension descriptors, it is 
therefore overfitting need to be handled with caution during the period of gene selection. 
In this study, methods include LOOCV and validation with independent data set was used 
to parameters optimization and overfitting avoidance.  
2.1.5 Performance evaluation 
The performance of SVM can be measured as true positive TP (the number of positive 
examples which are correctly predicted as positive), false negative FN (the number of 
positive examples which are incorrectly predicted as negative), true negative TN (the 
number of negative examples which are correctly predicted as negative) and false positive 
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FP (the number of negative examples which are incorrectly predicted as positive) (Table 
2-2). 
 
The simplest way to evaluate the performance of a classification is overall accuracy (Q), 







       (16) 
Another three concepts, sensitivity (SE), specificity (SP) and Matthew‘s correlation 
coefficient MCC [299], which measure the positive and negative prediction performance 












       (18) 






           (19) 
In some cases such as epidemiology and the evaluation of diagnostic tests [300], positive 
predictive value (PPV, also called precision rate) and negative predictive value (NPV) are 
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Typically, the performance of screening large data sets can be measured by the quantities 
of yield (similar to TP, the number of positive examples which are correctly predicted as 
positive), hit-rate (similar to PPV, percentage of virtual hits that are known positives), 
false-hit rate (similar to NPV, percentage of virtual hits that are known negatives), and 
enrichment factor (EF, magnitude of hit-rate improvement over random selection) [301].  
hit rate
( ) / ( )
EF
TP FN TP FN TN FP

   
                                              (22) 
 
2.2 Methodology for microarray data processing 
2.2.1 Preprocessing of microarray data 
The goal of data preparation in microarray data analysis is the same as for all data mining, 
which is to transform the data to make it suitable for analysis and to aid in producing the 
best possible models. Data preparation usually takes place in two stages. The first stage 
contains those aspects of data preparation which are independent of any class data; these 
are scaling normalization, thresholding, filtering, and missing data estimation.  
Thresholding and filtering are ―low-level‖ forms of data cleaning; techniques of this kind 
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are broadly applicable, but the details will vary with the microarray device used to produce 
the data. The thresholding and filtering details given in this study are specific to the paper 
suggestions.  
 
The second stage of microarray data processing contains aspects which make specific use 
of classification information of given data set, and is broadly termed as ―feature selection‖. 
Here we are performing a new data reduction method by narrowing the set of features to 
those relevant to the specific set of disease classes to be analyzed.  
2.2.2 Normalization and scaling  
Normalization is the attempt to compensate systematic experimental and/or technical 
variations affects the measured gene expression levels, so that biological difference can be 
easily distinguished and the comparison of expression levels across samples can be 
performed. Although normalization alone cannot control for all systematic variations, 
normalization plays an important role in the earlier stage of microarray data analysis 
because expression data can significantly vary from different normalization procedures. 
Subsequent analyses, such as differential expression testing would be more important such 
as clustering, and gene networks, though they are quite dependent on a choice of a 
normalization procedure[4,160]  
 
Normalization methods differ for experimental platforms (eg. dual-labeled platforms 
versus single labeled platforms such as the Affymetrix GeneChip arrays) [302,303]. Yang 
et al.[303] summarized a number of normalization methods for dual labelled microarrays 
such as global normalization and locally weighted scatterplot smoothing (LOWESS) 
[304]. There have been some extensions for global and intensity-dependent 
normalizations. For example, Kepler et al. [305] considered a local regression to estimate 
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a normalized intensities as well as intensity dependent error variance. Wang et al.[306] 
proposed an iterative normalization of cDNA microarray data for estimating a normalized 
coefficients and identifying control genes. Workman et al.[307,308] proposed a roust non-
linear method for normalization using array signal distribution analysis and cubic splines. 
Chen et al.[309] proposed a subset normalization to adjust for location biases combined 
with global normalization for intensity biases. Edwards [308] considered a non-linear 
LOWESS normalization in one channel cDNA microarrays mainly for correcting spatial 
heterogeneity. For affymetrix microarray data, many methods have been proposed in the 
literature for signal quantification, detection and normalization. Robust Multichip Average 
(RMA [310]) and Affymetrix Microarray Suite (MAS) 5.0 algorithms are two popular 
methods. MAS 5.0 yields scaled, background-subtracted, nonnormalized signal intensities, 
while RMA provides background-subtracted, log-transformed signal intensities. In this 
study, the approach used in microarray data normalization is conducted according to the 
platform properties. Data extraction was performed using affy library in 
BioConductor[311], an R-based package[312]. 
Molecular descriptors are usually scaled before they are used in machine learning 
methods.  This is to ensure that all descriptors have equal potential to affect the prediction 
model. The similar procedure is also applied via processing the microarray data for 
biomarker discovery. Currently, a typical scaling procedure for microarray data is (1) 
normalizing the expression levels of each sample to zero-mean and unit variance, and then 
(2) normalizing the expression levels of each gene to zero-mean and unit variance over all 
the samples. This scaling method have been shown to perform well [313,314] and is 
applied in this thesis. 
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2.2.3 Threshold filtering 
Since many genes are not expressed at all or do not vary sufficiently to be useful, a 
threshold filtering operation is usually applied before subsequent analyses, such as 
differential expression testing and clustering. Typical filtering 1) eliminates genes showing 
abnormal expression intensities, and 2) excludes genes showing minimal variation across 
samples.  
 
Studies of expression measurement error, which process the same sample several times, 
have shown that the measurements were reproducible above values of 100, and much less 
reproducible below 100 [315]. For data believed to contain noise, a lower threshold of 100 
would be appropriate. For classification problems that are very robust (e.g. distinguishing 
different types of brain tumors), we used a threshold of 100 units because there was a 
sufficiently large number of genes correlated with the distinction that the threshold could 
be set high, thereby minimizing noise, and maximizing potential biological interpretation 
of the marker genes. For the more subtle distinctions (e.g. outcome prediction), few 
correlates of the distinction are found, and for this reason the threshold was set at a lower 
level (20 units) so as to avoid missing any potentially informative marker genes. The 
upper threshold is usually 16,000 because this level has been observed as the fluorescence 
saturation of the scanner; values above this cannot be reliably measured and image 
intensities above this level tend to have a non-linear correlation with the actual expression 
levels. [316,317] 
Gene variation filtering be realized through variation filter tests for a fold-change and 
absolute variation over samples, for example  
MaxValue(G) / MinValue(G) < 5   
MaxValue(G) – MinValue(G) < 500  
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where MaxValue(G) and MinValue(G) are the maximum and minimum values of gene G 
across all samples. If maxValue/minValue is lower than the specified ratio (5 in this case) 
and maxValue - minValue is lower than the specified difference (500 in the above dialog), 
then the gene are excluded from the resulting data set. 
 
In this study, threshold filtering was performed accordingly with the purpose of the 
analysis. The precise parameters of the variation filtering for data sets of cancer biomarker 
identification are provided in method section of Chapter 6 (In most cases the variation 
filter excluded those where max/min < 5 and max – min < 500. In some cases more or less 
stringent values were used.) 
2.2.4 Missing data estimation 
Missing values is a common issue existing in microarray data. The missing values arise 
from experimental errors due to spotting problems (cDNA), dust, poor hybridization, 
inadequate resolution, fabrication errors (e.g. scratch) and image corruption [318,319]. 
They could also come from the suspicious data with low expression (e.g. background is 
stronger than signal) or censored data [117]. Repeating experiments could be a solution 
but often not be a realistic option because of economic reasons or limitations in biological 
material [170,320]. However, many microarray data analysis methods, such as 
classification, clustering and gene selection methods, require complete data matrix. 
Therefore in many microarray projects, one needs to determine how to estimate missing 
values. Proper missing value estimation can significantly improve performance of the 
analysis methods [321-323]. The simplest way is to remove all genes and arrays with 
missing values, or to replace missing values with an arbitrary constant (usually zero), row 
(gene) average or column (array) average. The better approaches had also been proposed 
such as k-nearest neighbors method (KNN) [323], least square methods (LS) [320,324], 
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and principal component analysis (PCA) [325,326]. Among these estimation methods, 
KNN is the most widely used and is also a standard method for missing value estimation 
currently [134,321,323]. 
 
The KNN-based method for missing value estimation involves selecting k neighbor genes 
with similar expression profiles to the target gene (the gene with missing values in one or 
more arrays), and estimating the missing value of the target gene in specific array as the 
weighted mean of the expression levels of the k neighbor genes in this array. A popular 
KNN-based method is KNNimpute [323], which is the only imputation method available 
in many microarray data analysis tools for missing value estimation [116,327,328]. 
KNNimpute can be downloaded from Stanford Microarray Database [134,329]. In this 
thesis, KNNimpute is employed if the microarray data contains missing values. 
 
2.3 Feature selection procedure 
Feature (gene) selection is a necessary step in supervised learning methodologies as many 
classifier algorithms cannot deal with thousands of input variables and require some type 
of dimensionality reduction or prior selection. Meanwhile, the problem of choosing 
statistically significant molecular markers or differentially expressed genes provides a 
subset of candidate predictor-genes for further validation with traditioned experimental 
technique (e.g. RT-PCR, immunochemistry, etc.). In this work, a new REF based 
biomarker selection procedure was developed by incooperating random sampling, feature 
elimination and consistency evaluation is described in detail in the following setions. 
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2.3.1 REF based gene selection procedure 
A novel gene selection procedure method based on Support Vector Machines classifier, 
recursive feature elimination, multiple random sampling strategies and multi-step 
evaluation of gene-ranking consisitency was established (Figure 2-4): (1) After 
preprocessing the original data, by using random sampling method, a large number of 
training-test sample combinations are generated from the original data set. 
(2) The large number of sample combinations is divided into n groups, and each group 
contains 500 sample combinations. 
(3) In each training-test sample combination of each group, SVM and RFE are used to 
classify the samples (SVM classifiers) and rank the genes (RFE gene rank criteria). 
Therefore 500 gene ranking sequences are formed. 
(4) The consistency evaluation can be performed based on the 500 sequences and a certain 
number of genes (for example, k genes) can be eliminated.  
(5) Step (3) and (4) can be iteratively done until no gene can be eliminated.  
(6) The gene subset which gives us the highest overall accuracies of the 500 test sample 
sets can be selected as gene signatures of this group. Using this method, we can obtain n 
gene signatures.  
(7) The stability evaluation of the gene signatures can be performed by looking into the 
overlap gene rate of the n gene signatures. 
 
In the following section Recursive feature elimination [330] is introduced first and 
followed by a detailed introduction of the whole feature selection procedure. 
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 Figure 2-4 Overview of the gene selection procedure  
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2.3.2 Recursive feature elimination 
During gene selection procedure, the genes are ranked according to their contribution to 
the SVM classifiers. The contributions of genes are calculated by Recursive feature 
elimination (RFE) procedure, which sort genes according to a gene-ranking function 
generated from SVM classifier. As described in Section 2.1, SVM training process needs 
to find the solution for the optimum problem (also known as objective function or cost 
function) shown in equation (14), which can be rewritten as 
1
2
1 TT HJ  
       (22) 









0i , i=1,2,…n. 
Where
),(),( jiji xxKyyjiH  , K is the kernel function. 
 
The gene-ranking function of RFE can be defined as the change in the objective function J 
upon removing a certain gene. When a given feature is removed or its weight wk is 
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where the change in weight Dwk=wk - 0 corresponds to the removal of feature k.  
 
Under the assumption that the removal of one feature will not significantly influence the 
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Where H is the matrix with elements
),( jiji xxKyy , and H (-k) is the matrix computed by 
using the same method as that of matrix H but with its kth component removed.  
 
The change in the cost function indicates the contribution of the feature to the decision 
function, and serves as an indicator of gene ranking position [331].  
2.3.3 Random sampling, feature elimination and consistency evaluation 
 
In order to present statistical meaning, gene selection is conducted based on multiple 
random sampling. Each random sampling divide all microarray samples into a training set 
which contains half number of samples and an associates test set which contains another 
half number of samples. This sampling method can be treated as a special case of the 
bootstrap technique. Many researchers showed that bootstrap-related techniques present 
more accurate estimation than cross-validation on small sample sets [332,333]. By using 
this random sampling, thousands of training-test sets, each containing a unique 
combination of samples, are generated. These thousands of randomly generated training-
test sets are randomly divided into several sampling groups, with equal number of 
training-test sets (such as 500 traing-test sets) in each group. Every sampling group is then 
used to derive a signature by RFE-SVM. 
 
In every training-test sampling group generated by multiple random sampling, each 
training-set (totally 500 training-test sets) is used to train a SVM class-differentiation 
system and the genes are ranked by using Recursive feature elimination (RFE), according 
to the contribution of genes to the SVM classifier. In order to derive a gene-ranking 
criterion consistent for all iterations and all the 500 training-test sets in this group, a SVM 
class-differentiation system with a universal set of globally optimized parameters, which 
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give the best average class-differentiation accuracy over all of the 500 test sets in this 
group, is applied by RFE gene-ranking function at every iteration step and for every 
training-test set. 
 
To further reduce the chance of erroneous elimination of predictor-genes, additional gene-
ranking consistency evaluation steps are implemented on top of the normal RFE 
procedures in each group: 
 
(1) For every training-set, subsets of genes ranked in the bottom (which give least 
contribution to the SVM classification procedure) with combined score lower than the first 
few top-ranked genes (which give highest contribution to the SVM classification 
procedure) are selected such that collective contribution of these genes less likely 
outweigh top-ranked ones; 
(2) For every training-set, the step (1) selected genes are further evaluated to choose those 
not ranked in the upper 50% in previous iteration so as to ensure that these genes are 
consistently ranked lower; 
(3) A consensus scoring scheme is applied to step (2) selected genes such that only those 
appearing in most of the 500 testing-sets were eliminated.  
 
For each sampling group, different SVM parameters are scanned, various RFE iteration 
steps are evaluated to identify the globally optimal SVM parameters and RFE iteration 
steps that give the highest average class-differentiation accuracy for the 500 testing-sets.  
 
The several signatures derived from these sampling-groups are then applied to evaluate the 
stability and performance. 
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2.4 Construction of the feature vector for peptide 
2.4.1 Feature vector for peptide 
Conventional computational methods, such as machine learning based approaches, have 
been widely applied in various protein studies. In protein classification problem, machine 
learning methods cannot accept the sequence information directly. It is essential to convert 
the sequences into numerical vectors as input. Various methods were proposed to 
construct a feature vector from protein sequence [238-244], most of which are 
straightforward by using original sequence directly or binary vector representation of the 
amino acid of the sequence. In this study, we constructed a digital feature vector from the 
encoded representations of tabulated residue properties including amino acid composition, 
hydrophobicity, normalized van der Waals volume, polarity, polarizability, charge, surface 
tension, secondary structure and solvent accessibility [254,274].  This well-formulated and 
high performance approach was firstly proposed by our research group [254,255]. 
Following are the detailed procedures of feature vector constructed for representing the 
structural and physicochemical properties of a given peptide.  
Given the sequence of a protein, its amino acid composition and the properties of every 
constituent amino acid are computed according to the amino acid physical and chemical 
properties, and used to generate this vector. The computed amino acid properties include 
hydrophobicity, normalized Van der Waals volume, polarity, polarizability, charge, 
surface tension, secondary structure and solvent accessibility [254]. Amino acids are 
divided into three groups for each properties such that those in a particular group are 
regarded to have approximately the same property[254].  
A typical peptide is mainly about 7~30 amino acids long in the case of MHC binding 
peptides study, which is quite shorter than protein sequence. For this reason, amino acids 
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are divided into three or even six groups in this study to improve the physical and 
chemical sensitivities of generated vectors. For instance, amino acids can be divided into 
hydrophobic (CVLIMFW), neutral (GASTPHY), and polar (RKEDQN) groups (Table 2-
3). Three descriptors, composition (C), transition (T), and distribution (D), are introduced 
to describe global composition of each of these properties. C is the number of amino acids 
of a particular property (such as hydrophobicity) divided by the total number of amino 
acids in a protein sequence. T characterizes the percent frequency with which amino acids 
of a particular property is followed by amino acids of a different property. D measures the 
chain length within which the first, 25%, 50%, 75% and 100% of the amino acids of a 
particular property is located respectively. Overall, there are 51 elements representing 
these three descriptors: 6 for C, 15 for T and 30 for D, with a six-grouped property.  
Overall, the feature vector of a peptide is constructed by combining the 51 elements of all 
of those 6-groups properties, 21 elements of those 3-groups properties and the 20 elements 
of amino acid composition in sequential order.  A total of 308 elements are used as feature 
vector for each protein as shown in Table 2-4.  
Table 2-5 gives the computed descriptors of the HLA-0201 binding peptide 
(VLFRGGPRGLLAVA [334]). The feature vector of a peptide is constructed by 
combining all of the descriptors in sequential order. 
2.4.2 Scaling of feature vector 
Molecular descriptors are usually scaled before they are used for machine learning 
methods.  This is to ensure that all descriptors have equal potential to affect the prediction 
model. There are four main types of descriptor scaling: autoscaling, range scaling, feature 
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weighting and Pareto scaling (Livingstone 1995 and Eriksson 2001). Range scaling is the 
most common type of descriptor scaling methods used in various applications. 
In range scaling, the minimum value of the descriptor is subtracted from the descriptor 
values and the resultant values are divided by the range: 
2 ( )
1










                                      (23) 
where min( )iA  and max( )iA  are the minimum and maximum value of descriptor i  
respectively. The range-scaled descriptors have a minimum and maximum value of -1 and 
1 respectively. Range scale can be carried out over any preferred range by multiplication 
of the range-scaled values by a factor. The disadvantage of range scaling is that it mainly 
depends on the minimum and maximum values of the descriptors, which makes it very 
sensitive to outliers.  
Table 2-3 Division of amino acids into different groups for different physicochemical 
properties. 
Property  Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 
Hydro-phobicity 
Type 0~0.043 0.165~0.359 0.45~0.501 0.616~0.738 0.825~0.88 0.943~1 
Amino Acids in Group RDE HNQKS TG ACPM VWY ILF 
Van der Waals 
volume 
Value 0~1.6 2.43~2.78 2.95~3 3.78~4.0 4.43~4.77 5.89~8.08 
Amino Acids in Group GAS CTPD NV EQIL MHK FRYW 
Polarity 
Value 0 0.352~0.456 0.6~0.608 0.648~0.696 0.792~0.8 0.864~1.0 
Amino Acids in Group VI LFWCMY PA TGS HQR KNED 
Polarizability 
Value 0~0.062 0.105~0.108 0.128~0.15 0.18~0.186 0.219~0.23 0.29~0.409 
Amino Acids in Group GAS DT CPNVE QIL KMH FRYW 
  Group 1 Group 2 Group 3 
Charge 
Type Positive Neutral Negative 
Amino Acids in Group KRH ANCQGHILMFPSTWYV DE 
Surface tension 
Value -0.20~0.16 -0.3~ -0.52 -0.98~ -2.46 
Amino Acids in Group GQDNAHR KTSEC ILMFPWYV 
Secondary 
structure 
Type Helix Strand Coil 
Amino Acids in Group EALMQKRH VIYCWFT GNPSD 
Solvent 
accessibility 
Type Buried Exposed Intermediate 
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Table 2-4 List of features for peptides  
 
Feature Description Number of group Number of dimensions 
Amino acid composition - 20 
Hydrophobicity 6 51 
Van der Waals volume 6 51 
Polarity 6 51 
Polarizability 6 51 
Charge 3 21 
Surface tension 3 21 
Secondary structure 3 21 
Solvent accessibility 3 21 
Total - 308 
 
Table 2-5 Computed descriptors of the HLA-0201 biding peptide (sequence: 
VLFRGGPRGLLAVA  [334]). The feature vector of a peptide is constructed by 
combining all of the descriptors in sequential order. 
Property Elements of descriptors 
Amino acid 
composition 
14.29 0.00 0.00 0.00 7.14 21.43 0.00 0.00 0.00 21.43 
0.00 0.00 7.14 0.00 14.29 0.00 0.00 14.29 0.00 0.00 
Hydro-
phobicity 
14.29 0.00 21.43 21.43 14.29 28.57 0.00 15.38 7.69 0.00 
7.69 0.00 0.00 0.00 0.00 7.69 0.00 7.69 15.38 7.69 
7.69 28.57 28.57 28.57 28.57 57.14 0.00 0.00 0.00 0.00 
0.00 35.71 35.71 35.71 42.86 64.29 50.00 50.00 50.00 85.71 
100.00 7.14 7.14 7.14 7.14 92.86 14.29 14.29 21.43 71.43 
78.57          
Van der 
waals volume 
35.71 7.14 14.29 21.43 0.00 21.43 7.69 15.38 15.38 0.00 
15.38 0.00 0.00 0.00 7.69 7.69 0.00 0.00 0.00 7.69 
0.00 35.71 35.71 42.86 64.29 100.0 50.00 50.00 50.00 50.00 
50.00 7.14 7.14 7.14 7.14 92.86 14.29 14.29 14.29 71.43 
78.57 0.00 0.00 0.00 0.00 0.00 21.43 21.43 21.43 28.57 
57.14          
Polarity 
14.29 28.57 21.43 21.43 14.29 0.00 7.69 15.38 0.00 0.00 
0.00 7.69 7.69 7.69 0.00 7.69 7.69 0.00 15.38 0.00 
0.00 7.14 7.14 7.14 7.14 92.86 14.29 14.29 21.43 71.43 
78.57 50.00 50.00 50.00 85.71 100.00 35.71 35.71 35.71 42.86 
64.29 28.57 28.57 28.57 28.57 57.14 0.00 0.00 0.00 0.00 
0.00          
Polarizability 
35.71 0.00 21.43 21.43 0.00 21.43 0.00 23.08 15.38 0.00 
15.38 0.00 0.00 0.00 0.00 7.69 0.00 7.69 0.00 7.69 
0.00 35.71 35.71 42.86 64.29 100.0 0.00 0.00 0.00 0.00 
0.00 7.14 7.14 7.14 50.00 92.86 14.29 14.29 14.29 71.43 
78.57 0.00 0.00 0.00 0.00 0.00 21.43 21.43 21.43 28.57 
57.14          
Charge 
14.29 85.71 0.00 30.77 0.00 0.00 28.57 28.57 28.57 28.57 
57.14 7.14 21.43 50.00 78.57 100.0 0.00 0.00 0.00 0.00 
0.00          
Surface 
tension 
50.00 0.00 50.00 0.00 53.85 0.00 28.57 28.57 42.86 64.29 
100.00 0.00 0.00 0.00 0.00 0.00 7.14 7.14 21.43 71.43 
92.86          
Secondary 
structure 
50.00 21.43 28.57 38.46 30.77 0.00 14.29 14.29 57.14 78.57 
100.00 7.14 7.14 7.14 21.43 92.86 35.71 35.71 42.86 50.00 
64.29          
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Solvent 
accessibility 
78.57 14.29 7.14 23.08 7.69 7.69 7.14 14.29 42.86 78.57 
100.00 28.57 28.57 28.57 28.57 57.14 50.00 50.00 50.00 50.00 
50.00          
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3 Mechanisms of drug combinations: interaction and network 
perspectives 
Combination therapies are increasingly becoming an important part of modern disease 
therapy. By exploiting targeted, mechanism-based treatments through the use of rational 
combinations, the personalized treatment and increased treatment efficacy can be 
achieved. Understanding the molecular mechanisms underlying synergistic, potentiative 
and other contrasting combinations can greatly facilitate the discovery of efficacious 
combinations and multi-targeting agents as well. In this study, we performed an extensive 
investigation of 117 drug combinations for which the combination effect has been 
evaluated by rigorous analysis methods and for which relevant molecular interaction (MI) 
profiles of the drugs involved are available. Seven general and specific modes of action 
are summarized based on the MI profiles and pathway analyzing of identified drug 
combinations. The study also highlights the potential value of molecular interaction 
profiles and network regulation in the discovery of novel multicomponent therapies. 
3.1 Introduction 
In recent years, drug discovery efforts have primarily focused on identifying agents that 
modulate preselected individual targets[335-337]. While new drugs have continuously 
been discovered, there is a growing productivity gap, despite major spending on research 
and development and advances in technology development[338]. This problem arises 
partly because agents directed at an individual target frequently show limited efficacies 
and poor safety and resistance profiles, which are often due to factors such as network 
robustness[24-26], redundancy[27], crosstalk[28-30], compensatory and neutralizing 
actions[31,32], and anti-target and counter-target activities[33]. With such issues in mind, 
            Chapter 3: Mechanisms of drug combinations: interaction and network perspectives  
                                        
                                                                                                                                                                                        
75                                                                                                                                                                                                                                                  
systems-oriented drug design has been increasingly emphasized[60-63] and supported by 
several clinical successes of multicomponent therapies that use drug-combinations and 
multi-targeting agents[54,339-341].  
 
Increasing interests and efforts have been directed at the discovery of new 
multicomponent therapies[26,54,60-62,342,343]. However, uncovering drug combinations 
by direct screening is quite challenging due to the large number of potential combinations. 
A recent high-throughput screen was able to systematically test about 120,000 different 
two-drugs combinations[58]. Yet, the campaign of NCI60 anticancer drug screen count 
with a stock of above 100,000 potential therapeutic agents[344] , resulting in more than 5 
× 10
9 
drugs pairs. The situation is worse when we address combinations that consist of 
more than two drugs. More important, assuming that most drug combinations will not 
improve significantly over single drugs, attempting such high-throughput screens is highly 
inefficient. Understanding the molecular mechanisms underlying the known synergistic, 
potentiative and other contrasting combinations is therefore important to provide general 
guideline for efficacious experimental design.   
 
Knowledge of the molecular mechanisms of currently explored multicomponent therapies 
provides useful clues for discovering new drug combinations and multi-targeting agents. 
Some key characteristics of the modes of multicomponent therapies have been outlined 
[33,54,62,342]. The multiple targets can reside in the same or different pathways and 
tissues. Their modulation produces more-than-additive (synergistic) effects triggered by 
actions converging at a specific pathway site, and by negative regulation of network 
compensatory and neutralizing responses, drug resistance sources, and anti-target and 
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counter-target activities. However, the exact mechanism has been fully elucidated for few 
of the explored drug combinations[62,345-350]. 
 
Advances in the comprehension of biological systems, driven by genomics and 
proteomics, have recently provided a framework in which preclinical scientists can predict 
the biological responses resulting from the modulation of multiple independent targets in 
combination. These advances provide a change in extensive investigations of the 
molecular basis of drug actions and responses, yielding a substantial amount of 
information on experimentally determined drug-mediated molecular interaction (MI) 
profiles and regulatory activities of many drugs and compounds[65,335,336,351-355]. The 
MI profile of a drug describes its interactions with individual biomolecules, pathways or 
processes attributable to its pharmacodynamic, toxicological, pharmacokinetic, and 
combination effects. Apart from using them for guiding the development of target 
discovery technologies[356-362], MI profiles may be explored for gaining further insights 
into general modes of actions of multicomponent therapies and the mechanism of specific 
drug combinations. Such a task may be accomplished by analyzing the relevant MI 
profiles from the perspective of coordinated interactions and network regulations[29-31].  
 
In this work we introduce a systematic framework to analyze effective drug combinations 
by comprehensively investigating literature reported synergistic and other types of drug 
combinations. The action modes of some of combination therapies and the multi-target 
therapeutics that are currently on the market or in development were evaluated based on 
the identified MI profiles and pathways analysis. This pathway-focused approach to target 
discovery could help lead to a greater understanding of disease biology, helping outline 
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some of the important aspects of the discovery of multi-targeting therapeutics using 
compounds and cell-based in vitro assays.  
3.2 Materials and Methods  
3.2.1 Mechanism of drug interactions  
Often, multicomponent therapies are developed and evaluated from cell-based in vivo test 
via acting simultaneously at multiple molecular targets. Some terminology, such as 
synergism, additivity, antagonism, independence, inertism and coalism, are commonly 
used to describe the mechanism of joint action of two agents in these cell-based in vivo 
tests[363]. When two drugs produce the same broad therapeutic effect, their combination 
produces the same effect of various magnitudes compared with the summed effects of the 
individual drugs. A combination can be pharmacodynamically synergistic, additive or 
antagonistic if the effect is greater than, equal to, or less than the summed effects of the 
partner drugs [364]. Drug combinations may also produce pharmacokinetically 
potentiative or reductive effects such that the therapeutic activity of one drug is enhanced 
or reduced by another drug via regulation of its absorption, distribution, metabolism and 
excretion (ADME) [364]. A further type of drug combination is a coalistic combination, in 
which all of the drugs involved are inactive individually but are active in 
combination[363,365-367]. 
 
Synergistic and potentiative drug combinations have been explored to achieve one or more 
favourable outcomes: enhanced efficacy; decreased dosage at equal or increased level of 
efficacy; reduced or delayed development of drug resistance; and simultaneous 
enhancement of therapeutic actions and reduction of unwanted actions (efficacy synergism 
plus toxicity antagonism)[54,62,367]. The mechanisms underlying these activities can be 
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better understood by studying the mechanistically contrasting additive, antagonistic and 
reductive drug combinations.  
3.2.2 Methods for drug-combination analysis  
Attempts have been made during the past century to quantitatively measure the dose-effect 
relationships of each drug alone and its combinations and to determine whether or not a 
given combined treatment would gain a synergistic effect [363,364,368]. We have 
carefully chosen 7 rigorous drug-combination analysis methods, which have been 
developed and extensively used for analyzing combinations from experimental 
data[54,60,369]. These include checkerboard, combination index, fractional effect 
analysis, isobolographic analysis, interaction index, median drug effect analysis, and 
response surface approach[369-373].  
 
3.2.3 Collection of literature-reported drug combinations 
PubMed remains an optimal tool in biomedical electronic research, which is accessed for 
free and offers optimal update frequency and includes online early articles[374]. We 
therefore searched Pubmed[375] to select literature-reported drug combinations that had 
been evaluated by rigorous combination analysis methods and for which relevant MI 
profiles were retrievable from Pubmed. Combinations of the keywords ―drug 
combination‖, ―drug interaction‖, ―multi-drug‖, ―additive‖, ―antagonism‖, ―antagonistic‖, 
―infra-additive‖, ―potentiated‖, ―potentiative‖, ―potentiation‖, ―reductive‖, ―supra-
additive‖, ―synergism‖, ―synergistic‖, and ―synergy‖ were used to search publications 
since 1999. Coalistic drug combinations were not evaluated because few of them are 
described in the literature. This is partly due to the focus on combinations of drugs that 
include at least one active drug; indeed, a Medline search using ―coalistic‖ and ―coalism‖ 
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returns only one abstract. In addition, a significantly higher percentage of the studies 
published before 1999 are based on non-rigorous drugcombination methods. It has been 
suggested that analysis without using a rigorous method may easily lead to errors in 
assessing synergism with respect to such effects as enhancement and potentiation[369]. 
Therefore, to maintain the level of reliability of our assessment without substantially 
losing statistical significance, we focused on studies published since 1999, which 
constitute approximately 50% of all abstract entries selected by using our search method. 
3.3 Results and discussion 
3.3.1 Statistics of collected drug combinations and MI profiles 
We collected 315, 88 and 62 abstract entries describing pharmacodynamically synergistic, 
additive, and antagonistic combinations, respectively, and 56 and 33 abstract entries 
describing pharmacokinetically potentiative and reductive combinations, respectively. We 
then removed 158, 53, 32, 15 and 18 of these entries, respectively, that are redundant (for 
example, the same combination or the same paper selected by different keyword 
combinations); ambiguous (for example, synergistic in one report or condition, additive in 
another report or condition); and involving more than two drugs so as to focus on simpler 
cases. We further removed 45, 12, 1, 1 and 2 papers, respectively, that described studies 
using nonrigorous drug-combination methods. For the remaining 217 papers, we searched 
additional literature for experimentally determined MI profiles related to the mechanism of 
the claimed combination effects. Our analysis showed that the available literature-reported 
MI profiles are insufficient or irrelevant to substantiate the claimed combination effects in 
110 (59 synergistic, 11 additive, 17 antagonistic, 20 potentiative and 3 reductive 
combinations) of the 217 remaining papers. This led to the identification of 107 
combinations that can be substantiated by available literature-reported MI profiles. These 
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comprise 53, 12 and 12 sets of pharmacodynamically synergistic, additive and antagonistic 
combinations, and 20 and 10 sets of pharmacokinetically potentiative and reductive 
combinations, respectively. Examples of our evaluated drug combinations are shown in 
Table 3-1 to Table 3-7. Full data are summarized in Appendix Table S1 to Table S7, 
together with literature-reported mechanisms related to their therapeutic and combination 
effects. The statistical significance of our assessment can be roughly estimated as follows: 
for the 110 combination sets that are not substantiated by the available MI profiles, it is 
reasonable to assume a high percentage of these combinations may eventually be 
substantiated by additional experimental findings. If one further assumes that the reported 
combination effects substantiated by MI profiles are at least partly true, then the estimated 
ratio of truly and falsely reported combinations should be substantially larger than 107 out 
of 110. Hence, there seems to be a statistically significant number of combinations and 
sufficient percentages of true claims for supporting a fair assessment of general 
combination types and mechanisms of drug combinations from the information collected 
by our search methods. 
3.3.2 Mechanism underlying the pharmacokinetic and pharmacodynamic drug 
interactions 
The general and specific modes of action of 4 pharmacokinetic interactions and 3 
pharmacodynamic interactions were studied based on the 117 drug combinations. These 
include pharmacodynamically synergistic drug combinations due to anti-counteractive 
actions, complementary actions, and facilitating actions, pharmacodynamically additive 
drug combinations, pharmacodynamically antagonistic, potentiative and reductive drug 
combinations, which are described separately in the following sections. 
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The use of multiple drugs with different mechanisms or modes of action may direct the 
different combined-actions and therapeutic benefits. The possible favorable or undesired 
outcomes can be explained by analyzing the relevant MI profiles of drugs from the 
perspective of coordinated interactions and network regulations. Many of the MI profiles 
directly point to a specific bimolecular as the inhibiting, activating or regulating target. 
Therefore, it is possible to determine the combination effects based on the expected 
therapeutic and pharmacokinetic consequences of these interactions. Although the 
molecular target is not exactly specified, some of the profiles identify a specific pathway 
or process as a target, and provide the pharmacodynamic or pharmacokinetic consequence 
of the interaction. For instance, in literature reports, arsenic trioxide produces anticancer 
activity by generating reactive oxygen species, which is partially counteracted by its 
activation of the AKT survival pathway[376]. The anticancer agent 17-(allylamino)-17-
demethoxygeldanamycin (17-AAG) produces its effects by inhibiting the nuclear factor-
κb (NF-κb), AP-1 (also known as Jun) and phosphatidylinositol 3-kinase(PI3K)–AKT 
pathways61. Therefore, when used in combination, 17-AAG abrogates arsenic trioxide‘s 
counteractive activation of AKT survival pathway[376]. 
3.3.2.1 Pharmacodynamically synergistic combinations  
It is known that pharmacodynamically synergistic may arise from anti-counteractive 
action, complementary action, and facilitating action[377]. Anti-counteractive actions 
reduce network‘s counteractive activities against a drug‘s therapeutic effect. 
Complementary actions positively regulate a target or process by interactions with 
multiple target/pathway sites, different target subtypes and states, and competing 
mechanisms[60]. Facilitating actions are secondary actions of one drug in enhancing the 
activity or level of another drug. The 53 sets of synergistic drug-combinations arise from 
anti-counteractive (21 sets), complementary (26 sets), and facilitating (6 sets) actions of 
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the drugs were involved in this stduy. The therapeutic and synergistic mechanism of the 
sets in these three combination groups are summarized in Appendix Table S1, Table S2, 
and Table S3 (examples are given in Table 3-1, Table 3-2 and Table 3-3) respectively.  
 
Anti-counteractive actions may arise from interactions against anti-targets or counter-
target[33] and from negative modulations of network‘s robustness[24-26], crosstalk[28-
30], and compensatory and neutralizing actions[31,32]. These anti-counteractive 
synergistic combinations act on different targets of related pathways (8 sets), different 
targets of corss-talking pathways (4 sets), different targets of the same pathway that 
crosstalk to each other via another pathway (1 set) or regulate the same (5 sets) or different 
targets (2 sets), and different sites of the same target (1 set). An example of actions on 
different targets is the anticancer cisplatin-topotecan combination[378-380]. Cisplatin binds 
to the major groove of GG, AG and TACT sites in DNA[381], which is bypassed by 
network‘s counteractive activity of mutagenic translesional bypass replication across 
cisplatin-DNA adducts[382]. Topotecan inhibits topoisomerase I, interacts with DNA, and 
stabilizes covalent topoisomerase-DNA complex to block DNA replication forks[383]. 
The last function reduces the counteractive effect against cisplatin, resulting in synergism. 
An example of actions on the same target is the anticancer cisplatin-trabectedin 
combination[384].  Trabectedin interacts with DNA and its repair systems in a way 
different from cisplatin[384] via covalent binding to the 2-amino group of the central 
guanine of selected DNA pyrimidine-G-G and purine-G-C triplets[385], which induces the 
formation of unusual DNA replication intermediates that strongly inhibits DNA 
replication[386] which subsequently reduces the counteractive effect against cisplatin. 
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Complementary actions primarily involve positive regulation of a target or process by 
targeting multiple points of a pathway[387,388] and its crosstalk pathways[387-391], 
interacting with multiple sites[381,392], states[393], conformations[60], and mutant 
forms[60] of the target, collectively modulating target activity and expression[348], and 
simultaneously enhancing the positive and reducing the negative effects of the 
target[394,395]. These combinations act on different targest of the related pathways that 
regualated the same targets (8 sets) or the same target/process (5 sets), different targets of 
related pathways that regulate different targets (6 sets), different targets of the same 
pathway that regulate the same target (2 sets), different target subtypes in related pathways 
(1 set), and the same target at different sites (2 sets), overlapping sites (1 set), and different 
states (1 set). An example of actions on different targets is the elecoxib-emodin 
combination, which synergistically represses the growth of certain cancer cells[396]. 
Celecoxib, a COX-2 inhibitor, suppresses cancer growth by inactivating protein kinase 
Akt to stop its suppression of apoptosis[397]. Emodin suppresses cancer growth by 
inhibiting tyrosine kinase[398] and down-regulating Akt via inhibition of PI3K pathway to 
reduce Akt suppression of apoptosis[399]. The later complements celecoxib‘s inactivation 
of Akt[397] to reduce its suppression of apoptosis. 
 
Facilitating actions can be illustrated by two examples. One is the gentamicin-vancomycin 
combination that produces synergistic antibacterial action against penicillin-resistant 
bacterial strains[400]. Gentamicin targets bacterial ribosome, causes misreading of the 
genetic code and inhibits translocation to disrupt protein synthesis[401]. Vancomycin 
inhibits bacterial cell wall peptidoglycan synthesis[402] and alters permeability of cell 
membrane and selectively inhibits ribonucleic acid synthesis[403]. The later enhances 
gentamicin penetration into bacterial cells thereby increasing its bioavailability. The 
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second example is the BQ-123 and enalapril combination that produces synergistic 
endothelium-dependent vasodilation enhancement[404]. BQ-123 is an ETA receptor 
antagonist that mediates vasodilatation[405], enalapril up-regulates ETB as well as inhibits 
ACE leading to vasodilation[406,407].  BQ-123 antagonism of ETA[405] displaces 
endogenous ET-1 from ETA onto upregulated ETB to enhance its activity by effectively 
increasing ETB agonist concentration[404].  
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Table 3-1 Examples of literature reported pharmacodynamically synergistic drug combinations due to anti-counteractive actions, in which 




Drug A (mechanism of actions related 
to synergy) 
Drug B (mechanism of actions 






Possible mechanism of synergism in anti-
counteractive actions 
Different targets 
of the same 
pathway  
 
Oxaliplatin (DNA adduct, preferably 
bind to major groove of GG, AG and 
TACT sites,  complex conformation 
different from that of cisplatin[408], 
caused DNA strand break and non-DNA 
initiated apoptosis[409]) 
Irinotecan (DNA topoisomerase 
I inhibitor, increased EGFR 
phosphorylation in Lovo & 
WiDR cells[410]) 
Synergistic anticancer 
effect in AZ-521 and 
NUGC-4 cells, 




Effect of oxaliplatin‘s DNA adduct formation[408] 
may be partially reduced by certain mutant DNA 
topoisomerase I acting on DNA adduct to generate 
different topoisomers[412]. Irinotecan inhibition of 
DNA topoisomerase I[410] partially off-sets this 
counteractive activity 
Different targets 




DL-cycloserine (bacterial cell wall 
synthesis inhibitor[413]) 
Epigallocatechin gallate 
(disrupted integrity of bacterial 
cell wall via direct binding to 
peptidoglycan[413]) 







Cell wall alteration may induce counteractive cell wall 
synthesis to restore cell wall integrity[414], DL-
cycloserine inhibition of cell wall synthesis hindered 
the restoration thereby enhanced Epigallocatechin 




Paclitaxel (stabilized microtubules via 
alpha-tubulin acetylation[395] distorted 
mitosis to trigger apoptosis[415], 
induced p53 and CDK inhibitors[416], 
activated caspase-10, caspases-8, -6, and 
-3, leading to apoptosis[417], activated 
ERK [418] and CDK2[419], activated 
p38 MAP kinase and p53[420]) 
NU6140 (CDK inhibitor, down-






Use of both drugs promoted complementary apoptosis 
activities via triple actions of surviving down-
regulation by NU6140[421], microtubule 
stabilization[395] and caspase activation[417] by 
paclitaxel. Paclitaxel‘s promotion of apoptosis may be 
partially offset by its counteractive pro-growth 
activation of ERK[418] and CDK2[419], which may be 




Gefitinib (EGFR tyrosine kinase 
inhibitor, induced cyclin-dependent 
kinase inhibitors p27 and p21, decreased 
MMP-2 and MMP-9 enzyme 
activity[422]) 
Taxane (disrupted microtubule 
by binding to beta-tubulin[423], 
induced tumor suppressor gene 
p53 and cyclin-dependent kinase 
inhibitors P21, down regulated 
Bcl-2, leading to 
apoptosis[416]) 
Strong synergistic 





Taxane produced anticancer effect by inducing 
apoptosis[416] and microtubule disruption[423]. 
Crosstalk between EGFR and hypoxia-inducible factor-
1alpha pathways increased resistance to apoptosis by 
up-regulating survivin[28]. Gefitinib produced 
anticancer effect via EFFR tyrosine kinase inhibition, 
which offsets the counteractive EGFR-hypoxia 
crosstalk in resisting taxane‘s pro-apoptosis activity 
Different targets 
in the same 
pathway that 
crosstalks via 
Gefitinib (EGFR tyrosine kinase 
inhibitor, induced cyclin-dependent 
kinase inhibitors p27 and p21, decreased 
MMP-2 and MMP-9 enzyme 
PD98059 (MEK inhibiton[425]) Synergistic antitumor 







An autocrine growth loop critical for tumor growth is 
formed in EGFR-Ras-Raf-MEK-ERK network such 
that activated MEK activates ERK which upregulates 
EGFR ligands which promotes the autocrine growth 
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other pathway activity[422]) loop[426]. This loop produced counteractive activity 
against gefitinib or PD98059 by reducing the effect of 
MEK or EGFR tyrosine kinase inhibition. 
Simultaneous use of both drugs helps disrupting this 




AZT (HIV-1 reverse transcriptase 
inhibitor[427]) 








AZT resistance is partly due to phosphorolytical 
removal of the AZT-terminated primer[430], NNRTI 
inhibited RT catalyzed phosphorolysis, thereby reduced 
AZT resistance[429] 
 
Table 3-2 Examples of literature reported pharmacodynamically synergistic drug combinations due to complementary actions, in which synergy 
has been determined by well established synergy/additive analysis methods and its molecular mechanism has been revealed 
Combination 
target relation 
Drug A (mechanism of actions 
related to synergy) 
Drug B (mechanism of actions 
related to synergy ) 
Reported 




Possible mechanism of synergism in promoting 
complementary actions 
Different 





Azithromycin (hindered bacterial 
protein synthesis by binding to 50S 
component of 70S ribosomal 
subunit[431]) 
Ceftazidime (blocked penicillin-
binding proteins and thus bacterial 








Hindered protein synthesis by azithromycin[431] 
reduces penicillin-binding proteins to complement 
ceftazidime‘s blocking of penicillin-binding 
proteins[432] 
Different 





Aplidin (induced apoptosis by 
activating and clustering death 
receptors of FasL[434],  activating  
JNK, EGFR, Src, and 
p38MAPK[435], inhibited VEGF 
release and secretion[436]) 
Cytarabine (DNA binder[437], 
inhibited synthesome associated DNA 
polymerase alpha activity[438], 
inhibited RNA synthesis and DNA 
repair that lead to increased cellular 
stress and reduced survival protein 
Mcl-1 which subsequently activate 
caspase and apoptosis[439]) 
Aplidin synergizes 
with cytarabine in 
exhibiting anticancer 
activities in leukemia 
and lymphoma 






Both drugs complement each other‘s activity by 
inducing apoptosis via each of the two major cascades 
of apoptosis pathway, aplidin activated and clustered 
death receptors of FasL[434] which subsequently 
activates the receptor-mediated extrinsic cascade 
[441], cytarabine increased cellular stress and reduced 
survival protein Mcl-1 [439] which subsequently 
triggers the mitochondrial intrinsic cascade [441] 
Different 
targets of the 
same pathway 
that regulate the 
same target 
Paclitaxel (stabilized microtubules 
via alpha-tubulin acetylation[395], 
distorted mitosis to trigger 
apoptosis[415] and induce p53 and 
CDK inhibitors[416]) 
Tubacin (histone deacetylase 6 
inhibitor, inhibited microtubule 








Both drugs complement each other‘s microtubule 
stabilization effects through enhanced acetylation 
activity of alpha-tubulin by paclitaxel[395] and 
reduced deacetylation activity of alpha-tubulin 
deacetylase by tubacin[442] 
Different Gefitinib (EGFR tyrosine kinase ST1926 (activated MAP kinases p38 Synergistic Combination Gefitinib 's inhibition of EGFR is complemented by 
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inhibitor, induced cyclin-dependent 
kinase inhibitors p27 and p21, 
decreased MMP-2 and MMP-9 
enzyme activity[422]) 
and JNK, released cytochrome c, 





Index ST1926's activation of MAP kinases p38[443] that 
subsequently mediates internalization of EGFR[445], 








Iloprost (prostacyclin receptor agonist 
leading to vascular relaxation[447], 
activated phospholipase C [448] that 
promoted VEGF-induced skin 
vasorelaxation [449], self-regulated 
endothelial cell adhesion 
molecules[450]) 




Dose effect curve 
surpassed that of 
individual drug 
alone combined 
Sildenafil produced vasodilation activity by inhibiting 
phosphodiresterase-5[446], iloprost produced 
vasodilation activity by agonizing prostacyclin 
receptor[447] and by activating phospholipase C[448]. 
Targeting of multiple vasodilatation regulation 
pathways  NO/cGMP[452], MaxiK channel -mediated 
relaxation[453], and phospholipase C[448] contribute 






receptor agonist, produced 
antinociceptive effect via an 
endogenous sleep-promoting 
pathway[454]) 
ST-91 (agonist of alpha2 receptor of 
other subtypes, produced 
antinociceptive effect via upraspinal 
receptors and at both spinal and 







ST-91 modulated spinal and supraspinal 
pathways[455] that regulate pain[390] , 
dexmedetomidine promoted sleepiness[454] that 





Mycophenolate mofetil (inosine 
monophosphate dehydrogenase 
inhibitor, drug metabolite 
mycophenolic acid binds to the site 
of nicotinamide adenine 
dinucleotide cofactor[393]) 
Mizoribine (inosine monophosphate 
dehydrogenase inhibitor, drug 
metabolite mizoribine 
monophosphate binds to the enzyme 
in transition state having a new 
conformation[457]) 
Mild synergistic 







Simultaneous inhibition of enzyme reactant-state and 
transition state have the advantage of covering more 
conformational space for the inhibitors to better 





Paclitaxel (stabilized microtubules 
via alpha-tubulin acetylation[395], 
distorted mitosis to trigger 
apoptosis[415] and induce p53 and 
CDK inhibitors[416]) 
Discodermolide (stabilized 
microtubule dynamics and enhanced 
microtubule polymer mass[459] 
resulting in aberrant mitosis that 
triggers apoptosis [415] and induced 
p53 and CDK inhibitors[416], 
retained antiproliferative activity 
against carcinoma cells resistant to 






Explanation 1: Binding sites of both drugs 
overlapping, certain mutations resistant to one drug are 
ineffective against the other, thereby covering more 
diverse range of mutant types[60,340,462]. 
Explanation 2: One drug binds and induces 
conformational change in tubulin that increases the 
binding affinity of the other[60,463]. Explanation 3: 
These drugs may differentially bind to or affect 
different tubulin subtypes, microtubule architectures, 
or microtubule regulators, thereby covering more 
diverse range of microtubule dynamics[57,60,463,464] 
Same target Paclitaxel (stabilized microtubules Peloruside A (binds at a different site Peloruside A Berenbaum‘s Explanation 1: Binding sites of both drugs 
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(different 
binding sites) 
via alpha-tubulin acetylation[395], 
distorted mitosis to trigger 
apoptosis[415] and induce p53 and 
CDK inhibitors[416]) 
from that of paclitaxel, stabilized 
microtubules via binding to a unique 
site on the tubulin alpha, beta 
heterodimer[465]) 
synergizes with 
paclitaxel to enhance 
the antimitotic action 
of the drugs[465] 
combination index overlapping, certain mutations resistant to one drug are 
ineffective against the other, thereby covering more 
diverse range of mutant types[60,340,462]. 
Explanation 2: One drug binds and induces 
conformational change in tubulin that increases the 
binding affinity of the other[60,463]. Explanation 3: 
These drugs may differentially bind to or affect 
different tubulin subtypes, microtubule architectures, 
or microtubule regulators, thereby covering more 
diverse range of microtubule dynamics[57,60,435,463] 
 
 
Table 3-3 Examples of literature reported pharmacodynamically synergistic drug combinations due to facilitating actions, in which synergy has been 





Drug A (mechanism of actions 
related to synergy) 
Drug B (mechanism of actions 











binding protein 2A and thus 
bacterial cell wall 
synthesis[466]) 







Most penicilling-binding proteins are associated 
with membrane[468], membrane disruption by 
daptomyci [467] likely hinders the functions of 
penicilling-binding proteins and further expose 








(angiotensin AT1 receptor 
antagonist[469] ) 
Ramipril (angiotensin converting 
enzyme inhibitor[470], reduced 






leftwards compared to 
hypothetic additive 
curve 
Candesartan-cilexetil reduced systolic blood 
pressure by antagonizing angiotensin AT1 
receptor[469], ramipril reduced systolic blood 
pressure by inhibiting angiotensin converting 
enzyme[470], ramipril inhibited AT1 receptor 
agonist formation[471] thereby facilitating the 
action of candesartan-cilexetil by reducing AT1 
agonist-antagonist competition 
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3.3.2.2 Pharmacodynamically additive and antagonistic combinations  
Investigation of additive and antagonistic combinations provides contrasting perspectives 
for facilitating the study of synergistic combinations. Additive combinations (Appendix 
Table S4, examples in Table 3-4) result from equivalent or overlapping actions (9 sets) 
and independent actions (4 sets) of the drugs involved. Equivalent and overlapping actions 
involve interactions with different targets of the same pathways that equivalently regulate 
the same target (7 sets) or interactions that directly or indirectly affect the same site of the 
same target (2 sets). For instance, retinoic acid and trichostatin A additively inhibit cell 
proliferation by overlapping actions of up-regulation of retinoic acid receptor beta and 
reactivation of its messenger RNA (mRNA) expression[473]. Independent actions involve 
interactions at different targets of un-related pathways (3 sets) or different sites of the 
same target (1 set). For instance, doxorubicin and trabectedin produce additive anticancer 
effect via equivalent action of DNA intercalation and covalent guanine adduct formation 
at specific sites in DNA minor groove[474]. Both drugs bind to DNA in non-interfering 
manner, and doxorubicin prefers AT regions[475], while trabectedin prefer to alkylates 
guanines[476]. Recent progresses in designing dual platinum-intercalator conjugates[477] 
suggest that it is possible for both drugs to act without hindering each other‘s binding 
mode. 
 
Antagonistic drug combinations (Appendix Table S5, examples in Table 3-5) involve 
interfering actions at the same target (2 sets) or different targets of related pathways that 
regulate the same target (2 sets). One possible mechanism for antagonistic drug 
combination against the same target is mutual interference at the same site, which can be 
illustrated by the aminophylline-theophylline combination[478]. Both aminophylline and 
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theophylline are adenosine receptor antagonist and phosphodiesterase inhibitor, and 
involved in the release of intracellular calcium[478].  Adenosine receptor antagonist 
binding may be associated with non-unique binding site conformations[479]. Therefore, 
aminophylline or theophylline binding likely locks the receptor into a unique conformation 
that hinders theophylline or aminophylline binding, leading to antagonism. Likewise, 
inhibitor-activator, antagonist-agonist, blocker-substrate, and other mutually interfering 
pairs of drugs that bind to the same site may also produce antagonism. One mechanism for 
antagonistic drug combination against different targets of related pathways is the 
counteractive actions that hinder a partner drug‘s normal actions, which can be illustrated 
by the cytarabine and 17-AAG combination[437]. Cytarabine is a DNA binder[437] and 
17-AAG is a heat-shock protein antagonist that abrogates Akt survival pathway[376,480]. 
17-AAG antagonizes the cytotoxic activity of cytarabine, due in part to the induction of 
G1 arrest, which subsequently prevent the incorporation of cytarabine into cellular 
DNA[437]. 
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Table 3-4 Examples of literature reported pharmacodynamically additive drug combinations, in which additive action has been determined by 





Drug A (mechanism of action 
related to additive effect) 
Drug B (mechanism of action 











Different targets of 
the same pathways 
that regulate the 
same target 
 
Diazoxide (ATP-sensitive K+ 
channel opener[481], enhanced 





channel[481], activated channel 
via a cGMP-dependent protein 






dose effect data 
analysis 
Diazoxide enhanced ATPase activity of 
channel regulatory subunits[482], Dibutyryl-
cGMP activated channel via a cGMP-
dependent protein kinase [483,484] 
Same target 
(different sites with 
direct contact with 
agonist site) 
Propofol (interacted with 
GABA A receptor, acting on at 
TM3 segment of the beta2 
subunit[486]) 
Sevoflurane (interacted with 
GABA A receptor at Ser270 of 
the alpha1 and alpha2 
subunits[487]) 
Additive action in 
producing 
consciousness and 
movement to skin 




Propofol binds to TM3 segment of the beta2 
subunit[486], Sevoflurane binds to Ser270 of 
the alpha1 subunit[487]. As agonist binding 
site is located between alpha1 and beta2 
subunits[489], both drugs likely hinder 
agonist activity, thereby producing mutually 
substitutable actions. 




binding protein 2A and thus 
bacterial cell wall 
synthesis)[466] 
Imipenem (inhibited penicillin-
binding protein -1A, -1B, -2, -4 









Both acted at the same active site of 
penicillin-binding protein 2A[491] but at 
relatively high MICs of ≥32g/ml [466]. The 
relatively high MICs make it less likely for 
both drugs to saturate target sites, thereby 




Different targets of 
unrelated pathways 
Artemisinin (interfered with 
parasite transport proteins 
PfATP6, disrupted parasite 
mitochondrial function, 
modulated host immune 
function)[492] 
Curcumin (generated ROS and 
down-regulated PfGCN5 
histone acetyltransferase 
activity, producing cytotoxicity 






Artemisinin blocked calcium transport to 
endoplasmic reticulum[492], Curcumin 
induced DNA damage and histone 
hypoacetylation[261]. They act at different 





intercalator[475], preferred AT 
regions[475]) 
Trabectedin (formed covalent 
guanine adduct at specific sites 
in DNA minor grove[476], 






Both bind to DNA in non-interfering manner, 
one preferred AT regions[475], the other 
alkylated guanines[476]. Recent progresses in 
designing dual platinum- intercalator 
conjugates[477] suggested that it is possible 
for both drugs to act without hindering each 
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Table 3-5 Examples of literature reported pharmacodynamically antagonistic drug combinations in 2000-2006, in which antagonism has been 
determined by established methods and its molecular mechanism has been revealed. The antagonism of the listed drug combinations is due to 
interfering actions of the partner drugs in each combination. 
Combination target 
relationship 
Drug A (mechanism of 
action related to 
antagonism) 
Drug B (mechanism of 







Possible mechanism of antagonism of interfering 
actions 
Different targets of 
related pathways that 
regulate the same target 
 
Amphotericin B (formed 
ion channels in fungal 
membranes[495]) 
Ravuconazole (inhibited 
biosynthesis of ergosterol, a 









Amphotericin B can form ion channels more easily in 
the presence of ergosterol [495], ravuconazole 
inhibition of ergosterol synthesis[496] can therefore 
reduce the activity of amphotericin B in forming ion 
channels[495] 







adenosine receptor antagonist, 
phosphodiesterase 
inhibitor[478]) 
Antagonism of inhibitory 
adenosine autoreceptors 




Adenosine receptor antagonist binding may be 
associated with non-unique binding site 
conformations [479]. Aminophylline binding may 
lock the receptor into a unique conformation that 
hinder theophylline binding, thereby producing 
antagonistic effect 
other‘s binding mode 
Independen














bacterial protein synthesis by 
binding to 50S component of 
70S ribosomal subunit[431]) 
Imipenem (inhibited penicillin-
binding protein -1A, -1B, -2, -4 









Azithromycin hindered bacterial protein 
synthesis[431] at MIC of 0.12g/ml[494]. 
Imipenem blocked bacterial cell wall 
formation[490] at MICs of ≥32g/ml[466]. 
At dosages significantly lower than MICs for 
both drugs, azithromycin‘s reduction of 
penicillin-binding proteins[490] may be 
insufficient for imipenem to saturate these 
proteins, allowing its unhindered inhibition of 
these proteins[490], thereby these actions 
proceed in non-interfering manner 
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3.3.2.3 Pharmacodynamically potentiative combinations  
Potentiative drug combinations (Appendix Table S6, examples in Table 3-6) involve 
positive modulation of drug transport or permeation (7 sets), distribution or localization (8 
sets), and metabolism (3 sets). Potentiative modulation of drug transport or permeation 
enhances drug absorption via disruption of transport barrier, delay of barrier recovery, or 
reduction of first-pass excretion by inhibiting drug efflux. Potentiative modulation of drug 
distribution or localization increases drug concentration in plasma or specific tissue by 
blocking drug uptake and inhibiting metabolic processes that convert drugs into excretable 
forms. Potentiative metabolism modulation stimulates the metabolism of drugs into active 
forms, or inhibits the metabolism of drugs into inactive forms.   
            Chapter 3: Mechanisms of drug combinations: interaction and network perspectives  
                                        
                                                                                                                                                                                        
94                                                                                                                                                                                                                                                  
Typical potentiative effects can be illustrated by two examples. One is the enhanced 
absorption of antithrombotic low molecular weight heparin (LMWH) by chitosan[499]. 
LMWH is an antithrombin binder that inhibits activated coagulation factors. Chitosan 
reversibly interacts with components of tight junctions to widen paracellular routes, which 
increases permeability of LMWH across mucosal epithelia and thus enhances its 
absorption and improved therapeutic effect. The second example is 2'-deoxyinosine 
enhancement of antitumor activity of 5-fluorouracil in human colorectal cell lines and 
colon tumor xenografts[500]. 5-fluorouracil is metabolized by thymidine phosphorylase 
and others into a metabolite that stabilizes P53 due to RNA-directed effects. 2'-
deoxyinosine enhances thymidine phosphorylase activity and thus the metabolism of 5-
fluorouracil into active metabolite, which is subsequently incorporated into cellular 
ribonucleic acid (RNA) in place of the normal metabolite, yielding fraudulent RNA[501]. 
3.3.2.4 Pharmacokinetically reductive combinations   
Appendix Table S7 (examples in Table 3-7) summarized 2, 1 and 4 of the 7 sets of 
reductive drug combinations involve negative modulation of drug transport or permeation, 
distribution or localization, and metabolism respectively. Reductive modulation of drug 
transport or permeation typically blocks drug absorption or promotion of first-pass 
excretion by such actions as drug-drug aggregation to reduce permeability and inhibition 
of drug transport into plasma or target site. Reductive modulation of drug 
distribution/localization decreases drug concentration in plasma or specific tissue, which 
typically involves stimulation of metabolic processes for converting drugs into excretable 
forms and inhibition of metabolic processes for increasing drug concentration. Drug 
activity can also be reduced by metabolism modulation to covert drugs into inactive forms. 
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Table 3-6 Literature reported pharmacokinetically potentiative drug combinations, in which potentiative effect has been determined by 
established methods and its molecular mechanism has been revealed 
Biochemical class of 
potentiative effect  
Drug A (therapeutic or toxic effects and 
mechanism of actions) 
Drug B (mechanism of action related 
to potentiative effect) 
Reported potentiative effect [Ref] Possible mechanism of 
potentiative actions 
Positive regulation of 
drug transport or 
permeation 
AZT (anti-HIV, HIV-1 reverse transcriptase 
inhibitor) 
1,8-Cineole (formed hydrogen bonds 
with lipid head groups of stratum 
corneum lipids[502]) 
Enhanced cross-skin permeation of 
AZT[503] 
Enabled drug transport across 
skin possibly by disrupting 
absorption barrier via binding to 




Cerivastatin (cholesterol-lowering, HMG-CoA 
reductase inhibitor) 
Gemfibrozil (inhibited CYP2C8 
mediated metabolism of statins, 
inhibited OATP2 mediated uptake of 
cerivastatin[504]) 
Increased plasma concentration of 
statins by inhibiting their 
metabolism and uptake[504-506] 
Enhanced level of drug in plasma 




Doxorubicin (anticancer by DNA intercalation, 
converted to doxorubicinol by NADPH-dependent 
aldo/keto or carbonyl reductases [507], which 
produced cardiotoxicity by mediating transition 
from reversible to irreversible damage) 
Paclitaxel (stimulated enzymatic 
activity of NADPH-dependent 
aldo/keto or carbonyl reductases[507]) 
Enhanced cardiotoxicity by 
increasing metabolism of 
doxorubicin into toxic 
metabolit[507] 
Enhanced metabolism of drug 
into toxic metabolite 
 
Table 3-7 Examples of literature reported pharmacokinetically reductive drug combinations, in which reductive effect has been determined by 
established methods and its molecular mechanism has been revealed. 
Biochemical class 
of reductive effect  
Drug A (therapeutic or toxic effects and 
mechanism of actions) 
Drug B (mechanism of action 
related to reductive effect) 
Reported reductive effect [Ref] Possible mechanism of 
reductive actions 
Drug transport and 
permeation  
Amphotericin B (antileishmanial, formed 
aggregate with miltefosine[508]) 
Miltefosine (antileishmanial, 
formed aggregate with 
amphotericin B[508]) 
Reduced miltefosine-induced paracellular 
permeability enhancement in Caco-2 cell 
monolayers, inhibited uptake of both drugs, 
decreased transepithelial transport of both drugs[509] 
Reduced drug permeability and 
transport  
Drug distribution 
and localization  
Cisplatin (DNA inter- and intra- strand 
adduct, preferably bind to the major groove 
of GG, AG and TACT sites[381] thereby 
inhibited DNA polymerization and induced 




Reduced cisplatin-induced hepatotoxicity via 
formation of less toxic platinum complex, leading to 
inactivation of cisplatin or its highly toxic 
metabolites and to a different subcellular distribution 
of platinum[511] 
Reduced level of toxic drug by 
formation of less toxic complex 
and rearrangement of its 
subcellular distribution 
Drug metabolism  Warfarin (anticoagulant and antithrombotic, 
affected coagulation proteins that act 
sequentially to produce thrombin, 
metabolized by CYP3A4[512]) 
Quinidine (stimulated CYP3A4 
mediated metabolism of 
warfarin[513]) 
Reduced anticoagulanet effect of warfarin by 
stimulating its metabolism[513] 
Enhanced metabolism of active 
drug into inactive metabolite 
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3.3.2.5 Further assessment of popularly-used combinations  
A number of drug combinations have been heavily used in clinical applications for 
decades 1999[514-520]. For some of these classical drug combinations, the studies of their 
combination effects have been primarily conducted and published before 1999, and are 
frequently based on non-rigorous combination analysis methods. Thus, some of these 
classical combinations were not selected by our search procedure. Non-the-less, their 
popular use is a strong indication of their possible beneficiary combination effects in 
comparison to those of individual drugs. Therefore, it is of interest to assess the effects and 
mechanisms of these classical drug combinations. 
 
We identified 10 sets of classical drug combinations that were missed by our search 
procedure and contain no drug of abuse and withdrawn drug. Table 3-8 summarizes 
literature-described modes of actions of individual drugs, suggested combination type and 
possible mechanism of these combinations. The 10 combinations include 5 
synergistic[514,
,
515,519-521], 1 dual synergistic/additive[515], 1 non-
synergistic[515,
,
522] combinations. This non-synergistic combination has been replaced 
by single drug therapy in clinical setting[515]. For the remaining 3 combinations, we were 
unable to find a literature report indicating their possible types of combination. It is also 
noted that 4 of the 10 combinations have been studied by rigorous drug combination 
analysis methods. 
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Table 3-8 Assessment of clinically heavily-used drug combinations not collected by our literature search procedure. These combinations have 






Drug A (mechanism of actions 
related to combination effect) 
Drug B (mechanism of 
actions related to 
combination effect ) 
Reported combination 











 Amoxicillin (inhibited bacterial cell 










Clavulanate maintained level of amoxicillin 
at bacterial cell wall by inhibiting its 
degradation enzyme beta-lactamase 
inhibitor[525], thereby potentiatived the 
antibacterial activity of amoxicillin. 
Synergistic 






same target  
 
Salmeterol (beta 2-adrenoceptor 
agonist[526] that activated T-cell 
subtypes
189
 and promoted apoptosis 









Synergistic  in vitro T-
cell activation and 






Salmeterol‘s agonistic activity on beta 2-
adrenoceptor[526] is facilitated by  
fluticasone‘s up-regulation of beta2- 
adrenoceptor[530], leading to synergistic T-





targets of the same 
single-route pathway 
Different targets 






synthase inhibitor[531], metabolite 





No synergy detected  
against E. coli[522], S. 
somaliensis strains[515], 
therapeutic effect due to 
sulphamethoxazole 
alone, clinical use of 
combination 
discontinued and 
converted to single 
drug[515] 
Chequerboard Both drug target the same single-route folate 
metabolism pathway, with 
suphamethoxazole targeting the upstream 
dihydropteroate synthase[531] and 
trimethoprin targeting the dounsstream 
dihydrofolate reductase[533]. Redundent 
combination if suphamethoxazole effectively 
inhibits  dihydropteroate synthase, 
trimethoprin inhibition of dihydrofolate 
reductase serves as a backup when 
suphamethoxazole becomes less effective 




dependent RNA polymerase 
inhibitor[534]) 
Fusidic acid (interfered 
with bacterial protein 
synthesis by inhibiting 
the translocation of 
peptide elongation factor 
G from the 
ribosome[535]) 
Synergistic effect against 
S. somaliensis strains in 
Vitro[515] 
Chequerboard Mechanism unclear. There is a report that 
transcribing activity of DNA-dependent 
RNA polymerase from Ecoli is inhibited in 
vitro by addition of preparations of 
elongation factor Ts purified to 
homogeneity[536] 
Synergistic 
combination due to 
Different targets 
of related 
Erythromycin (binds to bacterial 
70S ribosomal complex to inhibit 
Penicillin (binds to DD-
transpeptidase that links 
Combination inhibited 
80% of 
Chequerboard Weakening of bacterial cell wall by 
penicillin[537] enhanced erythromycin 
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facilitating action pathways bacterial protein synthesis[537]) peptidoglycan, which 
weakens bacterial cell 
wall[538]) 
the S. somaliensis strains 
both synergically and 
additively[515] 
penetration into bacterial cells, thereby 






 Ergotamine (5-HT1B/1D receptor 
agonist[539], agonist of presynaptic 
dopamine receptors and alpha 2-
adrenoceptors, postsynaptic alpha 1 
and alpha 2-adrenoceptors, and 








inhibitor[543] )   
Symptomatic treatment 
of chronic vascular 




Caffeine increased water solubility of 
ergotamine to enhance its absorption[544], 
producing potentiative effect. Possible 
synergy may occur at dopamine receptor that 
require further investigation 
Additive 





Niacin (niacin receptor HM74A 
agonist that inhibited hepatocyte 
diacylglycerol acyltransferase and 
triglyceride synthesis leading to 
increased intracellular apo B 
degradation and subsequent 
decreased secretion of VLDL and 
LDL cholesterol[545]) 
Simvastatin (HMG-CoA 
reductase inhibitor that 
reduced synthesis of 
LDL cholesterol and 











Niacin reduced secretion of  VLDL and LDL 
cholesterol[545], simvastatin reduced 
synthesis of LDL cholesterol and 
triglycerides[546], both drugs equivalently 
reduced the level of LDL cholesterol 
Synergistic 






Cisplatin (DNA inter- and intra- 
strand adduct, preferably bind to the 
major groove of GG, AG and TACT 
sites[381] thereby inhibited DNA 
polymerization and induced DNA 
damage to trigger apoptosis[510]) 
Cyclophosphamide 
(metabolite formed DNA 
adduct at 
phosphoester[547] and at 
G N-7 positions[548], 
thereby inhibited DNA 
polymerization and 
induced DNA damage to 
trigger apoptosis[485]) 
Combination produced 
response rates of 60% to 




Cisplatin and cyclophosphamide formed 
DNA adduct at different sites[510
,
547]  
possibly at mutually compatable binding 
conformation because of the small size of the 
drugs, thereby complementing each other‘s 
actions on DNA 
Synergistic 
combination duo to 
facilitating action 





that stopped DNA 
synthesis[550], stabilized 





Synergism in inhibiting 
viability of L1210 
murine tumor cells[519] 
Comparison 
of activity 
Apart from methotrexate‘s anticancer 
dihydrofolate reductase inhibitory 
activity[549],  methotrexate metabolite 
formed reversible ternary complexes with 
fluorouracil on one site of thymidylate 
synthase to enhance its binding to the 
enzyme[552], thereby facilitating 
fluorouracil‘s anticancer thymidylate 
synthase inhibitory activity 
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Synergistic 
combination duo to 
complementary 
action 
Same target Diclofenac (non-selective COX 
inihibitor[553], COX1 inhibition 
increased brain KYNA formation to 
produce analgesic effect[553]) 
Paracetamol (major 
ingredient of Tylenol 
and Panadol, metabolite 
agonized cannabinoid 
receptors to produce 
analgesic 
effect[489,554], reduced 
active oxidized form of 




Synergy in treatment of 




Apart from its analgesic action via 
cannabinoid receptors[489,554], paracetamol 
reduced active oxidized form of COX to 
resting form[555]  to complement 
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Literature-described MI profiles appear to provide clues to the possible reasons for 9 of 
the 10 combinations. The synergistic salmeterol-fluticasone, methotrexate-fluorouracil, 
and erythromycin-penicillin combinations likely involve facilitating actions[530,537,552], 
diclofenac-paracetamol synergism may arise from complementary action[553,555]. 
Amoxicillin-clavulanate synergism possibly stems from potentiative enhancement of drug 
distribution[525]. We were unable to find information for assessing the reported 
synergism of rifampicin-fusidic acid combination[515].  The reported non-synergistic 
suphamethoxazole-trimethoprin combination appears to involve redundant actions in 
targeting upstream and downstream targets of a single-route pathway, with the 
downstream drug acting as a second line of defense[531,533]. For the 3 combinations that 
did not report the types of combination actions, cisplatin-cyclophosphamide combination 
likely produces synergistically complementary action[510,547], caffeine in the 
ergotamine/caffeine combination may involve the potentiation of ergotamine‘s action by 
enhancing its distribution[544], and niacin-simvastatin combination possibly produces 
additive effect duo to their equivalent actions[546]. 
 
3.3.2.6 Pathway analysis 
Pathway analysis is an effective approach for more comprehensive assessment of drug 
combination effects[557] as well as other drug activities and responses[558,559]. 
Advances in systems biology and other areas of biomedical and pharmaceutical research 
have enabled the integration of biomolecular network information, individual MI profiles, 
omics data, and disease information for drug validation and for understanding of the 
mechanism of drug actions[560-562]. It is therefore of interest to explore pathway analysis 
approaches for further studying some of the drug combinations evaluated by MI profiling. 
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Figure 3-1 shows the related pathways of cisplatin-trastuzumab combination (Appendix 
Table S1) based on reference and conventional pathways in KEGG database, and literature 
reports of drug pathways. Cisplatin is a DNA adduct that inhibits DNA polymerization 
and induces DNA damage to trigger apoptosis[510] (via P53-Bax, P53-Fas, P38-JNK, and 
p73 paths in Figure 3-1). Trastuzumab is an anti-HER-2/neu antibody that inhibits HER2-
mediated proliferation, angiogenesis, survival and migration [563] (via PI3K-AKT-mTOR 
and RAS-ERK paths). Cisplatin‘s induction of DNA damage and apoptosis may be 
attenuated by DNA repair systems in certain cell types[510] (via P53-P21 paths). This 
counteractive DNA repair action may be reduced by trastuzumab's anti-HER2 activity that 
suppresses DNA repair pathway [564]  and inhibits PI3K-AKT pathway[565] to enhance 
apoptosis[566]. The corresponding paths (dashed lines in Figure 3-1) involve the 
inhibition of HER2-PI3K-AKT mediated activation of P21, which reduces P21‘s activity 
in facilitating Chk1-P53-P21 and Chk1-P53-Gadd45a-P21 mediated induction of cell 
cycle arrest important for ATM mediated DNA repair process. Reduction of AKT activity 
by trastuzumab‘s inhibition of HER2 also lowers Mdm2‘s activity in facilitating P53 
degradation, which enhances P21 activation to counter-balance the reduced AKT 
activation of P21. We were unable to identify another counter-balance path, and it is 
unclear to what extent the Mdm2 mediated counter-balance path affects the overall state of 
P21 activation. 
 
In addition to the paths of protein-protein, protein-substrate, and protein-nucleic acid 
interactions, pathway analysis also needs to take into consideration of drug metabolism, 
transport, drug-drug interaction and complex formation. This can be illustrated by 
comparative analysis of the anticancer methotrexate-fluorouracil[549,552] and 
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antibacterial suphamethoxazole-trimethoprin[531,533] combinations (Table 3-8) that 
target human and bacterial folate metabolism pathways respectively but produce 
contrasting combination effects. The pathways affected by these two combinations are 
shown in Figure 3-2 and Figure 3-3 respectively. Although both combinations target 
upstream and downstream targets in a single route path leading to DNA synthesis 
(assuming that synthesis of 7,8-dihydropteroate is essential for bacterial growth), only the 
suphamethoxazole-trimethoprin combination shows the expected redundant effect such 
that effective inhibition of dihydropteroate synthase by suphamethoxazole renders 
trimethoprin inhibition of dihydrofolate reductase unnecessary for reducing DNA 
synethesis[531,533]. The un-expected methotrexate-fluorouracil synergism arises because 
methotrexate metabolite forms reversible ternary complexes with fluorouracil on one site 
of thymidylate synthase to enhance its binding to the enzyme [549,552] (dashed line in 
Figure 3-2), which synergistically facilitates fluorouracil‘s anticancer thymidylate 
synthase inhibitory activity. 
3.4 Conclusion 
Understandings of MI profiles of individual drugs, network crosstalks and regulations, and 
modes of actions of drug combinations are useful starting points for investigating the 
effects of drug combinations. For the analyzed cases of synergistic, potentiative, additive, 
antagonistic and reductive combinations, and likely many others, the literature-described 
MI profiles of the drugs involved appear to offer useful clues to the mechanism of 
combination actions from the perspectives of coordinated molecular interactions and 
network regulations. Clues to other aspects of pharmacodynamic, toxicological, and 
pharmacokinetic effects may also be obtained from the relevant MI profiles.   
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Discovery of efficacious drug combinations may be facilitated by targeting key efficacy 
and toxicity regulating nodes of positive[388,390] and negative regulations[26,28-30], 
anti-targets and counter-targets[33], compensatory and neutralizing actions[31,32], and 
transporter and enzyme mediated pharmacokinetic activities[499]. Both the discovery and 
the analysis of drug combinations can be facilitated by the collective use of different 
approaches and methods. For instance, signs of MI profiles as well as genes, pathways 
affected by or responsive to drug-combinations[440] and individual drugs[567-569] may 
be detected from gene expression or proteomics profiles by using unsupervised 
hierarchical clustering and supervised machine learning methods[440,567,570,571]. These 
combined with knowledge of the characteristics and activities of targets[337] and ADME-
Tox proteins[355] enable the prediction of responses and markers[567-569], unknown 
therapeutic actions[570], targets and characteristics[570,572,573], efficacies[574], 
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Figure 3-1 Pathways affected by cisplatin-trastuzumab drug combination, figure was 
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Figure 3-2  Human folate metabolism pathway affected by the combination of 
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4 Integrated molecular profiling for predicting drug 
sensitivity 
Receptor tyrosine kinase inhibitors elicit markedly different anticancer clinical response 
rates in clinical trials[575]. These rates have been linked to mutation and amplification of 
drug target, activating mutation of RAS, BRAF and PIK3CA, and PTEN loss-of-
function[576,577]. The possible correlation with target expression is under 
investigation[578]. Compensatory and alternative signaling that bypass target inhibition 
also influence drug response[31,579]. In this work, we retrospectively analyzed mutation, 
amplification and microarray gene expression profiles of drug target and 8-11 known 
bypass and downstream drug-resistant genes in 53 NSCLC and 31 breast cancer cell-lines 
sensitive or resistant to gefitinib, erlotinib, lapatinib, and trastuzumab. The individual 
profiles correlate with sensitive and resistant cell-lines at levels comparable to the 
reported correlations with clinical response rates. The collective profiles showed more 
balanced and improved correlation with sensitive and resistant cell-lines.  
4.1 Introduction  
Receptor tyrosine kinase inhibitors, such as EGFR inhibitor gefitinib and erlotinib, HER2 
monoclonal antibody trastuzumab, and multi-target EGFR and HER2 inhibitor lapatinib, 
are highly successful anticancer drugs that elicit markedly different anticancer clinical 
response rates in clinical trials [575,578,580,581]. For instance, the reported clinical 
response rates of gefitinib and erlotinib are 19.9% and 8.9% for the treatment of NSCLC 
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[575,578], and those of lapatinib and trastuzumab are 8~24% and 12-34% for the 
treatment of breast cancer [580,581]. These clinical response rates have been linked to 
mutation and amplification of the drug target, activating-mutation of downstream 
signaling genes RAS, BRAF and PIK3CA, and loss-of-function of the downstream 
signaling regulator PTEN [576,577]. The possible correlation of the response rates with 
the expression level of the drug target is also under investigation on the basis that the drug 
target such as EGFR is known to induce carcinogenesis via overexpression, amplification 
and somatic mutations [578]. 
Moreover, compensatory, alternative and redundant signaling that bypass target inhibition 
also influence drug response [31,579].  As summarized in Table 4-1, several such bypass 
mechanisms against the inhibition of EGFR or HER2 have been reported in the literature. 
While these mechanisms may appear scattered in individual patients, they collectively are 
expected to have a significant impact on the overall drug response rates in large patient 
populations. Therefore, collective consideration of the profiles of the bypass genes that 
regulate these bypass mechanisms together with usual consideration of the mutational, 
amplification and expression profiles of the drug targets and the relevant downstream 
genes may improve the prediction of clinical response to the relevant drugs.  
To determine whether the collective profiles show a more balanced and improved 
correlation with sensitive and resistant cell-lines than the individual profiles, we 
retrospectively analyzed mutational, amplification and microarray gene expression profiles 
of drug target and 8-11 known bypass and downstream drug-resistant genes in 53 NSCLC 
and 31 breast cancer cell-lines sensitive or resistant to gefitinib, erlotinib, lapatinib, and 
trastuzumab. The clinical relevance of the correlation analysis against cell-line data was 
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evaluated by comparing the levels of correlation between the individual profiles and the 
sensitive and resistant cell-lines with the reported level of correlations between these 
profiles and clinical data to determine if they are consistent with each other. 
Gefitinib and erlotinib have been approved for lung and pancreatic cancers, trastuzumab 
and lapatinib have been approved for breast cancer [576,582]. These drugs were evaluated 
because of their clinical relevance, knowledge of drug-resistance mechanisms, and 
availability of drug sensitivity, genetic and expression data for statistically significant 
number of cell-lines. The analyzed genetic data include drug sensitizing mutations and 
copy number variations in EGFR, activating mutations in RAS, BRAF, PIK3CA and 
inactivating mutations in PTEN directly contribute to the resistance against EGFR 
inhibitors (EGFR-I) or HER2 inhibitors (HER2-I) in significant percentage of patients 
(>2%) [576,577]. The expression data include microarray gene expression data of EGFR, 
HER2, PTEN, and several bypass genes directly contribute to the resistance against 
EGFR-I or HER2-I [31,579].  
4.2 Materials and Methods  
4.2.1 Data collection and preprocessing  
4.2.1.1 Drug sensitivity data for NSCLC and breast cell-lines  
We identified from literatures 48, 85, and 83 NSCLC cell-lines with available sensitivity 
data for gefitinib, erlotinib, and lapatinib, and 24 and 22 breast cancer cell-lines with 
available sensitivity data for trastuzumab and lapatinib. Overall, 46 NSCLC and 17 breast 
cancer cell-lines with sensitivity data for one or more drugs were collected. A cell-line was 
considered to be sensitive to a drug if the drug inhibits it at IC50≤1µM[583], otherwise it 
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was considered to be resistant to the drug. Sensitivity data of NSCLC cell-lines treated 
with gefitinib, erlotinib, and lapatinib, and breast cancer cell-lines treated with 
trastuzumab and lapatinib are summarized in Table 4-2 and Table 4-3 respectively. Table 
4-4 listed the literature reported performance of the prediction of EGFR-I sensitive and 
resistant patients by using mutation-based and amplification-based methods.  
4.2.1.2 Molecular profiling used for NSCLC and breast cell-lines  
The genetic and microarray gene expression data for 53 NSCLC and 31 breast cancer cell-
lines were collected from the published literatures, and COSMIC and GEO databases. We 
further identified from GEO database the microarray gene expression data for 6 lung and 9 
breast cell-lines of healthy people respectively. The relevant data and literature sources for 
these cell-lines are summarized in Table 4-2, 4-3, and 4-5. These expression data retrieved 
from GEO database were processed by using R[312] and Bioconductor[311]. Raw data 
obtained from GEO database was filtering with imagine intensity  threshold in the range of 
20 to 16,000 units and followed by RMA normalization  [310].  
Table 4-1 The main therapeutic target, bypass genes, drug-resistant downstream signaling or 
regulatory genes, and the relevant bypass mechanisms in the treatment of NSCLC and breast 
cancer  
 
Targeted Cancer: NSCLC 
Main Target for the Treatment of Specific Cancer: EGFR  
Drugs Evaluated: Gefitinib, Erlotinib, and Lapatinib 
Bypass Gene Bypass Mechanism 
HER2 
EGFR inhibition upregulated HER2 and induced compensatory EGFR-HER2, HER2-
HER3, HER2-HER4 heterodimerisation to promote alternative signaling[34-36]  
HER3 EGFR inhibition induced compensatory transactivation of HER3 signaling[31]  
IGF1R 
EGFR inhibition upregulated IGF1R and induced EGFR-IGF1R heterodimerization 
and activation of IGFR signaling[40,42] 
c-MET 
EGFR inhibition countered by focal amplification of MET that transactivates HER3 
signaling and interacts with EGFR to promote alternative signaling[39,41,46]  
PDGFR EGFR inhibition countered by PDGFR transactivation of HER3 signaling[41]  
FGFR Contributed to EGFR inhibitor resistance via alternative signaling[44]  
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PTEN loss or inactivating mutation contributed to EGFR inhibitor resistance by 
activation of Akt and EGFR[37,47]  
KRAS 
KRAS activating mutation mediated EGFR-independent signaling and contributed to 
EGFR inhibitor resistance[43,45]  
PIK3CA 
PIK3CA activating mutation mediated EGFR-independent AKT signaling and 
contributed to EGFR inhibitor resistance[584]  
AKT 
AKT activating mutation mediated EGFR-independent AKT signaling and could lead 
to resistance against EGFR inhibitor[585]  
 
Targeted Cancer: Breast Cancer 
Main Target for the Treatment of Specific Cancer: HER2 
Drugs Evaluated: Trastuzumab, Lapatinib 
Bypass Gene Bypass Mechanism 
EGFR 
Compensatory crosstalk of HER2-EGFR heterodimerisation promoted alternative 
ERBB signaling[34,36]  
HER3 
HER2 inhibition increased HER3 localization[579] and induced compensatory 
transactivation of HER3 signaling[31] , HER2-HER3, HER2-HER4 heterodimerisation 
promotes alternative ERBB signaling[34]  
IGF1R 
Contributed to HER2 inhibitor resistance via IGF1R-HER2 crosstalk and alternative 
IGF1R signaling[579,580] 
c-MET 
HER2 inhibition countered by overexpressed MET that interacts with EGFR to 
promote alternative signaling[46] 
ESR1 
HER2 inhibition induced compensatory ER signaling via activation of FOXO3a and 
caveolin-1 mediated ESR1 transcriptional activity[586]  
AXL 
HER2 inhibition countered by overexpressed AXL that crosstalks with HER3, ER to 





PTEN loss and inactivating mutation contributed to HER2 inhibitor resistance by 
activation of Akt[579] 
PIK3CA 
PIK3CA activating mutation mediated HER2 independent AKT signaling and 
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Table 4-2  Clinicopathological features and data source of NSCLC cell-lines used in this study. 
The available gene expression data, EGFR amplification status, and drug sensitivity data for 



























A427 NS PT NA   KRAS  R R 
A549 NS PT GSM108799   KRAS R R R 
Calu1 EC PE GSM108801   KRAS R R R 
Calu3 AD PE GSM108803    S  S 
Calu6 APC PT GSM108805   KRAS R R R 
Colo699 AD PF NA Y    R R 
DV90 AD PE NA   KRAS  R R 
EKVX AD PT NA     R R 
H1155 LCC PT NA NA NA KRAS,PTEN R R  
H1299 LCC LN GSM108807   NRAS R R R 
H1355 AD PT GSM108809   
KRAS, 
BRAF 
R R R 
H1395 AD PT GSM108811   BRAF R R R 
H1437 AD PT GSM108813    R R R 
H1563 AD PT NA   PIK3CA  R R 
H1568 AD PT NA Y Y   R R 
H157 SQ PT GSM108815   KRAS,PTEN R R R 
H1648 AD LN GSM108817    R R S 
H1650 AD PE GSM108819 Y  EGFR R R R 
H1666 AD PE GSM108821   BRAF R R S 
H1734 AD PT NA Y  KRAS  R R 
H1755 AD Live NA   BRAF  R R 
H1770 NE LN GSM108825    R R  
H1781 AD PE NA   ERBB2 R R R 
H1792 AD PE GSM171848 Y  KRAS  R R 
H1819 AD LN GSM108827 Y   R R S 
H1838 AD PT NA Y Y   R R 
H1915 SCC Brain NA     R R 
H1944 AD ST NA   KRAS  R R 
H1975 AD PT GSM108829 Y  EGFR R R R 
H1993 AD LN GSM108831    R R R 
H2009 AD LN GSM108833   KRAS R R R 
H2030 AD LN NA   KRAS  R R 
H2052 MT PE GSM171854     R R 
H2077 AD PT NA     R R 
H2087 AD LN GSM108835   
BRAF, 
NRAS 
R R R 
H2110 NS PE NA     R R 
H2122 AD PE GSM108837   KRAS R R R 
H2126 LCC PE GSM108839    R R R 
H2172 NS PT NA     R R 
H2228 AD PT NA     R R 
H23 AD PT GSM171868   
KRAS, 
PTEN 
 R R 
H2347 AD PT GSM108841   NRAS R R R 
H2444 NS PT NA Y  KRAS  R R 
H28 MT PE GSM171870     R R 
H2882 NS PT GSM108843    R R R 
H2887 NS PT GSM108845   KRAS R R R 
H3122 AD PT GSM171874     R R 
H322 AD PT GSM171876 Y   R R R 
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H322M AD PT NA     R S 
H3255 AD PT GSM108847 Y Y EGFR S S S 
H358 AD PT GSM108849   KRAS R R R 
H441 AD PT GSM108851   KRAS R R R 
H460 LCC PE GSM108853   
KRAS, 
PIK3CA 
R R R 
H520 SQ PT NA    R R R 
H522 AD PT NA Y    R R 
H596 AD PT NA Y  PIK3CA  R R 
H647 ADSQ PE NA   KRAS  R R 
H661 LC LN GSM171884     R R 
H820 AD LN GSM108855 Y  EGFR R R R 
HCC1171 NS PT GSM108857   KRAS R R R 
HCC1195 ADSQ PT GSM108859 Y  NRAS R R R 
HCC1359 SGC PT GSM108861    R R R 
HCC15 SQ PT GSM108863   NRAS R R R 
HCC1833 AD PT GSM171898     R R 
HCC193 AD PT GSM108865 Y   R R R 
HCC2279 AD PT GSM108867 Y Y EGFR S S R 
HCC2429 NS PT GSM171900     R R 
HCC2450 SQ PT GSM171902   PIK3CA  R R 
HCC2935 AD PE GSM108869   EGFR S S S 
HCC364 AD PT NA   BRAF  R R 
HCC366 ADSQ PT GSM108871    R R R 
HCC4006 AD PE GSM108873 Y Y EGFR S S S 
HCC44 AD PT GSM108875   KRAS R R R 
HCC461 AD PT GSM108877   KRAS R R R 
HCC515 AD PT GSM108879   KRAS R R R 
HCC78 AD PE GSM108881    R R R 
HCC827 AD PT GSM108883 Y Y EGFR S S S 
HCC95 SQ PE GSM108885    R R R 
HOP62 AD PT NA   KRAS  R R 
HOP92 AD PT NA Y    R R 
LCLC103H LCC PE NA     R R 
LCLC97TM LCC PT NA   KRAS  R R 
LouNH91 SQ PT NA Y  EGFR  R R 
PC9 AD PT NA Y  EGFR S S R 
SKLU1 AD PT NA   KRAS  R R 
* Determined from the ATCC (http://www.atcc.org) and DSMZ (http://www.dsmz.de) websites, and references 
therein.Abbreviations: AD, lung adenocarcinoma; APC, anaplastic carcinoma; EC, epidermoid carcinoma; LCC, large 
cell lung cancer; LN, lymph node; MT, mesothelioma; NA: not available; NE, neuroendocrine neoplasm; NS, not 
specified; NSCLC: non-small cell lung cancer; PE, pleural effusion; PF, pleural fluid; PT, primary tumor; R, resistant; S, 














                              Chapter 4: Integrated molecular profiling for predicting drug sensitivity 
114        
Table 4-3 Clinicopathological features and data source of breast cancer cell-lines used in this 
study. The available gene expression data, HER2 amplification status, and drug sensitivity data for 


































BT20 AC (A) PT -/-/- GSM320590   PIK3CA R R 
BT474 IDC (L) PT +/+/+ GSM320596 Y Y  S S 
BT549 IDC (B) PT -/-/- GSM320598   PTEN R R 
CAL51 AC (B) PE -/NA/- GSM320616   PIK3CA  R 
CAMA1 AC (L#) PE +/-/- # GSM320599 Y Y PTEN R R 
EFM19 IDC (L) PE +/+/- GSM320618   PIK3CA  R 
EFM192A AC (L) PE +/+/+ GSM320619 Y Y PIK3CA R R 
HCC1143 DC (A) PT -/-/- GSM320631    R  
HCC1395 DC (B) PT -/-/- GSM320630    R  
HCC1419 DC (L) PT -/-/+ GSM320624 Y Y  R  
HCC1954 DC (A) PT -/-/+ GSM320627 Y Y PIK3CA R  
HCC70 DC (A) PT -/-/- GSM320625    R  
HS578T C Sar (B) PT -/-/- GSM320601   HRAS  R 
JIMT-1 IDC (B#) PE NA GSM320639 Y Y PIK3CA R R 
KPL1 IDC (L#) PE NA GSM320622     R 
MCF7 Met AC (L) PE +/+/- GSM320602   PIK3CA R R 
MDA-MB-157 Med C (B) PE -/-/- GSM421871     R 
MDA-MB-175VII IDC (L) PE +/-/- GSM320603     S 
MDA-MB-231 Met AC (B) PE -/-/- GSM320604   BRAF,KRAS R R 
MDA-MB-361 Met AC (L) BR +/+/+ GSM320605 Y Y PIK3CA R R 
MDA-MB-415 AC (L#) PE +/-/- # GSM320606 Y Y PTEN R  
MDA-MB-435s IDC (B#) PE -/-/- # GSM320607 Y Y BRAF R R 
MDA-MB-436 AC (B) PE -/-/- GSM320608    R  
MDA-MB-453 Met C (L) PE -/-/+ GSM320609 Y Y PIK3CA,PTEN S  
MDA-MB-468 Met AC (A) PE -/-/- GSM320610   PTEN R R 
SK-BR-3 AC (L) PE -/-/- GSM320611 Y Y  S S 
T47D IDC (L) PE +/+/- GSM320612   PIK3CA R R 
UACC812 IDC (L) PT +/-/+ GSM320613 Y Y  S S 
UACC893 IDC (L) PT -/-/+ GSM320638 Y Y PIK3CA R S 
ZR-75-1 IDC (L) AF +/-/- GSM320614     R 
ZR-75-30 IDC (L) AF +/-/+ GSM320633 Y Y  S  
* Determined from the ATCC (http://www.atcc.org) and DSMZ (http://www.dsmz.de) websites, and references therein, 
or from this study. # information only obtained from Ref [596] 
Abbreviations: A, basal A subtype; AC, adenocarcinoma; AF, ascites fluid; B, basal B subtype; C Sar, carcinoma 
sarcoma; CWN, chest wall nodule; DC, ductal  carcinoma; IDC, invasive ductal carcinoma; Inf, inflammatory 
carcinoma; ILC, invasive lobular carcinoma; L, luminal subtype; Med C, medullary carcinoma, Met AC, metastatic 
adenocarcinoma; Met C, metastatic carcinoma; NA, not available; PE, pleural effusion; PT, primary tumor; R, resistant; 
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Table 4-4 The literature reported performance of the prediction of EGFR-I sensitive and resistant 
patients by using mutation-based and amplification-based methods  
Study Study Details 



























Chan et al. 
2006  
15 studies 
3,016 patients  
509 with EGFR mutations 





Wu et al. 
2007  
6 studies 
506 patients  
152 with EGFR mutations 





Murray et al. 
2008  
202 studies 
12,244 patients  
3,188 with EGFR mutations 





Uramoto et al. 
2007 
27 studies  
1170 patients  
437 with EGFR mutations 








1008 patients  
165 with KRAS mutation 








756 patients  
127 with KRAS mutation 





Uramoto et al. 
2007  
7 studies 
663 patients  
211 with EGFR amplification 






Table 4-5 Normal cell-lines (6 from the lung bronchial epithelial tissues and 9 from breast 
epithelial tissues) obtained from GEO database 
Gene Expression Sample 
ID of Normal Cell-line at 
GEO Database 
Cell-lines Source of Cell-lines Reference 
GSM427196 NHBE Normal human bronchial epithelial cells 
Ref  [605] 
GSM427197 NHBE Normal human bronchial epithelial cells 
GSM427198 BEAS-2B Immortalized bronchial epithelial cells 
GSM427199 BEAS-2B Immortalized bronchial epithelial cells 
GSM427200 1799 Immortalized lung epithelial cells 
GSM427201 1799 Immortalized lung epithelial cells 
GSM158659 BPE Normal human mammary epithelial cells 
Ref  [606] 
GSM158660 BPE Normal human mammary epithelial cells 
GSM158661 BPE Normal human mammary epithelial cells 
GSM158662 BPE Normal human mammary epithelial cells 
GSM158663 BPE Normal human mammary epithelial cells 
GSM158670 HME Normal human mammary epithelial cells 
GSM158672 HME Normal human mammary epithelial cells 
GSM158673 HME Normal human mammary epithelial cells 
GSM158674 HME Normal human mammary epithelial cells 
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4.2.2 Bypass mechanism of studied tyrosin kinase inhibitors  
The clinical efficacy of gefitinib, erlotinib, and lapatinib against NSCLC, and that of 
trastuzumab and lapatinib against breast cancer are mostly due to their inhibition of the 
main targets, EGFR and HER2, respectively [576,582]. Resistance to EGFR-I and HER2-I 
primarily arises from resistant mutations and amplification of the main target, activating 
mutations of down-stream signaling genes and loss of function of down-stream regulatory 
genes [31,576,577], and compensatory, alternative and redundant signaling genes 
frequently up-regulated or amplified in resistant patients [31,39,579]. Efflux-pumps, 
primarily responsible for the resistance of chemotherapy drugs [607], are not expected to 
significantly contribute to the resistance of the evaluated drugs because these drugs are 
either efflux-pump inhibitors [608-610], or monoclonal antibody un-affected by efflux-
pumps [611]. Table 3-1 summarizes the literature-reported 11 and 8 bypass-genes and 
downstream signaling and regulatory genes that directly contribute to EGFR-I and HER2-I 
resistance respectively, the corresponding bypass and resistance mechanisms, and relevant 
literatures.  
4.2.3 Drug sensitivity evaluation procedure   
We retrospectively evaluated the capability of the individual and combinations of the 
genetic and expression profiles of the main target, downstream signaling and regulatory 
genes, and bypass genes in Table 3-1 for predicting the sensitivity of the 53 NSCLC cell-
lines to gefitinib (6 sensitive, 38 resistant), erlotinib (7 sensitive, 46 resistant), and 
lapatinib (8 sensitive, 40 resistant), and that of the 31 breast cancer cell-lines to 
trastuzumab (5 sensitive, 19 resistant) and lapatinib (5 sensitive, 17 resistant). We 
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evaluated 11 mutation-based, amplification-based, expression-based, and combination 
methods. Due to inadequate copy number data, the amplification-based methods exclude 
the profiles of the bypass and downstream genes, which directly contribute to EGFR-I and 
HER2-I resistance [39], Non-the-less, copy number variation significantly influence gene 
expression, with 62% of amplified genes showing moderately or highly elevated 
expression [612]. Thus the effects of amplification of bypass genes are expected to be 
partially reflected by the expression profiles. 
In mutation-based method M1, a NSCLC cell-line is predicted as sensitive to a drug if 
EGFR contains a mutation sensitizing to the drug [578] and the drug inhibits EGFR at 
IC50≤500nM [583] (a stricter condition of IC50≤100nM gives the same results in all 
studied cases), otherwise it is predicted as drug-resistant. In mutation-based method M2, a 
NSCLC cell-line is predicted as sensitive to a drug if the drug inhibits EGFR at 
IC50≤500nM [583], and the un-inhibited KRAS has no activating mutation [45]. In 
mutation-based method M3, a NSCLC or breast cancer cell-line is predicted as sensitive to 
a drug if: 
 (1) the drug inhibits EGFR or HER2 at IC50≤500nM [583] and EGFR in NSCLC cell-
line has at least one sensitizing mutation [578]; 
 (2) the un-inhibited KRAS, NRAS, BRAF, PIK3CA in NSCLC cell-line [576] or 
PIK3CA in breast cell-line [578] has no activating mutation; 
(3) there is no PTEN loss or PTEN inactivating mutation in NSCLC [576] and breast 
[578] cell-line.  
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The mutation profiles of the relevant genes in each cell-line were generated by 
comparative sequence analysis with respect to the reported sensitizing, activating or 
inactivating mutations, which are summarized in Appendix Table S8 and Table S9. PTEN 
loss was assumed to occur if its microarray gene expression level is ≤1/5 of the median 
level of PTEN in the normal tissue cell-lines [613], based on the comparison of the 
western-blot staining of a PTEN-deficient cell-line ZR-75-1[614] with that of a PTEN-
normal cancer cell-line MCF-7 [614] (variation of this cut-off from 0 to 1/3 of the median 
level gives the same results in all studied cases). 
 
In amplification-based method A1 and A2, a NSCLC or breast cell-line is predicted as 
sensitive to a drug if EGFR or HER2 in the respective cell-line is amplified and inhibited 
by the drug at IC50≤500nM [583]. A gene in a cell-line is considered amplified if its copy 
number is ≥4 [615] in method A1 and ≥3 [616] in method A2 respectively. Copy numbers 
of the evaluated genes in the studied cell-lines were from literatures [616,617]. In 
expression-based method E1, a NSCLC or breast cell-line is predicted as sensitive to a 
drug if EGFR or HER2 in the respective cell-line is over-expressed [578] and inhibited by 
the drug at IC50≤500nM [583]. The expression-based method E2 differs from method E1 
by an additional condition: all un-inhibited bypass genes in a cell-line are not over-
expressed. Bypass genes are frequently up-regulated or amplified in resistant patients 
[31,39,579], which likely enable the promotion of drug-resistant signaling at significant 
levels. A gene in cancer cell-lines was assumed as over-expressed if its microarray gene 
expression level is ≥2-fold higher than the lowest level of the same gene in the 
corresponding healthy tissue cell-lines [618]. 
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4.3 Results and discussion  
4.3.1 Assesment of EGFR-I sensitivity prediction by mutation and amplification 
profiles 
The performance and clinical relevance of the methods M1, M2, A1 and A2 in predicting 
gefitinib and erlotinib sensitive and resistant NSCLC cell-lines were evaluated. The results 
are summarized in Table 4-6 together with the reported performance of the mutation-based 
[45,578,619] and amplification-based [619] methods in predicting EGFR-I sensitive and 
resistant patients, and are detailed in Appendix Table S10 and Table S11 together with the 
respective cell-line sensitivity data. The EGFR-I sensitizing mutations in these Tables are 
applicable to all 3 drugs against NSCLC. The methods M1 and M2 correctly predicted 
67% and 100% EGFR-I sensitive and 100% and 47% of EGFR-I resistant cell-lines 
respectively, which are comparable to the reported 77%~82% and 95%~98% accuracies in 
predicting EGFR-I sensitive, and 54%~84% and 19%~23% accuracies in predicting 
EGFR-I resistant patients by EGFR-I sensitizing mutation [578] and KRAS activating 
mutation [45] methods respectively. The method A1 and A2 correctly predicted 67% and 
67% EGFR-I sensitive and 100% and 83% of EGFR-I resistant cell-lines respectively, 
which are comparable to the reported 61% and 74% accuracy in predicting EGFR-I 
sensitive and resistant patients by the EGFR amplification method [619]. Thus, the 
evaluated methods are capable of predicting EGFR-I sensitivity from NSCLC cell-lines at 
performance levels that reflect the sensitivity of real patients.  
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Table 4-6 Comparison of the literature reported performance of the prediction of EGFR-I sensitive 
and resistant patients with that of EGFR-I sensitive and resistant NSCLC cell-lines by using 
mutation-based and amplification-based methods  




























Chan et al. 
2006  
15 studies 
3,016 patients  
509 with EGFR mutations 





Wu et al. 
2007  
6 studies 
506 patients  
152 with EGFR mutations 








12,244 patients  
3,188 with EGFR mutations 







27 studies  
1170 patients  
437 with EGFR mutations 
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165 with KRAS mutation 
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4.3.2 Assessment of integrated molecular profiling for predicting TKIs sensitivity  
Both the reported studies and our analyses in Table 4-6 indicated that the individual-
profile tends to show good performance for sensitive cell-lines at the expense of resistant 
cell-lines or vice versa. Combined mutation and amplification profiles have shown good 
correlation with clinical response [620]. It is of interest to evaluate whether more balanced 
performance can be achieved by using combination-profile methods. We therefore 
evaluated 5 two-profile methods in both NSCLC and breast cell-lines: M3+A1 (C1), 
M3+E1 (C2), M3+E2 (C3), A1+E1 (C4), and A1+E2 (C5), and 2 three-profile methods: 
M3+A1+E1 (C6) and M3+A1+E2 (C7).  Overlapping of drug resistant mutation was not 
identify between drug target and downstream genes in EGFR-I sensitive cell-lines, 
resulting the similar prediction performance of M1 and M3 in these cell-lines. We 
therefore used M3 in combined profiles. M2 is KARS drug resistant mutation-based 
method which was used to compare the reported diagnositic accuracy in clinical trails. 
Forthermore, gene amplification cutoff in A1 showed better performance than that of A2 
in drug resistant cell-lines. Only A1 was included in combined profiles. The results of 5 
two-profile and 2 three-profile methods are summarized in Table 4-7, and detailed in Table 
4-8 and Table 4-9 which also include the cell-line sensitivity data and the genetic and 
expression profiles of the main target, bypass genes and downstream signaling and 
regulatory genes. 
 
Overall, the combination-profile methods showed more balanced and improved predictive 
performance over the individual-profile methods. Consideration of the contribution of 
bypass genes substantially improved the predictive performance for resistant cell-lines, 
except one drug trastuzumab at the expense of reduced performance for sensitive cell-
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lines. C4 method showed slightly lower performance than the other combination methods 
probably due to its limited focus on the amplification and expression profiles of the main 
target only. The three-profile methods did not show improved performance over the two-
profile methods possibly due to two reasons. One is the substantial level of redundancy 
among drug sensitizing mutation, amplification and expression profiles and among drug 
resistant activating/inactivating mutation and expression profiles. Another is the high noise 
levels of microarray gene expression data [140] that negatively affect the performances of 
the combination methods with expression profiles.  
 
4.3.3 The distribution and coexistence of drug sensitive and resistant profiles 
Table 4-10 shows the distribution and coexistence of drug sensitizing mutation, 
amplification and expression profiles, and drug resistant mutation and expression profiles 
in the evaluated NSCLC and breast cancer cell-lines. In NSCLC cell-lines, EGFR-I 
sensitizing mutations are mostly distributed in EGFR-I sensitive cell-lines and 
substantially coexist with EGFR amplification and over-expression, and the resistance 
profiles are dominated by RAS activating mutation and HER3 over-expression, which are 
consistent with literature reports [31,578]. In breast cell-lines, HER2 amplification occurs 
in majority of the cell-lines and primarily coexists with HER2 over-expression, and with 
PIK3CA activating mutations and HER3 and IGF1R over-expression that dominate the 
resistance profiles, which is consistent with recent findings [31,579,621]. Up to 3 of the 7 
NSCLC cell-lines with EGFR-I sensitizing mutations and up to 6 of the 11 HER2 
amplified breast cancer cell-lines are EGFR-I and HER2-I resistant respectively,  primarily 
due to EGFR resistance mutation and over-expression of bypass genes and downstream 
genes, suggesting the importance of these genes in drug sensitivity analysis. Drugs 
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targeted on the EGFR resistance mutation and over-expressed bypass genes can 
compensate the resistant profiles observed in NSCLC and breast cancer cells.  Two 
NSCLC cell-lines (HCC366, HCC1650) with EGFR sensitizing mutation and one NSCLC 
cell-line with EGFR amplification (HCC2279) are with null resistance profile but are 
resistant to gefitinib/erloitinib and lapatinib respectively, probably due to other bypass 
mechanism not yet included in Table 4-1.  
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Table 4-7 Percentages of gefitinib,  erlotinib, or lapatinib sensitive and resistant NSCLC cell-lines, and percentages of trastuzumab or lapatinib 
sensitive and resistant breast cancer cell-lines correctly predicted by mutation-based method M1, M2, and M3, amplification-based method A1 
and A2,  expression-based method E1 and E2,  and combination methods C1, C2, C3, C4, C5, C6, and C7.  Ps and Pr is percentage for sensitive 















Based Method  
Expression- 
Based Method   
Combination of Two Methods Combination 
of Three 
Methods 






















PS 67% 100% 67% 67% 67% 50% 50% 83% 50% 50% 83% 83% 83% 83% 
PR 92% 39% 97% 100% 82% 95% 97% 97% 92% 97% 95% 97% 92% 95% 
Erlotinib 
(EGFR) 51(5/46) 
PS 80% 100% 80% 80% 80% 60% 60% 100% 100% 100% 100% 100% 100% 100% 
PR 93% 37% 98% 100% 87% 96% 98% 98% 96% 98% 98% 100% 96% 98% 
Lapatinib 
(HER2, EGFR) 48(8/40) 
PS 38% 100% 38% 38% 50% 38% 38% 50% 50% 50% 50% 50% 50% 50% 





PS - - 71% 71% - 100% 71% 57% 71% 57% 100% 71% 71% 57% 
PR - - 58% 74% - 74% 84% 95% 95% 100% 74% 84% 95% 100% 
Lapatinib 
(HER2, EGFR) 22(5/17) 
PS - - 80% 80% - 100% 100% 80% 80% 80% 100% 100% 80% 80% 
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Table 4-8 The genetic and expression profiles of the main target, downstream genes and regulator, and bypass genes of 53 NSCLC cell-lines, 
and the predicted and actual sensitivity of these cell-lines against 3 kinase inhibitors: gefitinib (D1), erlotinib (D2), and lapatinib (D3).  
NSCLC 
Cell lines 
Profile of Main Target (EGFR) 
Related to Drug Sensitivity 
 






Profile of Downstream 
Signaling Gene or Regulator 
Directly  Contributing to Drug 
Resistance 
 
Profile of Bypass Gene Directly  Contributing to Drug 
Resistance 
 
Predicted (Pre) and 
Actual (Act) 
Sensitivity to 




and Actual (Act) 
Sensitivity to 
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Notes: ―1‖ and ―0‖ indicates the corresponding profile is positive (over-expressed, amplified or mutated) and negative (not over-expressed, amplified or mutated) 
respectively.  ―S‖, ―R‖, ―NA‖, ―s-mut‖, ―r-mut‖, ‗a-mut‘, ―amp‖, ―over exp‖, ―pre‖, and ―act‖ stands for sensitive to drug, resistant to drug, no available drug sensitivity, drug 
sensitive mutation, drug resistance mutation, activating mutation, amplification, over expression, predicted drug sensitivity, and actual drug sensitivity respectively.  The 
prediction methods M1, M2, M3, A1, E1, E2, C1, C2, C3, C4, C5, C6, and C7 are described in the text. 
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Table 4-9 The genetic and expression profiles of the main target, downstream signaling genes and regulator, and bypass genes of 31 breast 
cancer cell-lines, and the predicted and actual sensitivity of these cell-lines aganist 2 kinase inhibitors trastuzumab (D4) and lapatinib (D3). 
Breast Cancer 
Cell line 
Profile of Main Target 
Related to Drug Sensitivity 
Profile of Downstream 
Signaling Gene or 
Regulator Directly  
Contributing to Drug 
Resistance 
Profile of Bypass Gene Directly  Contributing to 
Drug Resistance 
Predicted  (Pre) and Actual 
(Act) Sensitivity to 
Trastuzumab (D4) 
Predicted  (Pre) and Actual 

















































Pre by M3, A1, E1, E2, 






Pre by M3, A1, E1, E2, 





BT474 1 1 1 0 0 0 0 0 0 0 0 0 S,S,S,S,S,S,S,S,S,S,S S S,S,S,S,S,S,S,S,S,S,S S 
HCC1419 1 1 1 0 0 0 0 1 0 0 0 0 S,S,S,R,S,S,R,S,R,S,R S S,S,S,R,S,S,R,S,R,S,R NA 
MDA-MB-453 1 1 1 1 0 0 0 0 0 0 0 0 R,S,S,S,R,R,R,S,S,R,R S R,S,S,S,R,R,R,S,S,R,R NA 
MDA-MB-175VII 1 0 0 0 0 0 0 0 0 0 0 0 S,R,S,S,R,S,S,S,S,S,S NA S,R,S,S,R,S,S,S,S,S,S S 
SK-BR-3 1 1 1 0 0 0 0 0 0 0 0 0 S,S,S,S,S,S,S,S,S,S,S S S,S,S,S,S,S,S,S,S,S,S S 
ZR-75-30 1 1 1 0 0 0 0 1 0 0 0 0 S,S,S,R,S,S,R,S,R,S,R S S,S,S,R,S,S,R,S,R,S,R NA 
UACC812 1 1 1 0 0 0 0 0 0 0 0 0 S,S,S,S,S,S,S,S,S,S,S S S,S,S,S,S,S,S,S,S,S,S S 
UACC893 1 1 1 1 0 0 0 0 0 0 0 0 R,S,S,S,S,R,R,S,S,R,R R R,S,S,S,S,R,R,S,S,R,R S 
BT20 0 0 0 1 0 0 0 0 0 0 0 0 R,R,R,R,R,R,R,R,R,R,R R R,R,R,R,R,R,R,R,R,R,R R 
BT549 0 0 0 0 1 0 0 0 0 0 0 0 R,R,R,R,R,R,R,R,R,R,R R R,R,R,R,R,R,R,R,R,R,R R 





CAMA1 0 0 0 0 1 0 0 0 0 0 0 0 R,R,R,R,R,R,R,R,R,R,R R R,R,R,R,R,R,R,R,R,R,R R 





EFM192A 1 1 1 1 0 0 0 1 0 0 0 0 R,S,S,R,R,R,R,S,R,R,R R R,S,S,R,R,R,R,S,R,R,R R 
HCC1143 0 0 0 0 0 0 0 0 0 0 1 0 S,R,R,R,R,R,R,R,R,R,R R S,R,R,R,R,R,R,R,R,R,R NA 
HCC1395 0 0 0 0 0 0 0 0 0 0 0 0 S,R,R,R,R,R,R,R,R,R,R R S,R,R,R,R,R,R,R,R,R,R NA 
HCC1954 1 1 1 1 0 0 0 0 0 0 0 0 R,S,S,S,R,R,R,S,R,R,R R R,S,S,S,R,R,R,S,R,R,R NA 
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HCC70 0 0 0 0 0 0 0 0 0 0 0 0 S,R,R,R,R,R,R,R,R,R,R R S,R,R,R,R,R,R,R,R,R,R NA 
JIMT-1 1 1 1 1 0 0 0 0 0 0 0 0 R,S,S,S,R,R,R,S,S,R,R R R,S,S,S,R,R,R,S,S,R,R R 










MCF7 0 0 0 1 0 0 0 1 0 1 0 0 R,R,R,R,R,R,R,R,R,R,R R R,R,R,R,R,R,R,R,R,R,R R 





MDA-MB-231 0 0 0 0 0 0 0 0 0 0 1 0 S,R,R,R,R,R,R,R,R,R,R R S,R,R,R,R,R,R,R,R,R,R R 
MDA-MB-361 1 1 1 1 0 0 0 1 0 1 0 0 R,S,S,R,R,R,R,S,R,R,R R R,S,S,R,R,R,R,S,R,R,R R 
MDA-MB-415 0 0 0 0 1 0 0 1 0 0 0 0 R,R,R,R,R,R,R,R,R,R,R R R,R,R,R,R,R,R,R,R,R,R NA 
MDA-MB-435s 0 0 0 0 0 0 0 0 0 0 0 0 S,R,R,R,R,R,R,R,R,R,R R S,R,R,R,R,R,R,R,R,R,R R 
MDA-MB-436 0 0 0 0 0 0 0 0 0 0 0 0 S,R,R,R,R,R,R,R,R,R,R R S,R,R,R,R,R,R,R,R,R,R NA 
MDA-MB-468 0 0 0 0 1 0 1 0 0 0 0 0 R,R,R,R,R,R,R,R,R,R,R R R,R,R,R,R,R,R,R,R,R,R R 
T47D 0 0 0 1 0 0 0 1 0 0 0 0 R,R,R,R,R,R,R,R,R,R,R R R,R,R,R,R,R,R,R,R,R,R R 





Notes: ―1‖ and ―0‖ indicates the corresponding profile is positive (over-expressed, amplified or mutated) and negative (not over-expressed, amplified or mutated) 
respectively.  ―S‖, ―R‖, ―NA‖, ―s-mut‖, ―r-mut‖, ‗a-mut‘, ―amp‖, ―over exp‖, ―pre‖, and ―act‖ stands for sensitive to drug, resistant to drug, no available drug sensitivity, drug 
sensitive mutation, drug resistance mutation, activating mutation, amplification, over expression, predicted drug sensitivity, and actual drug sensitivity respectively.  The 
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Table 4-10 The distribution and coexistence of drug sensitizing mutation, amplification and expression profiles, and the drug resistance mutation 
and expression profiles in NSCLC and breast cancer cell-lines  
Cancer: NSCLC 
Main Target for the Treatment of Specific Cancer: EGFR  
Drugs Evaluated: gefitinib (D1), erlotinib (D2), and lapatinib (D3) 
Drug Sensitizing or 





Number of These Cell-Lines 
with Another Sensitizing 
Profile 
Number of These Cell-Lines with Another Resistance Profile 
Number of These 
Cell-Lines Sensitive/ 
Resistant to Drug  
Drug Sensitizing Profile Drug Resistance Profile 
Drug Sensitizing profile S1 S2 S3 R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 D1 D2 D3 
EGFR s-mut (S1) 7  3 2 2      1      4/3 4/3 3/4 
EGFR amp(copy no≥4) (S2) 4 3  2             4/0 4/0 3/1 
EGFR over exp (S3) 5 2 2         1     3/2 3/1 3/2 
Drug Resistance profile 
EGFR r-mut (R1) 2        1      0/2 0/2 0/2 
RAS a-mut (R2) 22    1    7 2    1 0/20 0/22 0/21 
BRAF a-mut (R3) 3   1     1      0/3 0/3 1/2 
PIK3CA a-mut (R4) 2        2      0/1 0/2 0/2 
PTEN loss (R5) 0                 
HER2 over exp (R6) 2        2      1/1 0/1 2/0 
HER3 over exp (R7) 18  1 7 1 2  2  1    1 1/14 0/17 3/12 
MET over exp (R8) 5   2     1      0/5 0/5 1/4 
PDGFR over exp (R9) 4                 
IGF1R over exp (R10) 0                 
FGFR1 over exp (R11) 0                 
VEGFR2  over exp (R12) 1   1     1      0/1 0/1 0/1 
Cancer: Breast cancer    
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Main Target for the Treatment of Specific Cancer: HER2     
Drugs Evaluated: trastuzumab (D1) and lapatinib (D2) 
Drug Sensitizing or 





Number of These Cell-Lines 
with Another Sensitizing 
Profile 
Number of These Cell-Lines with Another Resistance Profile Number of These 
Cell-Lines Sensitive/ 
Resistant to Drug 
Drug Sensitizing Profile Drug Resistance Profile 
Drug Sensitizing profile S1 S2 R1 R2 R3 R4 R5 R6 R7 R8 R9 D1 D2 
HER2 amp (copy no ≥4) (S1) 11 11  5 1   4 1    5/6 4/3 
HER2 over exp (S2) 13  11 7 1   6 2    5/8 5/4 
Drug Resistance profile 
PIK3CA a-mut (R1) 11       5 3    1/8 1/8 
PTEN ina-mut (R2) 4      1 2     0/4 0/3 
PTEN loss (R3) 0              
EGFR over exp (R4) 1    1        0/1 0/1 
HER3 over exp (R5) 9   5 2    3    1/6 0/6 
IGF1R over exp (R6) 4   3    3     0/2 0/4 
AXL over exp (R7) 3            0/2 0/2 
ESR1 over exp (R8) 0              
MET over exp (R9) 0              
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4.4 Summary 
In summary, collective analysis of mutation, amplification and expression profiles of 
target, bypass genes, and drug-resistant downstream signaling and regulatory genes are 
potentially useful for facilitating drug sensitivity prediction. Drug sensitivity prediction 
can be greatly potentiated by collective analyzing the profiles of target, bypass genes, and 
drug-resistant downstream signaling and regulatory genes. In the long run, an accurate 
patient differentiation, better safety profile, improved response rate and personalized 
treatment can also be archieved by this system-oriented approach. Development, 
integration and expanding application of next generation sequencing [622], microarrays 
[623], and copy number variation [624] detection tools and methods coupled with 
expanded knowledge of cancer biology and drug resistance bypass mechanisms enable 
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5 Collective approach for tumor-specific antigen discovery 
An important application of high-throughput technique, such as DNA microarray, is to 
discover potential disease targets which can be used for therapeutic molecule design and 
achieve the goal of effective disease treatment and prevention. Our previous study 
indicates that disease molecular profiles are useful sources of discover new diagnostic 
and effective therapeutic targets with targeted disease population. Tumor-speciﬁc antigens 
(TSAs), often overexpressed or mutated on particular tumors, but nonetheless present at 
lower frequencies in normal tissues, can potentially be explored for applications in cancer 
diagnosis and immunotherapy vaccine. The lack of effective vaccines for many cancers 
has prompted strong interest in improved TSA search methods. In this chapter, a 
collective method of analyzing genome-scale TSA was developed, which helps to identify 
the novel TSA in human cancer genome scale. We collectively analyzed genome-scaled 
tumor-speciﬁc somatic mutations, microarray gene expression data, and T-cell 
recognition of peptides derived cancer genome. Collectively considering the available 
profiles of TSAs showed a fairly prediction performance in melanoma and lung cancer.   
With improved data quality and analysis methods, the collective approach is potentially 
useful for facilitating genome-scale TSA search. 
5.1   Introduction 
Among the tumor antigens, some may be tumor specific, namely tumor-specific antigens 
(TSAs), while others may be also expressed by normal tissues, namely tumor-associated 
antigens (TAAs). In practice, cancer antigens targeted by active immunotherapies have 
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more often been tumor associated: overexpressed or mutated on tumors, but nonetheless 
present at lower frequencies in normal tissues [212]. TSA is therefore have been explored 
as sources of vaccines for cancer immunotherapy and immunoprevention [217,218,220] 
and biomarkers for cancer diagnosis.  
 
TSAs elicit cancer immunogenicity by presenting genetically variant and differentially 
over-expressed epitopes distinguished from those of normal cells [211,625,626]. Tumor-
speciﬁc mutations in these ―self-antigens‖ provide structural or physicochemical features 
distinguished from those of normal cells for them to be recognized as―non-self‖ [626]. 
Moreover, these antigens are primarily genes prevalently over-expressed in cancer 
patients, and less expressed in normal persons to override immune tolerance thresholds 
[627] and weak immunogenicity [211], and to prevent outgrowth of non-immunogenic 
variants in cancer patients[216]. Many known TSAs are cytotoxic T lymphocyte (CTL) 
epitopes [216,217,220] that are cleaved from intracellular protein antigens by 
proteasomes, transported to the endoplasmic reticulum by TAP, assembled with MHC-I, 
and presented at the surface of cancer cells to be recognized by CTLs [221] .  
 
In recent years, the diagnosis and treatment of cancers have improved, but the long-term 
survival rate, especially the survival rate for advanced cases, still has not been markedly 
increased. Therefore, it is very important to search for tumor-specific antigen (TSA) and 
tumor-associated antigen (TAA) to ensure the early detection, early diagnosis and early 
treatment of list of various cancers. In spite of extensive efforts, effective vaccine for most 
cancer types is still lacking partly due to difficulties in overcoming immunosuppressive 
activities[628,629], selective pressures towards non-epitope variants[630] and other 
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factors in immune tolerance and evasion [631,632].  There is a need to search for cancer 
vaccines from more diverse sources[37,216,217,219] that takes into consideration not only 
tumor-speciﬁc mutations and MHC-binding but also the expression proﬁles of the 
antigens, processing and transport of the epitopes, and availability of T-cell repertoire in 
speciﬁc tumors [220] 
 
The discovery of potential therapeutic targets from human cancers is greatly facilitated by 
microarray technology [211,629]. Furthermore, there have been signiﬁcant progresses in 
genome-wide proﬁling of tumor-speciﬁc somatic mutations[633-635] and in improving T-
cell epitope prediction by collective analysis of proteasomal cleavage, TAP mediated 
transport and MHC-binding[223,231,247-249,251,261]. These progresses make it possible 
to conduct genome-scale search of TSAs via collective analysis of tumor-speciﬁc 
mutations, expression proﬁles, and T-cell recognition of the epitopes that include the 
cleavage, transport and MHC-binding of the epitopes. 
 
This chapter covers the usage of collective approach in genome-scale search of TSAs from 
melanoma and lung cancer, which early on was found to have tumor-specific antigens and 
has been targeted frequently using the protein or peptide approach. Genome-scaled tumor-
speciﬁc somatic mutations, microarray gene expression data, and in silico T-cell 
recognition were incorporated into this collective approach. Collectively considering the 
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5.2  Materials and Methods 
5.2.1 Collection of genomic, mutation and expression data 
The human genome sequence (release 38) was obtained from NCBI database 
(http://www.ncbi.nlm.nih.gov/projects/genome/guide/human/), which contains 180,000 
full-length protein-coding transcripts. Tumor-specific somatic mutation data for melanoma 
and lung cancer were from comprehensive literature search from sources such as COSMIC 
database (release 35) and a number of other publications in PubMed (1970–March 2008) 
using key words “mutation” and “melanoma” or “lung cancer” in the title or 
abstract.Our search identified 2361 articles (2315 from COMIC database and 46 from 
PubMed), which report 841 and 340 somatic nonsynonymous mutations in 491 and 338 
encoded proteins for melanoma and lung cancer respectively.  
 
The microarray gene expression data for melanoma (GSE4845) and lung cancer 
(GSE1037) were from GEO database. The melanoma dataset contains the expression 
profiles of 33,000 genes from 12 melanoma patients and 3 normal persons, and the lung 
cancer dataset is composed of the expression patterns of 14,211 genes and 15,276 ESTs 
from 27 lung cancer patients and 19 normal persons.  
5.2.2 Collection of tumor-specific antigen  
Tumor cells expressing epitopes derived from TSAs and TAAs is recognized and 
destroyed by Cytotoxic T-lymphocytes (CTLs) derived from T8-lymphocytes (CD8+ T 
cells) [636] . CTLs recognize antigen on target and APCs[637] as epitopes composed of 
peptide fragments, 8–12 amino acids long, that are completed to MHC-I molecules [637-
639]. Several CTL epitopes restricted by HLA-A2, the most common human 
                                       Chapter 5: Collective approach for tumor-sepcific antigen discovery 
 
137 
histocompatibility molecule (40–50%), have been previously reported [640]. Definition of 
HLA-A restricted TSAs is thus an important step in the development of specific CTL-
based cancer immunotherapies.  
In this study, with the focus of HLA-A restricted TSAs, the collection of human tumor 
antigens recognized by CD8+ CTLs were carried out by search Cancer Immunity database 
(http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm) and literatures. The 
12 known melanoma TSAs of the 5 MHC-I alleles A1, A2, A3, A24, and A6801, and the 
4 known lung cancer TSAs of the 3 MHC-I alleles A1, A2, A6802 were collected in this 
study for validation purpose. The sequence, binding HLA alleles, and information of host 
proteins of these known TSAs are given in Tables 5-2 and Tables 5-3 for melanoma and 
lung cancer respectively. 
5.2.3 Computational procedures 
5.2.3.1 Identify overexpressed candidates from microarray data 
 
All of the known tumor-specific somatic mutations of melanoma and lung cancer were 
substituted into the protein products of human genome sequence to generate the human 
cancer genomes for melanoma and lung cancer. Since the length of identified the 16 
known TSAs are in range of 8 to 11 amino acids, only the 8–11mer tumor-specific mutant 
peptides were extracted from the corresponding encoded protein sequences such that each 
peptide contains at least one mutated residue uniquely found in melanoma or lung cancer. 
The expression levels of the corresponding host proteins of these tumor-specific mutant 
peptides were evaluated.  
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We calculated the percentage of cancer patients whose selected genes were at least x-fold 
overexpressed, in comparison with y% of normal people. A range of x (1.5, 2, 2.5, 3) and y 
(50% to 100%, which means to compare with at least half of normal samples) values were 
tested. When y value was varied at a fixed value of x, a stable percentage (>40%) of patients 
carrying the overexpressed genes were observed with the increase in y. We therefore fix the x 
to 2 and y to 50%.  
 
Therefore, peptides were selected such that their host proteins are expressed at higher 
levels (2 fold-change) in >40% of patients (5 out of 12 for melanoma, and 11 out of 27 for 
lung cancer) than those in >50% of normal persons (2 out 3 for melanoma, and 10 out of 
19 for lung cancer) in the melanoma and lung cancer datasets respectively.  
5.2.3.2 Derivation of structural and physicochemical properties from 
peptide sequence 
As introduced in the chapter of methodology, a feature vector can be constructed for 
representing the structural and physicochemical properties of a peptide. Given the 
sequence of a peptide, its amino acid composition and the properties of every constituent 
amino acid are computed and then used to generate this vector. The computed amino acid 
properties include hydrophobicity, normalized Van der Waals volume, polarity, 
polarizability, charge, surface tension, secondary structure and solvent accessibility [254]. 
For each of these properties, amino acids are divided into three or six groups such that 
those in a particular group are regarded to have approximately the same property. Three 
descriptors, composition (C), transition (T), and distribution (D), are introduced to 
describe global composition of each of these properties. Overall, there are 51 elements 
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representing these three descriptors: 6 for C, 15 for T and 30 for D, with a six grouped 
property; and 21 elements: 3 for C, 3 for T and 15 for D, with a three grouped property.  
Construction of peptide feature vectors can be illustrated by the generation of the amino 
acid composition descriptors of two hypothetical peptides, sequence I 
(AEAAAEAEEAAAA) and sequence II (AEAEEEAAEEAEEEAAE).  Sequence I 
contains 9 alanines (n1=9) and 4 glutamic acids (n2=4) and sequence II includes 7 
alanines (n1=7) and 10 glutamic acids (n2=10). The composition is C1= (n1×100/ 
(n1+n2), n2×100/ (n1+n2)) = (69.23, 30.77) for sequence I, and C2= (41.18, 58.82) for 
sequence II. There are 6 A=>E and E=>A transitions in sequence I, and 9 such transitions 
in sequence II. The total number of transitions is 12 in sequence I and 16 in sequence II. 
The percent frequency of transition is thus T1= (6/12) ×100=50.00 for sequence I, and 
T2= (9/16) ×100=56.25 for sequence II. The first, 25%, 50%, 75% and 100% of As and Cs 










































 residues respectively for sequence II. The distribution is then D1=(1/13×100, 
4/13×100, 10/13×100, 11/13×100, 13/13×100, 2/13 ×100, 2/13×100, 6/13×100, 8/13×100, 
9/13×100)=(7.69, 30.77, 76.92, 84.62, 96.67, 15.38, 15.38, 46.15, 61.54, 69.23) for 
sequence I, and D2=(1/17 ×100, 3/17×100, 8/17×100, 15/17×100, 16/17×100, 2/17 ×100, 
5/17×100, 9/17×100, 13/17×100, 17/17×100)=(5.88, 17.65, 47.06, 88.23, 94.12, 11.76, 
29.41, 52.94, 76.47, 100.00) for sequence II. Overall, the amino acid composition feature 
vector is x1=(C1, T1, D1)=(69.23, 30.77, 50.00, 7.69, 30.77, 76.92, 84.62, 96.67, 15.38, 
15.38, 46.15, 61.54, 69.23) for sequence I, and x2=(C2, T2, D2)=(41.18, 58.82, 56.25, 
5.88, 17.65, 47.06, 88.23, 94.12, 11.76, 29.41, 52.94, 76.47, 100.00) for sequence II. The 
two vectors x1 and x2 thus have equal length, which is useful for classification of peptides 
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of variable lengths by using statistical learning methods. 
5.2.3.3 Application of computational method for T-cell recognition prediction  
The differentially overexpressed peptides and their neighboring residues in the host 
proteins were analyzed by NetChop3.0 (Nielsen et al., 2005), a neural networks based 
prediction tool developed form  the experimental validated MHC Class I molecules[641], 
to determine which of them are cleavable by the proteasome (C-term 3.0 score with cutoff 
larger than 0.5). The predicted cleavable peptides were then screened by NetCTL1.2 [223] 
to select those transportable by TAP (TAP transport efficiency score with cutoff lower 
than 1). The selected proteasome cleavable and TAP transportable peptides were then 
screened by using MHC-BPS[261], a SVM-based MHC binding prediction software 
developed by our research group, to determine which of them can bind to MHC-I alleles 
A1, A2, A3, A24, A6801 for melanoma and MHC-I alleles A1, A2, A0301, A6802 for 
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Table 5-2 Known melanoma tumor-specific antigens presented by MHC-I. The label “E”, “C
”, “T”, “B” indicates the tumor-specific antigen was selected by gene expression, 











of TSA  
 Host protein and gene  








 A1  
 
FLEGNEVGKTY(G)   446–455   11  
Hedgehogacyltransferase 
(MART2)   Hedgehogsignaling   11160356   CTB  
 A1   ILDTAGREEY(Q)   55–64   10  
Neuroblastoma RAS 
viral (v-ras) oncogene 
homolog (NRAS)   Signaling   11971032   C  
 A2   ACDPHSGHFV(R)   23–32   10  
Cyclin-dependent kinase 
4 (CDK4)   Cellcycle   7652577   CTB  
 A2   GIVEGLITTV(M)   168–177   10  
Glyceraldehyde3-
phosphate  
dehydrogenase(GAPDH)   Energymetabolism   15614045   CTB  
 A2   SLADEAEVYL(H)   281–290   10  
Growth arrest-specific 7 
(GAS7)   Cellcycle   15614045   ECTB  
 A2   LLLDDLLVSI(S)   163–172   10  Peroxiredoxin5(PRDX5)   Oxidativestress   15695408   ECTB  
 A24   SYLDSGIHF(S)   29–37   9  Catenin 1(CTNNB1)  
 Cell–
celladhesion/Wntsignaling   8642260   ECTB  
 A3   KILDAVVAQK(E)   668–677   10  
Elongation factor Tu 
GTP  binding domain 
containing 2(EFTUD2)   RNAprocessing   16247014   ECTB  
 A3   TLDWLLQTPK(G)   179–188   10  
Glycoproteinnmb 
(GPNMB)   Melanosomalprotein   16247014   CT  
 A3   KINKNPKYK(E)   911–919   9  MyosinclassI(MYO1B)   Cellularmotility   10064075   ECTB  
 A3   KIFSEVTLK(P)   192–200   9  Sirtuin-2(SIRT2)   Transcriptionalsilencing   16247014   CTB  
 A6801   EAFIQPITR(S)   322–330   9  
Melanoma associated 
antigen-3(MUM3)   Nucleicacidmetabolism   10820291   ECTB  
 
 
Table 5-3 Known lung cancer tumor-specific antigens presented by MHC-I. The label ―E‖, ―C‖, 
―T‖, ―B‖ indicates the tumor-specific antigen was selected by gene expression, proteasome 




TSA and mutated 




of TSA  
Host protein and 
gene name  
Function of 












signaling  11160356 ECTB  
A2  FIASNGVKLV(K)  118–127  10 
Actinin, alpha 4 
(ACTN4)  Adhesion  11358829 ECTB  
A2  FLDEFMEG(A)  224–231  8 
Malic enzyme 1 
(ME1)  
Energy 
metabolism  11325844 EB  
A6802  ETVSEQSNV(E)  581–589  9 
Eukaryotic 
translation elongation 
factor 2 (EEF2)  
Protein 
translation  9823325 ECTB  
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5.3 Results and Discussion 
5.3.1 Performance of collective approach in genome-scaled TSAs identification 
The results of the collective approach in predicting melanoma and lung cancer TSAs from 
the human cancer genomes are given in Tables 5-4 and Tables 5-5 respectively. A total of 
36, 250, 31, 22, and 8 putative melanoma TSAs were predicted for HLA A1, A2, A24, A3, 
and A6801 alleles, and a total of 17, 359, and 14 putative lung cancer TSAs were 
predicted for HLA A1, A2, and A6802 alleles respectively.  
 
The differentially overexpressed peptides and their neighboring residues in the host 
proteins were analyzed by NetChop3.0[231] (Nielsen et al., 2005), a neural networks 
based prediction tool developed form  the experimental validated MHC Class I 
molecules[641], to determine which of them are cleavable by the proteasome (C-term 3.0 
score with cutoff larger than 0.5). The predicted cleavable peptides were then screened by 
NetCTL1.2 [223] to select those transportable by TAP (TAP transport efficiency score 
with cutoff lower than 1). The selected proteasome cleavable and TAP transportable 
peptides were then screened by using MHC-BPS[261], a SVM-based MHC binding 
prediction software developed by our research group, to determine which of them can bind 
to MHC-I alleles A1, A2, A3, A24, A6801 for melanoma and MHC-I alleles A1, A2, 
A0301, A6802 for lung cancer respectively.  
 
The predicted TSAs include 50% and 75% of the 12 and 4 known T-cell defined tumor-
specific melanoma and lung cancer antigens in Cancer Immunity database. Overall, the 
yields, hit rates and enrichment factors (with respect to mutation analysis alone) of the 
collective approach are 50% and 75%, 1.9% and 0.8%, and 29 and 35 for melanoma and 
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lung cancer respectively. The yields are slightly less than the 70–90% levels of the 
prediction tools that solely predict T-cell epitopes [238,240,242,244], suggesting that the 
collective approach is capable of identifying TSAs at accuracy levels not too far away 
from those of the tools that only predict T-cell epitopes.  
 
Table 5-4 Results of genome-search of melanoma tumor-specific antigens by collective analysis of 
mutation, expression and T-cell recognition. The number of ―√‖ represents the number of known 




Table 5-5 Results of genome-search of lung cancer tumor-specific antigens by collective analysis 
of mutation, expression and T-cell recognition. The number of ―√‖ represents the number of 
known tumor-specific antigens passed a particular search step 
 
  
Evidences indicative of higher expression levels of some of the host proteins of these 
malnoma TSAs have been reported. CDK4 [642] and GPNMB [643] has been reported to 
be amplified in melanoma. Hedgehog signaling has been found to be required for 
melanoma [644], which suggests the possibility of higher levels of hedgehog 
acyltransferase in melanoma patients. Therefore, increased sampling sizes as well as the 
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enhancement of the quality of measurement and analysis of microarray data [645] may 
enable the further improvement of the TSA prediction performance of the collective 
approach in genome-scale search studies. 
5.4 Conclusion 
The collective consideration of somatic mutations, expressions, and T-cell recognition 
appears to show fairly good capability in predicting TSAs in genome-scale search 
campaigns. The numbers of predicted putative TSAs from genome-scale search studies are 
within the range manageable by typical screening campaigns, and the hit rates are enriched 
to levels that enable effective identification of TSAs. The prediction performance, the 
yield and hit rates, of the collective approach may be further improved by expanding the 
sampling size as well as improving the quality of measurement and analysis of gene 
expression data[645]. With expanding knowledge of the respective peptides and the 
further development of in silico tools, the performance for predicting proteasomal 
cleavage, TAP mediated transport, and HLA-binding are expected to be further improved 
[223,231,261], which helps to increase the capability of the collective approach in 
facilitating the genome-scale search of TSAs. 




6 Lung adenocarcinoma survival marker selection 
Micoarrays have been explored for deriving molecular signatures, subsets of genes 
differentially expressed in patients of different outcomes, for determining disease-
outcomes, mechanisms, targets, and treatment-strategies. While exhibiting good predictive 
performance, derived signatures are unstable due to noises arising from measurement 
variability and biological differences. Improvements in measurement, annotation and 
signature-selection methods have been proposed. We explored a new gene signature 
selection method by incorporating consensus scoring of multiple random sampling and 
multi-step evaluation of gene-ranking consistency for maximally avoiding erroneous 
elimination of predictor-genes. The best prediction performance was achieved in cancer 
biomarkers discovery of a well-studied 62-sample colon-cancer dataset. This chapter 
provides a case study of applying this gene selection system to survival biomarker 
selection from a 86-sample lung adenocarcinoma dataset. The derived gene signatures of 
10 sampling-sets, composed of 5,000 training-testing sets, are fairly stable with 40%~62% 
of all predictor-genes shared by all 10 sampling-sets. These shared predictor-genes 
include 15 cancer-related and 5 cancer-implicated genes. The predictive ability of these 
survival markers are evaluated by neural network models, SVM models, and unsupervised 
hierarchical clustering methods. The derived signatures outperform all previously-derived 
signatures in predicting patient outcomes from an independent dataset, suggesting its 









The fundamental goals of discovery cancer biomarker  includes the prediction of cancer 
stages, the likelihood of disease redeveloping following an apparent resolution of a disease 
or to predict outcomes such as life expectancy, survivability, progression, and drug 
sensitivity after initial diagnosis [646]. Molecular risk factors are commonly used 
prognostically to stratify the subtype of cancer patients and to prescribe the appropriate 
treatment regimens that match their risk profiles, so that proper treatment regimen can be 
applied and ultimately extend the survival of the patients[11]. Certain cancer types, such 
as lung cancer, are prescribed various types of treatments such as chemotherapy and 
radiation therapy based on the known molecular factors, such as the status of EGFR 
expression[647,648]; however, there is no assurance that metastases and recurrence will 
never occur[647,648]. The ability to predict the metastases and invasions behavior of lung 
cancer still remains one of the greatest clinical challenges in thisfield.  
 
In order for clinician developing proper treatment regime and ultimately extend the 
survival of the patients, the accurate identification of cancer subtype and prognosis effect 
is crucial [11]. Extensive studies have been recently conducted to discover cancer subtype 
and prognostic prediction based on disease and patients molecular expression 
profiles[4,5,117-120]. The successful rate of current prediction is low due to the complex 
and very heterogeneous of lung cancer[120]. However, studies on lung adenocarcinoma 
survival marker discovery and prognosis prediction still provide a platform for subtype 
discovery and prognostic prediction based on disease and patients molecular details 
[4,5,117-120] 




Lung cancer is the leading cause of cancer-related mortality not only in the United States 
but also around the world[649].  In 2007, lung cancer accounts for 29% of all cancer 
deaths (31% in men, 26% in women) in US [650].  The 2 main types of lung cancer are 
small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC); NSCLC accounts 
for approximately 85% of all cases of lung cancer[651]. The NSCLC can be further 
classified as squamous cell carcinoma and adenocarcinoma, and large-cell lung 
cancer[652].  The proportional of squamous cell carcinoma is around 20~25%, and the 
proportional of adenocarcinoma is 50~60% [651]. Despite advances in early detection and 
standard treatment, prognosis for both NSCLC and SCLC lung cancers are poor. NSCLC 
is often diagnosed at an advanced stage and has a poor prognosis. The average survival 
time of advanced NSCLC is 6 months for untreated patients, and 9 months for patients 
treated with chemotherapy [651]. Five-year survival rate is 60~70% for patients with stage 
I disease and zero for patients with stage IV disease [651]. The treatment and prevention 
of lung cancer are major unmet needs that can probably be improved by a better 
understanding of the molecular origins and evolution of the disease.  
  
The lung cancer patients can be roughly stratified from the morphological assessment 
based on conventional sputum cytology and chest radiography. These techniques have not 
yet demonstrated an impact on decreasing lung-cancer mortality [653]. In one study, only 
41% of cases that independent lung pathologists agreed on lung adenocarcinoma 
subclassification [654]. Recently some specific indicators, including tumor size, poor 
differentiation and high tumor-proliferative index, have been identified to predict the 
survival of lung cancer patients [655-658], However, these indicators have only limited 
power in survival prediction.  




It is suggested that common molecular features may be able to predict such outcome 
discrepancies among patients more reliably. For instance, the efficacy of EGFR 
antagonists has been shown to depend on expression and mutation status of its target 
EGFR in the tumor [659]. Also, the beneficial effect of chemotherapies might depend on 
the expression of certain enzymes such as thymidine synthetase for pemetrexed[660]. 
Thus, improved classification of NSCLC by using molecular indicators is of considerable 
clinical interest.  
 
The development of microarray technology holds the potential to find molecular 
biomarkers of lung cancer subtype and outcome prediction systematically [661-664]. 
These biomarkers allow new insights in the process of lung carcinogenesis, and they may 
provide new tools for determination of prognosis and identification of innovative 
treatments. However, the reproducibility of gene expression signatures to predict high-risk 
of relapse or recurrence is rarely reported. The molecule marker selection is strongly 
dependent on the patient samples, causing the significantly different marker signatures in 
different groups for lung adenocarcinoma prognosis (Table 6-1) [662,663] and 
diminishing their application potential for prognosis [139]. Moreover, the prognostic 
power of previous selected survival genes for individual patients was seldom reported in 
their studies [662,663]. Guo et al. provided the prediction accuracy for their selected 
survival genes. However, their selected survival genes were only applicable to one dataset, 
and the predictive power to the independent dataset was very limited [661]. It is therefore 
highly desirable to identify stable molecular markers that can reliably determination of 
prognosis and predict specific subgroups of high- and low-risk patients. This would be 
helpful to select the most appropriate therapy for individual patient 




Table 6-1  Statistics of lung adenocarcinoma survival marker signatures from references 
Study 
Number of selected 
survival genes in 
signature 
Number of genes selected by other N studies 
4 3 2 1 0 
Lu et al [665] 125 0 0 0 8 116 
Chen et al [666] 16 0 0 0 0 16 
Xu et al [667] 5 0 0 0 2 3 
Beer et al [662] 100 0 0 0 8 92 
Guo et al [661] 37 0 0 0 4 34 
 
In this chapter, we developed a new recursive feature selection method based on a model 
built from SVM in identifying novel survival markers with respect to the interactions 
among genes. The consensuses scoring of multiple random sampling and the evaluation of 
gene-ranking consistency have been embedded in the recursive feature selection system to 
reduce the chances of erroneous elimination of predictor-genes and improving the stability 
across the different sample groups. The new method has been applied to identify important 
biomarkers in prediction of the survivability of individual patients with lung 
adenocarcinoma. A total of 21 genes were selected after repeating smapling of the same 
experiment for 10 times. . Results show that the prediction models can accurately predict 
the clinical outcome for individual patients with lung adenocarcinoma by use of 
independent datasets. The differential expression analysis, function prediction, and 
literature searches of the identified biomarkers implies that this group of genes plays 










6.2 Materials and Methods  
6.2.1 Lung adenocarcinoma microarray datasets and data preprocess 
Two independent datasets of clinical samples were used for lung adenocarcinoma survival 
marker gene selection and validation of the effect of our selected genes. The original gene 
expression profiles of patient samples have been reported in previous publications 
[662,663].  
 
The dataset for survival marker gene selection contained the gene expression profiles from 
86 primary lung adenocarcinomas (Beer‘s dataset) [443,662], including 67 stage I and 19 
stage III tumors, from oligonucleotide arrays seen at the University of Michigan Hospital 
between May 1994 and July 2000. This gene expression profile, containing 7129 gene 
expression levels, was obtained before surgery. Sixty two patients survived (survivable 
patients) whereas 24 patients died at last follow-up (non-survivable patients). The detailed 
clinical information of samples is listed in Appendix Table S12. For preprocessing, those 
genes with little variation (less than 2) across all of 86 samples were removed, and 6009 
genes were used for survival gene selection [139,331]. Although this gene filtering 
procedure may potentially result in the loss of some information, it in this manner 
decreased the possibility of introduce the noise  into the machine learning method and 
clustering algorithm which might be strongly influenced by genes with little or no 
expression[443,662].   
 
The robustness of our selected signatures in predicting survivability in lung 
adenocarcinomas was tested using oligonucleotide gene-expression data obtained from a 




completely independent lung adenocarcinoma dataset (Bhattacharjee‘s dataset) [663,668]. 
To ensure equivalent testing power and comparability of samples, 84 primary lung tumor 
samples of which at least 40% samples being cancer cells were selected [662]. In these 84 
samples, 41 patients were alive at last follow-up (survivable patients), whereas 43 died 
(non-survivable patients). The detailed sample clinical information is listed in Appendix 
Table S13.  
 
In order to present a statistically meaningful evaluation, signature selection was conducted 
based on multiple random sampling on the Beer‘s dataset [662]. In multiple random 
sampling, this dataset was randomly divided into a training set containing 43 samples 
(including 12 poor outcome samples and 31 good outcome samples) and an associated test 
set containing the other 43 samples (including the other 12 poor outcome samples and 31 
good outcome samples). To reduce computational cost, 5,000 training-test sets, each 
containing a unique combination of samples, were generated. These 5,000 training-test 
sets were randomly placed into 10 sampling groups; each containing 500 training-test sets. 
Every sampling group was then used to derive a signature by using the similar way as 
colon cancer marker discovery. Finally, the 10 different signatures derived from these 
sampling groups were compared in order to test the level of stability of selected predictor-
genes. 
 
Repeated random sampling was used to archieve statistically meaningful evaluation in 
analyzing Beer‘s dataset [139]. In multiple random sampling, the dataset was randomly 
divided into a training set containing 43 samples (including 12 poor outcome samples and 
31 good outcome samples) and an associated test set containing the other 43 samples 




(including the other 12 poor outcome samples and 31 good outcome samples). To reduce 
computational cost, 5,000 training-test sets, each containing a unique combination of 
samples, were generated. These 5,000 training-test sets were randomly placed into 10 
sampling groups; each containing 500 training-test sets.  Finally, the 20 different 
signatures derived from these sampling groups were compared in order to test the level of 
stability of selected predictor-genes. 
 
Each of the 10 sampling groups was used to derive a set of survival marker genes. In the 
500 training-testing sets in every sampling group, each training-set was used to select 
genes by RFE based on SVM system. For all iterations and testing-sets, SVM system 
employed a set of globally modified parameters which gave the best average class-
differentiation accuracy over the 500 testing-sets. 
 
In every sampling group, three gene-ranking consistency evaluation steps were 
implemented on top of the normal RFE procedures in all sampling groups: 
(1) For every training-set, subsets of genes ranked in the bottom 10% (if no gene was 
selected in current iteration, this percentage was gradually increased to the bottom 
40%) with combined score lower than the first top-ranked gene were selected such that 
collective contribution of these genes less likely outweighed higher-ranked ones; 
(2) For every training-set, genes selected from the step (1) were further evaluated to 
choose those not ranked in the upper 50% in previous iteration so as to ensure that 
these genes were consistently ranked lower; 
(3) A consensus scoring scheme was applied to genes selected from the step (2)such that 
only those appearing in >90% (if no gene was selected in current iteration, this 




percentage was gradually reduced to 60%) of the 500 training-sets were eliminated..  
6.2.2 Performance evaluation of survival marker signatures 
The predictive capability of survival marker signatures were evaluated by using the SVM 
and PNN classification system on 500 randomly-generated training-testing sets generated 
from the Bhattacharjee‘s dataset [663] and the Beer‘s dataset [662]. For each training-
testing set, the training data was used to construct a classifier model, whereas the testing 
data was used to evaluate the performance of the model. The predictive performance of 
selected signatures was evaluated by the accuracies for survival patients (Sensitivity, SE) 
(Equation 2-17),  non-survivable patients (Specificity, SP) (Equation 2-18), and overall 
accuracies (Q) (Equation 2-16) over the 500 models. Besides the evaluation by using 
supervised classifiers, unsupervised hierarchical clustering analysis was also applied to 
evaluate the performance of signatures. 
 
Hierarchical cluster analysis was conducted by using the selected survival on the 86 
samples from Beer et al. [662] and the independent dataset from Bhattacharjee et al. [663]. 
Kaplan-Meier survival analysis, often referred as survival analysis, was used in this study 
together with hierarchical cluster analysis. This analysis is popularly employed in medical 
research to estimate the percentage of patients living for a certain amount of time after 
surgery. It allows the estimation of survival over time, even when patients drop out or are 
studied for different lengths of time. A typical application of Kaplan-Meier analysis 
involves (1) grouping patients into different categories, and (2) comparing the survival 
curves from those categories by the log-rank test to assess the statistical significance of the 




difference among the survival curves for the categories. The Kaplan-Meier analysis was 
performed by using XLSTAT software [669]. 
 
6.3 Results and discussion  
6.3.1 System of the lung adenocarcinoma survival marker selection 
10 sets of survival marker genes were obtained. The number or predictor-genes in each 
sampling group ranged from 34 to 57 (Table 6-2, Appendices Table S14). The stability of 
selected signatures was evaluated from the percentage of predictor-genes shared across 
every sampling group. As shown in Table 6-2 and Table 6-3 a total of 21 predictor-genes 
were presented in all experiments, accounting 40% to 62% genes identified by 10 
sampling groups. The identified survival markers shown a moderate stability when 
comparing to the results from 5 previous studies (Table 6-1), which shows that 5~125 
selected predictor-genes in each of the 5 previous studies were seldom presented in the 
other 4 studies. 
PNN and SVM classifiers were used to evaluate classifier accuracy of selected predictor-
genes. The classification capability of selected 21 predicator-genes was further evaluated 
by PNN and SVM classifiers, hierarchical clustering method and Kaplan-Meier survival 





































Table 6-2  Statistics of the lung adenocarcinoma survival markers by class-differentiation systems 
constructed from 10 different sampling-sets, each composed of 500 training-testing sets generated 





genes in signature 
Number of survival-genes also included in N other signatures derived by 
using different sampling-set 
9 8 7 6 5 4 3 2 1 0 
1 51 21 4 1 7 5 3 3 2 1 4 
2 54 21 6 1 6 3 2 5 5 2 3 
3 42 21 6 2 4 3 2 2 2 0 0 
4 34 21 3 2 1 2 2 1 2 0 0 
5 46 21 6 2 7 5 1 2 2 0 0 
6 54 21 6 2 8 5 3 2 2 2 3 
7 57 21 5 1 7 2 1 3 5 2 10 
8 50 21 6 2 6 2 1 4 5 2 1 
9 53 21 6 1 5 5 1 4 3 4 3 
10 47 21 6 2 5 4 1 2 3 1 2 
 
Microarray data (6009 genes, 86 samples) 
Survival marker 
genes 1  
Survival marker 
genes 2 
… Survival marker 
genes 10 
Genes shared by ten sampling groups  
SVM prediction system 
PNN prediction system 
Hierarchical cluster analysis and Kaplan-Meier analysis 
 
Evaluation on the independent dataset 
from Bhattacharjee et al.  




6.3.2 Consistency analysis of the identified markers 
The optimal SVM parameter, σ, for the 10 sample sets were in the range of 41 to 46, and 
the highest average accuracies across the 10 sampling-sets were 84.1%~88.4% for non-
survivable (those died at last follow-up) and 100% for survivable patients (those alive at 
last follow-up) respectively (Table 6-4). The accuracies for the 5,000 individual testing-
sets ranged from 63.6%~100% for non-survivable and 100% for survivable patients 
respectively. The relatively small variations of optimal SVM parameters and prediction 
accuracies across the 10 sampling-sets suggest that the performance of the SVM class-
differentiation systems constructed by using globally optimized parameters and RFE 
iteration steps are fairly stable across different sampling combinations. 
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Gene Ontology: Process 
















target for lung 
cancer therapy 
extracellular matrix 
binding; growth factor 







factor receptor binding 
angiogenesis; anti-apoptosis; cell 
migration; cell proliferation; epithelial 
cell differentiation; eye photoreceptor 
cell development; induction of positive 
chemotaxis; lung development; 
mesoderm development; multicellular 
organismal development; nervous 
system development; nervous system 
development; positive regulation of 
epithelial cell proliferation; positive 
regulation of vascular endothelial 
growth factor receptor signaling 
pathway; regulation of progression 
through cell cycle; response to 
hypoxia; signal transduction; 
vasculogenesis 
VEGF Pathway; Inhibition of 
Angiogenesis by TSP1; eNOS 
Signaling; Relaxin Pathway; 
Phospholipase-C Pathway; CRHR 
Pathway; mTOR Pathway; Paxillin 
Interactions; PAK Pathway; Ras 
Pathway; Cellular Apoptosis 
Pathway; Rap1 Pathway; GPCR 
Pathway; TGF-Beta Pathway; MAPK 
Family Pathway; P2Y Receptor 
Signaling; RhoGDI Pathway ; NF-
KappaB Family Pathway; FGF 
Pathway; HIF1Alpha Pathway; Rac1 
Pathway; JAK/STAT Pathway; 
Renin-Angiotensin Pathway; 
Mitochondrial Apoptosis; NF-
KappaB (p50/p65) Pathway; 
Telomerase Components in Cell 












activity; sugar binding 




















G-protein coupled receptor protein 
signaling pathway; chemotaxis; 
immune response; inflammatory 
response 































ion transport; signal transduction; 
synaptic transmission 
 [675,685,686]  
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activity; chloride ion 
binding; ion channel 
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Ras protein signal transduction; cell 
communication; chemotaxis; lipid 
catabolic process; metabolic process; 
phospholipid metabolic process 
Ras pathway; Rho Family GTPases; 
RhoA Pathway ;Rac1 Pathway; 









11q14    




DNA synthesis during DNA repair; 
mismatch repair 
DNA polymerase; Purine 
metabolism; Pyrimidine metabolism; 
Cell Cycle (Mitotic); DNA Repair; 




























G-protein signaling, coupled to cAMP 
nucleotide second messenger; protein 
amino acid phosphorylation; signal 
transduction 
Apoptosis; Calcium signaling 
pathway; Gap junction; GnRH 
signaling pathway; Hedgehog 
signaling pathway; Insulin signaling 
pathway; Long-term potentiation; 
MAPK signaling pathway; Olfactory 
transduction; Taste transduction; Wnt 
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binding; sugar porter 
activity; transporter 
activity 















epidermis development; keratinization; 










GTP binding; GTPase activity; 
nucleotide binding; protein binding; 
structural molecule activity 

















metal ion binding; 
protein binding; 
sequence-specific 
DNA binding; steroid 
hormone receptor 
activity; transcription 
factor activity; vitamin 
D3 receptor activity; 
calcium ion homeostasis; calcium ion 
transport; intestinal absorption; 
multicellular organismal development; 
negative regulation of transcription; 
organ morphogenesis; regulation of 
transcription, DNA-dependent; signal 
transduction; skeletal development; 
transcription 
MAPK [713] 
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9p22.1        
ANXA8 annexin A8 10q11.2    
calcium ion binding; 
calcium-dependent 
phospholipid binding 































anaerobic glycolysis; tricarboxylic acid 
cycle intermediate metabolic process 
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Table 6-4  Average survivability prediction accuracy of 500 SVM class-differentiation systems on 
the optimal SVM parameters for lung adenocarcinoma prediction. The sigma is the optimal SVM 
parameter which gives the best average class-differentiation accuracy over the 500 testing-sets. 















TP FN SE TN FP SP 
1 45 51 5275 814 86.6% 14908 3 100% 96.1% 
2 44 54 5175 939 84.6% 14886 0 100.% 95.5% 
3 43 42 5173 909 85.1% 14918 0 100% 95.7% 
4 41 34 5347 802 87.0% 14845 6 100% 96.2% 
5 43 46 5340 703 88.4% 14956 1 100% 96.6% 
6 45 54 5230 865 85.8% 14905 0 100% 95.9% 
7 45 57 5139 972 84.1% 14889 0 100% 95.4% 
8 46 50 5201 949 84.6% 14850 0 100% 95.5% 
9 43 53 5313 801 86.9% 14886 0 100% 96.2% 
10 46 47 5333 757 87.6% 14910 0 100% 96.4% 
 
6.3.3 Disease relevant of identified markers 
The 21 predictor-genes shared by all 10 sampling-sets included 16 cancer-related genes (4 
anticancer targets, 1 oncogene, 2 angiogenesis genes, 1 organ-specific metastases gene, 1 
tumor stability gene, 2 apoptosis genes, 1 cancer growth gene, and 4 cancer-pathway-
affiliated genes). In our analysis, anticancer targets were obtained from the latest version 
of therapeutic target database (http://bidd.nus.edu.sg/group/cjttd/ttd.asp) [337,714], and 














Chapter 6: Lung adenocarcinoma survival marker selection 
  
162 
Table 6-5  List of predictor-genes of lung adnocacinoma cancer dataset shared by all 10 sampling-
sets.  
Gene Group Predictor-genes selected by this work only 
Therapeutic target VEGFA, CHRNA2, TUBA4A, VDR 
Oncogene CXCL3 
Organ-specific metastases FUT3  
Cellular growth of carcinomas  FXYD3  
Apoptosis  RPS3, REG1A 
Stability genes POLD3 
Cancer pathway affiliated gene PRKACB, PLD1, SERPINE1, SLC2A1 
 
6.3.4 The predictive ability of identified markers 
 
The predictive capabilities of our selected and 10 previously-derived signatures were 
evaluated using the SVM and PNN classification system on 500 randomly-generated 
training-testing sets that were generated from the Bhattacharjee‘s dataset [663] and the 
Beer‘s dataset [662]. For each training-test set, the training data was used to construct a 
classifier model, whereas the test data was used to evaluate the performance of the model. 
The predictive performance of selected signatures was evaluated by the overall accuracies 
(Q) of the 500 models.  
 
Table 6-6 gives the prediction accuracies from the SVM prediction system constructed by 
independent samples from Bhattacharjee‘s dataset [663] using our selected gene signatures 
and 9 other previous-derived signatures. The accuracies for non-survival patients, survival 
patients and all patients of the our selected 10 gene signatures over the 500 test sets were 
in the range of 77.8% to 81.2%, 74.3% to 80.1% and 77.6% to 80.2% correspondingly, 
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while the standard deviations of the accuracy of all patients were ranged from 4.7% to 
4.9%. The accuracies for non-survival patients, survival patients and overall accuracies for 
all patients of the 21 survival genes shared by all of the 10 signatures over the 500 test sets 
were 78.9%, 76.8% and 77.9% respectively, while the standard deviation of the accuracy 
of all patients was 4.8%. In contrast, the accuracies for non-survivable patients, survival 
patients and all patients of the 9 previous-derived signatures were in the range of 
70.1%~77.2%, 56.4% to 78.0% and 66.0% to 77.6% respectively, and the standard 
deviations of the accuracy of all patients were in the range of 5.5%~6.9%. These results 
suggest that the performance of our signatures is more stable than those of other signatures 
by using independent database and by applying the SVM models. 
 
Table 6-7 illustrates the predictive performance of the 500 testing sets by using the PNN 
classification system and the 500 randomly generated training-testing dataset generated 
from the independent Bhattacharjee‘s dataset [663] using our selected genes. The 
accuracies for non-survivable patients, survival patients and all patients of our selected 10 
signatures over the 500 test sets were, respectively, in the range of 69.3% to 80.2%, 64.5% 
to 78.0% and 69.1% to 76.6%, while the standard deviations of the accuracy of all patients 
were in the range of 4.2% to 4.9%. The accuracies for non-survivable patients, survivable 
patients and all patients of the 21 survival genes shared by all the 10 signatures over the 
500 test sets were 75.2%, 62.6% and 69.2% respectively, while the standard deviation of 
the overall accuracy was 4.4%. The accuracies for non-survivable patients, survival 
patients and patients of the 9 previous-derived signatures were in the range of 
53.5%~95.6%, 45.7% to 76.8% and 64.0% to 71.7% respectively, while the standard 
deviations of accuracy of all patients were in the range of 4.7%~6.1%. These results 
recommend that the survival genes we selected have a slightly better consistency and more 
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stable predictive performance than those of the signatures selected by other studies with 
the PNN classification system.  
 
Table 6-6  Average survivability prediction accuracy of the 500 SVM class-differentiation systems 
constructed by 84 samples from independent Bhattacharjee‘s lung adenocarcinoma dataset [663] 
using each of the signatures derived from this study and 9 previous studies. The accuracies were 









TP FN SE TN FP SP 
1* 51 8495 2369 78.2% 7864 2272 77.6% 77.9% 4.8% 
2* 54 8602 2262 79.2% 7783 2353 76.8% 78.0% 4.7% 
3* 42 8745 2119 80.5% 8014 2122 79.1% 79.8% 4.8% 
4* 34 8452 2412 77.8% 7837 2299 77.3% 77.6% 4.8% 
5* 46 8723 2141 80.3% 8117 2019 80.1% 80.2% 4.9% 
6* 54 8600 2264 79.2% 7731 2405 76.3% 77.8% 4.7% 
7* 57 8802 2062 81.0% 7807 2329 77.0% 79.1% 4.8% 
8* 50 8414 2450 77.4% 7533 2603 74.3% 75.9% 4.8% 
9* 53 8655 2209 79.7% 7992 2144 78.8% 79.3% 4.7% 
10* 47 8823 2041 81.2% 7899 2237 77.9% 79.6% 4.8% 
Genes selected by 
all sampling sets* 
21 8571 2293 78.9% 7788 2348 76.8% 77.9% 4.8% 
Beer et al [662] 100 8287 2577 76.3% 7540 2596 74.4% 75.4% 6.2% 
Beer et al [662] 50 7616 3248 70.1% 7407 2729 73.1% 71.5% 6.3% 
Chen et al [666] 16 7755 3109 71.4% 7255 2881 71.6% 71.5% 6.6% 
Chen et al [666] 5 7684 3180 70.7% 6820 3316 67.3% 69.1% 6.4% 
Guo et al [661] 37 8088 2776 74.4% 7443 2693 73.4% 74.0% 6.4% 
Guo et al [661] 8 8386 2478 77.2% 7904 2232 78.0% 77.6% 6.6% 
Lu et al [665] 125 8348 2516 76.8% 7588 2548 74.9% 75.9% 5.8% 
Lu et al [665] 64 8237 2627 75.8% 7612 2524 75.1% 75.5% 5.5% 
Xu et al [667] 5 8141 2723 74.9% 5720 4416 56.4% 66.0% 6.9% 


















Table 6-7 Average survivability prediction accuracies of the 500 PNN class-differentiation 
systems constructed by 84 samples from independent Bhattacharjee‘s lung adenocarcinoma dataset 












TP FN SP TN FP SE 
1* 51 7769 3156 71.1% 7270 2805 72.2% 71.6% 4.5% 
2* 54 7837 3088 71.7% 7478 2597 74.2% 72.9% 4.9% 
3* 42 8762 2163 80.2% 7333 2742 72.8% 76.6% 4.6% 
4* 34 8656 2269 79.2% 6810 3265 67.6% 73.6% 4.3% 
5* 46 7995 2930 73.2% 7863 2212 78.0% 75.5% 4.6% 
6* 54 8019 2906 73.4% 6502 3573 64.5% 69.1% 4.5% 
7* 57 8177 2748 74.8% 7518 2557 74.6% 74.7% 4.4% 
8* 50 8000 2925 73.2% 7514 2561 74.6% 73.9% 4.2% 
9* 53 7575 3350 69.3% 7140 2935 70.9% 70.1% 4.6% 
10* 47 8379 2546 76.7% 7413 2662 73.6% 75.2% 4.7% 
Genes selected by 
all sampling sets* 
21 8217 2708 75.2% 6305 3770 62.6% 69.2% 4.4% 
Beer et al [662] 100 7537 3388 69.0% 7515 2560 74.6% 71.7% 5.5% 
Chen et al [666] 5 10446 479 95.6% 4600 5475 45.7% 71.6% 4.7% 
Guo et al [661] 8 7752 3173 71.0% 7189 2886 71.4% 71.1% 5.2% 
Guo et al [661] 37 7537 3388 69.0% 7284 2791 72.3% 70.6% 5.5% 
Xu et al [667] 5 7884 3041 72.2% 6844 3231 67.9% 70.1% 5.6% 
Beer et al [662] 50 9220 1705 84.4% 5310 4765 52.7% 69.2% 4.9% 
Chen et al [666] 16 6780 4145 62.1% 7734 2341 76.8% 69.1% 5.7% 
Lu et al [665] 125 6874 4051 62.9% 7591 2484 75.3% 68.9% 6.1% 
Lu et al [665] 64 5845 5080 53.5% 7591 2484 75.3% 64.0% 6.1% 
* Data from this study 
 
The predictive accuracies of the 500 SVM survivability prediction systems from the 
original Beer‘ dataset [662] are shown in Table 6-8. These 500 training sets and 500 test 
sets were different from those used for survivability gene signatures selection. The 
accuracies for non-survivable patients, survival patients and all patients of the 10 survival 
gene signatures over the 500 test sets were in the range of 94.2% to 96.1%, 99.8 to 100% 
and 98.3% to 98.9% respectively, and the standard deviations of accuracy of all patients 
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were in the range of 3.2~3.7%. The accuracies for non-survival patients, survival patients 
and all patients of the 21 survival genes shared by all the 10 signatures over the 500 test 
sets were 90.5%, 99.5% and 96.9% respectively, and the standard deviation of the 
accuracy of all patients was 4.0%. The performances of our selected genes were both 
higher and more stable than those of the other 9 studies, in which the accuracies for non-
survivable patients, survival patients and all patients were in the range of 52.5% to 66.6%, 
81.8% to 96.8% and 75.6% to 88.3% respectively, and the standard deviations of accuracy 
of all patients were in the range of 5.8% to 8.0%. Overall, the survival predictor-genes 
selected from this study showed a better performance and relative low standard deviations 
than those previously identified ones when evaluated by the similar SVM classification 
system.   
 
The predictive accuracies of the 500 PNN classification systems for survivability 
prediction from the original Beer‘ dataset [662] are shown in Table 6-9. The accuracies for 
non-survivable patients, survival patients and all patients of the 10 survival gene 
signatures over the 500 test sets were in the range of 79.6% to 89.8%, 95.9% to 98.9% and 
93.4% to 95.5% respectively, and the standard deviations (STDEV) were in the range of 
4.3% to 5.2%. The accuracies for non-survivable patients, survival patients and all patients 
of the 21 survival genes shared by all the 10 signatures over the 500 test sets were 75.1%, 
96.2% and 90.2% respectively, and the standard deviations of the overall accuracy was 
5.7%. In contrast, the accuracies for non-survivable patients, survival patients and all 
patients of the 9 gene signatures from other studies over the 500 test sets were in the range 
of 57.2% to 76.1%, 73.5% to 89.7% and 72.1% to 80.6% respectively, and the standard 
deviation were in the range of 7.5% to 11.0%. This comparison indicated that the 
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performance of our selected gene signatures is better and stabler than those of other 
studies using the PNN classification methods for survivability prediction. 
 
Table 6-8 Average survivability prediction accuracy of 500 SVM class-differentiation systems 







Non-survival patients Survivable patients 
Q STDEV 
TP FN SE TN FP SP 
1* 51 5589 342 94.2% 15047 22 99.9% 98.3% 3.4% 
2* 54 5671 260 95.6% 15043 26 99.8% 98.6% 3.2% 
3* 42 5622 309 94.8% 15061 8 99.9% 98.5% 3.5% 
4* 34 5630 301 94.9% 15037 32 99.8% 98.4% 3.3% 
5* 46 5679 252 95.8% 15039 30 99.8% 98.7% 3.5% 
6* 54 5664 267 95.5% 15054 15 99.9% 98.7% 3.7% 
7* 57 5678 253 95.7% 15059 10 99.9% 98.7% 3.4% 
8* 50 5694 237 96.0% 15069 0 100% 98.9% 3.3% 
9* 53 5702 229 96.1% 15047 22 99.9% 98.8% 3.3% 
10* 47 5686 245 95.9% 15052 17 99.9% 98.8% 3.3% 
Genes selected by 
all sampling sets * 
21 5369 562 90.5% 14987 82 99.5% 96.9% 4.0% 
Beer et al [662] 100 3951 1980 66.6% 14589 480 96.8% 88.3% 5.8% 
Beer et al [662] 50 3302 2629 55.7% 14134 935 93.8% 83.0% 6.7% 
Lu et al [665] 64 3526 2405 59.5% 13658 1411 90.6% 81.8% 6.4% 
Lu et al [665] 125 3467 2464 58.5% 13570 1499 90.0% 81.1% 6.2% 
Guo et al [661] 37 2760 3171 46.5% 13974 1095 92.7% 79.7% 7.0% 
Chen et al [666] 16 2925 3006 49.3% 13702 1367 90.9% 79.2% 7.0% 
Xu et al [667] 5 3696 2235 62.3% 12432 2637 82.5% 76.8% 7.5% 
Chen et al [666] 5 3577 2354 60.3% 12325 2744 81.8% 75.7% 8.0% 
Guo et al [661] 8 3113 2818 52.5% 12760 2309 84.6% 75.6% 7.3% 
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Table 6-9 Average survivability prediction accuracies of the 500 PNN class-differentiation 











TP FN SE TN FP QN 
 1* 51 5069 862 85.5% 14635 434 97.1% 93.8% 4.8% 
 2* 54 5062 869 85.3% 14726 343 97.7% 94.2% 4.6% 
 3* 42 4939 992 83.3% 14715 354 97.7% 93.6% 4.7% 
 4* 34 4719 1212 79.6% 14904 165 98.9% 93.4% 5.2% 
 5* 46 5210 721 87.8% 14798 271 98.2% 95.3% 4.5% 
 6* 54 5326 605 89.8% 14730 339 97.8% 95.5% 4.3% 
 7* 57 5214 717 87.9% 14533 536 96.4% 94.0% 4.9% 
 8* 50 5089 842 85.8% 14707 362 97.6% 94.3% 4.5% 
 9* 53 5319 612 89.7% 14450 619 95.9% 94.1% 4.4% 
 10* 47 5100 831 86.0% 14571 498 96.7% 93.7% 4.8% 
Genes selected by 
all sampling sets* 
21 4454 1477 75.1% 14495 574 96.2% 90.2% 5.7% 
Beer et al [662] 50 3393 2538 57.2% 13523 1546 89.7% 80.6% 7.5% 
Beer et al [662] 100 4183 1748 70.5% 12648 2421 83.9% 80.1% 9.0% 
Lu et al [665] 64 4515 1416 76.1% 11700 3369 77.6% 77.2% 10.0% 
Xu et al [667] 5 4205 1726 70.9% 11960 3109 79.4% 77.0% 7.5% 
Chen et al [666] 5 3601 2330 60.7% 11985 3084 79.5% 74.2% 7.9% 
Guo et al [661] 8 3743 2188 63.1% 11768 3301 78.1% 73.9% 8.2% 
Chen et al [666] 16 3569 2362 60.2% 11936 3133 79.2% 73.8% 7.8% 
Lu et al [665] 125 4310 1621 72.7% 11078 3991 73.5% 73.3% 12.5% 
Guo et al [661] 37 3903 2028 65.8% 11232 3837 74.5% 72.1% 11.0% 
* Data from this study 
 
6.3.5 Patient survival analysis using survival markers 
Hierarchical cluster analysis can cluster the samples according to their expression profiles 
across the gene we selected. The comparison of the survival curves from these clusters can 
be used to assess the statistical significance of the survivability difference among the 
clusters.  
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By using 21 identified markers, hierarchical cluster analysis grouped 86 lung 
adenocarcinoma patients in the Beer‘s dataset [662] into three clusters (Figure 6-2). 
Kaplan-Meier survival analysis showed that the survival time after therapy was 
significantly different in the three patient clusters (P<0.0001, log-rank test, Figure 6-3). 
Cluster 1 was the poor prognosis group. The average survival time of patients in this 
cluster was 50.6 months. In this cluster, the numbers of survivable patients (SP) and non-
survivable patients (NSP) were 12 and 14 respectively (Table 6-10). The survival 
percentage, which defined by SP/(SP+NSP), were 46%. Cluster 2 was the good prognosis 
groups with average survival time of 82.2 months. The SP, NSP and survival percentage 
were 26, 1 and 96% respectively. Cluster 3 was the moderate prognosis group with 
average survival time of 74.8 months. The SP, NSP and survival percentage were 22, 9 
and 72% respectively. By using the similar way, Guo et al [661] clustered these samples 
[662] into three clusters by using 37 genes and the survival percentages were 69%, 72% 
and 75% for poor, moderate and good prognosis clusters, respectively (Table 6-10). The 
survival percentage for three clusters generated by 100 genes in Beer et al [662] are 43%, 
57% and 88% for poor, moderate and good prognosis clusters, respectively (Table 6-10). 
These results indicated that the 21 genes selected by using our method can be classified 
into better clinically meaningful groups for further prognosis than the genes selected by 
other group. 
 
Hierarchical clustering of the 21 genes on the independent validation dataset - 
Bhattacharjee‘s dataset [663] showed the similar results (Figure 6-4). Three clusters had 
significant difference by using Kaplan-Meier analysis with P<0.001 from log-rank test 
(Figure 6-5). The average survival time for cluster 1, which was poor prognosis group, 
was 35.7 months. The average survival time for cluster 2, which was moderate prognosis 
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group, was 32.0 months. The average survival time for cluster 3, which was good 
prognosis group, was 78.3 months. The survival percentages of the three clusters were 
30%, 43 % and 73% for poor, moderate and good prognosis clusters, as shown in Table 6-
11. By using the similar strategies, Guo et al [661] clustered the sample into three clusters. 
However, the survivability percentages among the clusters were 45%, 46% and 51% for 
three clusters by using the Kaplan-Meier analysis, showing little statistically different 
among the clusters (Table 6-10). The survival percentage of three clusters formed by 21 
genes we selected were more spread out than those formed by the genes selected by other 
researchers, further suggesting that 21 genes we selected have robust behavior for 
prognosis prediction.  
Table 6-10  Comparison of the survival rate in clusters with other groups, by using different 
















SP NSP Survival 
rate 
SP NSP Survival 
rate 
This study 21 12 14 46% 22 9 72% 26 1 96% 
Guo‘s group [661] 37 25 11 69% 15 6 71% 20 7 74% 
Beer‘s group [662] 4 100 25 19 43% 23 19 57% 37 5 88% 
1 
SP: the number of survivable patients 
2 
NSP: the number of non-survivable patients 
3 
Survival rate= SP/(SP+NSP)  
4 
The cluster analysis was done on 128 lung cancer samples
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Figure 6-2   Hierarchical clustering analysis of the 21 lung adenocarcinoma survival 
markers from Beer‘s microarray dataset [662]. The tumor samples were aggregated into 
three clusters. Substantially elevated (red) and decreased (green) expression of the genes is 
observed in individual tumors. 
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Patient cluster 2 
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Figure 6-3  Kaplan-Meier survival analysis of the three clusters of patients from Figure 6-
2. Average survival time of patients in cluster 1 is 50.6 months; average survival time of 
patients in cluster 2 is 82.2 months; average survival time of patients in cluster 3 is 74.8 
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SP NSP Survival 
rate 
SP NSP Survival 
rate 
This study 21 12 14 46% 22 9 72% 26 1 96% 
Guo‘s group [661] 37 25 11 69% 15 6 71% 20 7 74% 
Beer‘s group [662] 4 100 25 19 43% 23 19 57% 37 5 88% 
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Figure 6-4 Hierarchical clustering analysis of the 21 lung adenocarcinoma markers from 
Bhattacharjee‘s microarray dataset [663]. The tumor samples were aggregated into three 
clusters. This 21-gene signature are shared by 10 survival genes sets of lung 
adenocarcinoma derived by using datasets from Beer et al [662] and by using multiple 
random sampling method. 
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Figure 6-5 Kaplan-Meier survival analysis of the three clusters of patients from Figure 6-
4. Average survival time of patients in cluster 1 is 35.7 months; average survival time of 
patients in cluster 2 is 32.0 months; average survival time of patients in cluster 3 is 78.3 
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This study 21 10 23 30% 9 12 43% 22 8 73% 
Guo‘s group 
[661] 
37 9 11 45% 11 13 46% 20 19 51% 
 
6.3.6 Hierarchical clustering analysis of the survival markers  
In the hierarchical analysis for 86 lung adenocarcinoma patients in the Beer‘s dataset 
[662], 21 survival genes were formed into two clusters (Figure 6-6). Genes in gene cluster 
1 are correlated with a poor prognosis of lung adenocarcinoma, whereas genes in cluster 2 
are correlated with a moderate prognosis of lung adenocarcinoma. Figure 6-6 shows that 
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higher expression of the genes in cluster 1 is associated with poor prognosis in patients in 
lung adenocarcinoma, and higher expression of the genes in cluster 2 is associated with 
moderate prognosis in patients in lung adenocarcinoma. On the other hand, the lower 
expression of all these 21 genes in both cluster 1 and 2 is associated with good prognosis. 
The 11 poor-prognosis genes in cluster 1 are CXCR7, POLD3, ADFP, VEGF, SLC2A1, 
RPS3, LDHB, PLD1, SPRR1B, VDR, and TUBA4A, of which four genes, VEGF, 
CXCR7, TUBA4A and VDR, are therapeutic tumor targets. The 10 moderate-prognosis 
genes in cluster 2 consist of PRKACB, CXCL3, REG1A, FUT3, GALNT4, FXYD3, 
CHRNA2, ANXA8, SERPINE1 and BSG. CHRNA2 is a molecular target for lung cancer 
therapy. The target information was obtained from the latest version of therapeutic target 
database [337,714], 
 
Figure 6-6 Hierarchical clustering analysis of the 21 lung adenocarcinoma survival 
markers from Beer‘s microarray dataset [662] 
 
Most of the selected genes were experimentally proved that high expression of these genes 
was related to adverse survivability of patients. High level of serum VEGF (vascular 
endothelial growth factor) in the NSCLC may directly predict worse survival [721,722], 
and acts as a crucial parameter in lung cancer, especially associated with NSCLC 
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[721,722]. The expression of VDR (Vitamin D receptor) was observed in lung 
adenocarcinoma [723]. Increased SLC2A1 (solute carrier family 2) expression in tumors 
was identified as an adverse prognostic factor and a predictive prognosis marker [724]. 
Elevated PLD1 (phospholipase D1) activity could promote tumor progress and show high 
invasive potential [694,725-727]. Up-regulated expression of FXYD3 (FXYD domain 
containing ion transport regulator 3) in cancer indicated that FXYD3 might contribute to 
the proliferative activity of malignancy [691]. In vivo experiments demonstrated that BSG 
(basigin; CD147) overexpression stimulated tumor angiogenesis and growth [678]. Higher 
expression of FUT3 (fucosyltransferase 3) was often observed in high grade and poor 
prognosis tumors [728]. The expression level of SERPINE1 (plasminogen activator 
inhibitor-1) in tissue was significantly and positively correlated with tumor severity and 
tumor size [729], and high level of SERPINE1 could indicate an aggressive phonotype of 
carcinomas [730,731], serving as an indicator of poor prognosis in adenocarcinomas of the 
lung [732]. REG1A (regenerating islet-derived 1 alpha) expression was reported to be 
closely related to the carcinoma invasiveness of neoplasm [733], and to be an independent 
predictor of overall cancer patient survival as well [734]. The over-expression of SPRR1B 
(small proline-rich protein 1B) for prolonged periods might disrupt normal progression of 
mitosis [708]. Therefore, the expression of most of our selected survival marker genes has 
been validated as either directly or closely related to cancer metastasis and prognosis in 
the literatures indicated in Table 6-3. 
6.4 Summary 
In this chapter, the comprehensive gene selection system was further evaluated on the 
selection of survival marker for lung adenocarcinoma. By way of multiple random 
sampling, 21 genes were selected by all of ten sets of lung adenocarcinoma survival 
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marker signatures, in which 34 to 53 genes were selected. These 21 markers were then 
used to develop PNN and SVM prediction models to predict prognosis for lung 
adenocarcinoma patients from different datasets. The survivability analysis by hierarchical 
clustering analysis and Kaplan-Meier survival analysis further suggested that the derived 
signatures from our system could provide better performance when comparing with other 
signatures. Most of the selected genes have been experimentally proved that high 
expression of the genes is relevant to adverse survivability of patients. 12 markers, 
including 5 known targets and 7 novel targets, were successfully predicted as therapeutic 
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7 Conclusion and Future Work  
This last chapter summarizes the major findings and contributions (section 7.1) of this 
work to the progress of using integrated molecular profiling and machine learning 
approaches for therapeutic mechanism, response, target, and biomarker discovery. 
Limitations of the present work (section 7.2) and possible areas for future studies (section 
7.3) are also discussed.  
7.1  Major findings and contributioins 
Drug discovery efforts are nowadays to search for therapeutic regimens that comprise 
more than one active ingredient and drugs that are composed of a single chemical entity 
but combat multiple targets. In chapters 3, a focus study in the early drug discovery 
process on identifying and optimizing the activity of combinations of molecules was 
carried out and the newly identified drug combination actions can result in the 
identification of more effective drug regimens in clinical setting. It is the first time that we 
comprehensivly observed the coordinated interactions and network regulations from a 
systems perspective to understand the mechanism and mode of actions of successful drug 
combinations. The identified modes of actions of drug combinations reveal seven 
important categories of multicomponents therapeutics of current successful drug-
combinations and multi-targeting agents, which will be a starting point to guide a rational 
combination screening by using different mode of actions. 
 
In chapters 4 and 5, the application of integrated molecular profiling, including mutational, 
amplification and microarray gene expression profiles, suggests a useful approach for 
efficiously exploring of drug efficacy issues and developing of novel therapeutic target. 
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First of all, the use of integrated molecular profilingprovide a reasonable explanation for 
the variations observed in clinical TKI drug responses and prediction as its application in 
the future. The identified co-altered genes may serve as potential targets for new drug 
development and choice of combination therapy. Secondly, the exploration of the potential 
epitopes help better understanding of the antigen recognition mechanism and dramatically 
reduce the workload for experimental identification of antigenic scources. The 
methodology developed in this work could be further extended to the studies of other 
fields of immunology in disease treatment.. 
Finally, a robust computational system for gene signature derivation from microarray data 
was developed. A popular and accurate machine learning method, support vector 
machines, was applied to classify the samples. Recursive feature selection incorporating 
with multiple random sampling method and gene consistency evaluation strategies was 
used in gene selection procedure. This system has been successfully applied to selection 
colon cancer markers and lung adenocarcinoma survivability markers. A total of 21 lung 
adenocarcinoma survivability biomarkers were identified and shared by all of the 10 
sampling-sets.  The results from the lung adenocarcinoma survival gene selection suggest 
that, our system is able to derive stable and good predictive marker signatures. The use of 
consensus scoring for multiple random sampling and evaluation of gene-ranking 
consistency seem to have impressive capability in avoiding erroneous elimination of 
predictor-genes due to such noise as measurement variability and biological differences. 
This approach can be further implemented in biomarker selection for other highthroughput 
biological data.  
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7.2 Limitations 
Some obvious limitations of using microarray data are the main obstacles hindering the 
identification of the real TSAs and biomarkers in this study In tumor antigen discovery, 
six known melanoma TSAs were misidentified which mainly because of failing of 
expression analysis. Due to the high cost of microarray experiments, the sample size is 
much smaller than what is required for a satisfactory diagnosis and prognosis of a certain 
disease such as cancer. The currently available platforms for microarray data are different. 
Increasing sample size via synchronizing the different platforms remains a challenged 
task. Although we introduced a multiple random sampling strategies in cancer biomarker 
identification from microarray data, which has shown improved consistency and stability 
while feature selection from 5000 different microarray dataset combinations. The 
combination is far from the complex of heterogenic cancer patients [Ref]. Therefore, large 
size of representative samples may improve the accuracy of our system. Further 
improvement in experimental design, measurement quality, annotation accuracy and 
coverage, and signature-selection will enable the derivation of more accurate signatures 
for facilitating biomarker and target discovery. 
 
In this study, the application integrated molecular profiling is currently limited to the 
RTKs, in which the signaling pathways are rather well established. Sufficient information 
could also be collected for their possible assistant genes. However, it may be much more 
difficult to do so for less characterized pathways involving novel genes. Moreover, 
downstream signaling genes and proteins themselves could be not only actively mutated 
but also highly activated due to the posttranslational modifications and translocation 
activiation. This way makes the analysis on the profiles of gene expression and genetic 
variation is extremely complicated and susceptible to errors. Therefore, more factors 
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should be considered in the cilincial application despite the importance of the drug 
effeicacy evaluation strategy. On the other heand, there is still lack of information about 
clinical trials for many drugs, such as those targeting IGFR-1 and MET. Once their results 
are released, the information could be added to further validate the usefulness of method. 
7.3 Directions for future research 
Both therapeutic selectivity and rational combination therapeutics are major challenge in 
drug discovery. This is especially true for the treatment of cancer, metabolic, or 
inflammation disorders, which must rely on targets that are present in both healthy and 
diseased tissues, and which are thwarted by the compensatory mechanisms available to 
complex biological systems. This work aims to translate the fundamental insight of 
disease causing-genes for systemic drug efficacy studies. Development strategies to 
improve selectivity of targeted and multicomponent therapy will be the focus of my 
research in the near future. To address these challenges, I will mainly focus on the 
development of efficient computational methods for agnostic screening of compound 
combination and multi-target agents from a library of chemical and biological agents that 
perturb a diverse set of molecular targets.   
In practical study of compound combination, a comparatively small number of compounds 
will provide a very large number of combinations; a collection of 1,000 compounds yields 
more than 500,000 pairwise combinations, and many more higher-order combinations. 
Moreover, variations in molar ratio and timing of compound addition can be relevant and 
increase the size of the search space. Therefore, efficient methods, such as improving the 
strategy of dose-response matrix design, are needed to facilitate the screening or 
simulation the possible and rational combination pairs. Moreover, experimental strategies, 
including antibodies, negative dominant controls, antisense oligonucleotides, ribozymes, 
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small-interfering RNAs, and mouse reverse genetics such as knockout phenotypes, are 
need to be established for validation of developed combinations and various ratios of the 
component drugs.  
  
Currently  multi-target kinase inhibitors are among the most successful clinical anticancer 
drugs (e.g. sunitinib against PDGFR and VEGFR, dasatinib against Abl and Src, sorafenib 
against Braf and VEGFR, and lapatinib against EGFR and HER2) and have been actively 
pursued in current drug discovery efforts[735,736]. Methods for efficient search of multi-
target agents are highly desired. It is known that virtual screening (VS) methods have been 
widely explored for facilitating lead discovery against individual targets[737-739].  In 
particular, molecular docking[740], pharmacophore[741], QSAR[742], machine 
learning[743], and combination methods[744] have been extensively used for VS of 
single-target kinase inhibitors, but few multi-target VS studies have been 
reported[745,746]. Thus, it is interesting to develop strategies by using VS method from 
the know multi-target kinase inhibitors and facilicate the highthrouput screening of novel 
agents targeting the larger kinase set[746]. 
 .  
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APPENDICES 
Appendix  Table S1 Literature reported pharmacodynamically synergistic drug combinations due to anti-counteractive actions, in which synergy 
has been determined by well established synergy/additive analysis methods and its molecular mechanism has been revealed. 
Combination target 
relationship 
Drug A (mechanism of actions 
related to synergy) 
Drug B (mechanism of actions 
related to synergy ) 
Reported 




Possible mechanism of synergism in anti-
counteractive actions 
Different targets of 
the same pathway  
 
17-AAG (heat-shock protein 
antagonist, induced cell cycle 
inhibition and apoptosis by 
inhibiting NF-kappaB, AP-1 and 
PI3K/Akt pathways[376], 
Hsp90/FLT3 inhibitor[480]) 
Arsenic trioxide (degraded 
aberrant PML-retinoic acid 
receptor alpha fusion protein, 
generated reactive oxygen 








Arsenic trioxide‘s anticancer generation of reactive 
oxygen species is partially off-set by its own 
counteractive activation of Akt survival pathway[376]. 
17-AAG abrogated arsenic trioxide‘s activation of Akt 
survival pathway[376] to reduce the counteractive effect  
Oxaliplatin (DNA adduct, 
preferably bind to major groove of 
GG, AG and TACT sites,  
complex conformation different 
from that of cisplatin[408], caused 
DNA strand break and non-DNA 
initiated apoptosis[409]) 
Irinotecan (DNA topoisomerase 
I inhibitor, increased EGFR 




in AZ-521 and 
NUGC-4 cells, 





Effect of oxaliplatin‘s DNA adduct formation[408] 
may be partially reduced by certain mutant DNA 
topoisomerase I acting on DNA adduct to generate 
different topoisomers[412]. Irinotecan inhibition of 
DNA topoisomerase I[410] partially off-sets this 
counteractive activity 
Different targets of 
the same pathway 
that regulated the 
same target 
Cisplatin (DNA inter- and intra- 
strand adduct, preferably bind to 
the major groove of GG, AG and 
TACT sites[381] thereby inhibited 
DNA polymerization and induced 
DNA damage to trigger 
apoptosis[510]) 
Trabectedin (bind covalently to 
central G in the minor groove of 
selected DNA pyrimidine-G-G 
and purine-G-C triplets[385], 
formed unusual DNA 
replication intermediates 
thereby inhibited DNA 
replication[386],  interacted 
with DNA and DNA repair 








Trabectedin inhibition of DNA replication[386] reduced 
the counteractive activity of DNA polymerase mediated 
mutagenic translesional bypass replication across 
cisplatin-DNA adducts[382] 
Cisplatin (DNA inter- and intra- 
strand adduct, preferably bind to 
the major groove of GG, AG and 
Topotecan (topoisomerase I 
inhibitor, interacted with DNA, 







Topotecan blocking of DNA replication[383] reduced 
the counteractive activity of mutagenic translesional 
bypass replication across cisplatin-DNA adducts[382] 
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TACT sites[381] thereby inhibited 
DNA polymerization and induced 
DNA damage to trigger 
apoptosis[510]) 
topoisomerase-DNA complex, 
thereby blocked DNA 
replication forks[383]) 
index, median- 
drug effect method 
Cisplatin (DNA inter- and intra- 
strand adduct, preferably bind to 
the major groove of GG, AG and 
TACT sites[381] thereby inhibited 
DNA polymerization and induced 
DNA damage to trigger apoptosis 
[510]) 





cytotoxic effect in 
tumour cell lines 




Sabarubicin blocking of DNA replication
17
 reduced the 
counteractive activity of mutagenic translesional bypass 
replication across cisplatin-DNA adducts[382] 
DL-cycloserine (bacterial cell wall 
synthesis inhibitor[413]) 
Epigallocatechin gallate 
(disrupted integrity of bacterial 
cell wall via direct binding to 
peptidoglycan[413]) 
Synergistic effect 






Cell wall alteration may induce counteractive cell wall 
synthesis to restore cell wall integrity[414], DL-
cycloserine inhibition of cell wall synthesis hindered the 
restoration thereby enhanced Epigallocatechin gallate‘s 
cell wall disruption activity 
Gefitinib (EGFR tyrosine kinase 
inhibitor, induced cyclin-
dependent kinase inhibitors, 
inhibited p27 and p21, decreased 
MMP-2 and MMP-9 enzyme 
activity[422]) 
Irinotecan (DNA topoisomerase 
I inhibitor, increased EGFR 









Irinotecan produced anticancer effect via DNA 
topoisomerase inhibition, but promoted proliferation by 
increased phosphorylation of EGFR in certain cell 
types[410]. Gefitinib produced anticancer effect via 
EFFR tyrosine kinase inhibition and others [422], which 
offsets the counteractive effect of increased EGFR 
phosphorylation 
Different targets of 
related pathways 
17-AAG (heat-shock protein 
antagonist, induced cell cycle 
inhibition and apoptosis by 
inhibiting NF-kappaB, AP-1 and 
PI3K/Akt pathways[376]) 
Etoposide (topoisomerase II 
inhibitor, induced DNA double-
strand breaks during DNA 
replication[748], increased 
expression of DNA repair-
related protein Rad51[749]) 
Synergism 
between etoposide 







The effect of etoposide‘s DNA strand break is partially 
offset by its own counteractive increase of expression of 
DNA repair-related protein Rad51[749]. Higher levels 
of Rad51 and its interacting partner Chk1 are associated 
with presence of FLT3[480]. Inhibition of Hsp90/FLT3 
by 17-AAG may reduce Rad51 and Chk1 to reduce the 
counteractive effect 
Artemisinin (interacted with heme 
to mediate its decomposition into 
free radicals that alkylate essential 
malarial proteins[750] ) 




guanylate cyclase inhibitor[753] 
Synergistic  
antimalarial 






Artemisinin's antimalarial activity possibly arise from 
its interaction with heme that facilitates heme 
conversion into free radical[755], which can be off-set 
by parasite's counteractive actions of heme 
polymerization into insoluble hemozoin and heme 
degradation by glutathione[756]. These counteractive 
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falciparum 
strains[754] 
actions are partially reduced by methylene blue's 
inhibition of heme polymerization[751] and glutathione 
reductase[752], resulting in synergistic antimalarial 
effect 
Erlotinib (EGFR tyrosine kinase 
inhibitor[757]) 
Pemetrexed (dihydrofolate 
reductase,  thymidylate synthase 
and glycinamide ribonucleotide 
formyl transferase 
inhibitor[758-760];increased 








Erlotinib's inhibition of EGFR may trigger  activation of 
Akt-mediated negative-feedback signaling, leading to 
increased membrane HER3 expression and reduced 
HER3 phosphatase activity, thereby evading EGFR 
inhibition[31]. This counteractive action can be partially 
reduced by pemetrexed's reduction of Akt 
phosphorylation[761], leading to synergistic effect 
Bortezomib (proteasome inhibitor, 
protected pro-apoptotic pathways 
by inhibiting proteasome 
degradation of P53[762], inhibited 
NF-kappaB and induced 
endoplasmic reticulum stress[763]) 
Sodium butyrate or 
suberoylanilide hydroxamic acid 
(Histone deacetylase inhibitor, 
promoted histone acetylation 
and chromatin structure 
relaxation[764], down-regulated 
expression levels of Bcr-abl, c-
Myc and HDAC3[765]; 











HDAC inhibitor's pro-apoptotic down-regulation of 
Bcr-abl is partially offset by its mediation of NF-
kappaB activation [763]. This counteractive action can 
be partially reduced by bortezomib's pro-apoptotic 
inhibition of NF-kappaB[766] 
Lonafarnib (farnesyl transferase 




apoptotic pathways by inhibiting 
proteasome degradation of 
P53[762], inhibited NF-kappaB 







Bortezomib produced anticancer effect by inhibiting 
proteasome degradation of P53[762]. But protesome 
inhibition reduced ubiquitin-dependent cyclin D1 
degradation, which hindered Ras-mediated cell growth 
arrest and apoptosis[769] thereby reduced bortezomib‘s 
anticancer effect. This counteractive activity can be 
partially offset by lonafamib inhibition of Ras 
farnesylation[767] that subsequently induced apoptosis 
by activating the pro-apoptotic protein BAD in BCL2 
family[770] 










ER crosstalks with EGFR and HER-2/neu[774], 
signaling via EGFR and HER-2/neu can activate ER and 
its coactivator AIB1, ER of cell membrane can activate 
EGFR/HER-2[773]. Anti-HER-2/neu antibody 
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trastuzumab[563] stopped HER-2/neu induced 
activation of ER and AIB1. ER antagonist 
tamoxifen[771] stopped ER induced activation of 
EGFR/HER-2. Use of both drugs reduced the 
counteractive crosstalks  
Rapamycin or deforolimus  
(mTOR inhibitor[775]) 




in animal models 
of human lung 









method of Chou 
and Talalay 
Effects of the inhibition of mTOR by rapamycin or its 
analogue deforolimus may be partially offset by 
NPM/ALK-induced mTOR activation that is transduced 
through the MEK-ERK signaling pathway[778]. This 
countractive action may be reduced by CI-1040 or 
PD0325901's inhibition of MEK[776] 
Paclitaxel (stabilized microtubules 
via alpha-tubulin acetylation[395] 
distorted mitosis to trigger 
apoptosis[415], induced p53 and 
CDK inhibitors[416], activated 
caspase-10, caspases-8, -6, and -3, 
leading to apoptosis[417], 
activated ERK [418] and 
CDK2[419], activated p38 MAP 
kinase and p53[420]) 
NU6140 (CDK inhibitor, down-







Use of both drugs promoted complementary apoptosis 
activities via triple actions of surviving down-regulation 
by NU6140[421], microtubule stabilization[395] and 
caspase activation[417] by paclitaxel. Paclitaxel‘s 
promotion of apoptosis may be partially offset by its 
counteractive pro-growth activation of ERK[418] and 
CDK2[419], which may be partially reduced by 
NU6140‘s inhibition of CDK[421] 
Different targets of 
cross-talking 
pathways 
Gefitinib (EGFR tyrosine kinase 
inhibitor, induced cyclin-
dependent kinase inhibitors p27 
and p21, decreased MMP-2 and 
MMP-9 enzyme activity[422]) 
Taxane (disrupted microtubule 
by binding to beta-tubulin[423], 
induced tumor suppressor gene 
p53 and cyclin-dependent kinase 
inhibitors P21, down regulated 
Bcl-2, leading to 
apoptosis[416]) 
Strong synergistic 






Taxane produced anticancer effect by inducing 
apoptosis[416] and microtubule disruption[423]. 
Crosstalk between EGFR and hypoxia-inducible factor-
1alpha pathways increased resistance to apoptosis by 
up-regulating survivin[28]. Gefitinib produced 
anticancer effect via EFFR tyrosine kinase inhibition, 
which offsets the counteractive EGFR-hypoxia crosstalk 
in resisting taxane‘s pro-apoptosis activity 
Gleevec (selective inhibitor of c-
Abl, p210bcr-abl, c-Kit, and 






Gleevec inhibition of Abl may leed to selection of 
resistant mutatons in Bcr-Abl[783], some of the Bcr-Abl 
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method of Chou 
and Talalay 
mutants bind to Ras associated proteins to activate an 
alternative Ras mediated tansformation[784] and 
survival[785] signal. The survival signal involves 
activation of survival cascades via Ras/Raf/MEK/ERK 
signaling[785]. This counteractive alternative signal 
may be partially blocked by using farnesyltransferase 
inhibitor to inhibit Ras farnesylation  
Cisplatin (DNA inter- and intra- 
strand adduct, preferably bind to 
the major groove of GG, AG and 
TACT sites[381] thereby inhibited 
DNA polymerization and induced 






216 as an HER2- 






Cisplatin formed DNA adduct to induce DNA damage 
and apoptosis, which may be attenuated by DNA repair 
systems in certain cell types[510]. This counteractive 
DNA repair action may be partially reduced by 
herceptin's anti-HER2 activitity that suppressed DNA 
repair pathway known to crosstalk to HER2[564] and 
inhibited PI3K-AKT pathway[565] to enhance 
apoptosis[566] 
Dasatinib(inhibitor of c-abl,src, 
fyn, lck and kit[787,788]) 
PKC412 (inhibitor of Flt[789], 








Inhibition of c-abl and src enhances catalytic activity of 
some PKC subtypes and their binding to Bcr/Abl in 
specific cell types[792]. Complex of abl with certain 
PKC subtypes enable communication of ER stress to 
mitochondria, which is an essential step in subsequent 
apoptosis [793]. This possible counteractive action 
against dasatinib's inhibition of c-abl and src
77
 may be 
partially alleviated by PKC412's inhibition of PKC
80
 
Different targets in 
the same pathway 
that crosstalks via 
other pathway 
Gefitinib (EGFR tyrosine kinase 
inhibitor, induced cyclin-
dependent kinase inhibitors p27 
and p21, decreased MMP-2 and 
MMP-9 enzyme activity[422]) 
PD98059 (MEK inhibiton[425]) Synergistic 








An autocrine growth loop critical for tumor growth is 
formed in EGFR-Ras-Raf-MEK-ERK network such that 
activated MEK activates ERK which upregulates EGFR 
ligands which promotes the autocrine growth loop[426]. 
This loop produced counteractive activity against 
gefitinib or PD98059 by reducing the effect of MEK or 
EGFR tyrosine kinase inhibition. Simultaneous use of 
both drugs helps disrupting this autocrine growth loop, 
thereby enhancing each other‘s effect 
Same target 
(different sites) 
AZT (HIV-1 reverse transcriptase 
inhibitor[427]) 






& Theorell plot 
AZT resistance is partly due to phosphorolytical 
removal of the AZT-terminated primer[430], NNRTI 
inhibited RT catalyzed phosphorolysis, thereby reduced 
AZT resistance[429] 
                                                                                                                                          Appendices   
                                                                                                                                                               
                                                                                                                            233                                                                                                                                                                                                            
Appendix  Table S2 Literature reported pharmacodynamically synergistic drug combinations due to complementary actions, in which synergy 




Drug A (mechanism of actions 
related to synergy) 
Drug B (mechanism of 
actions related to synergy ) 
Reported 




Possible mechanism of synergism in promoting 
complementary actions 
Different targets of 
the related pathways 
that regulate the 
same targets 
17-AAG (Inhibited 
Hsp90/FLT3[480], which degraded 
ALK and Akt, dephosphorylated 
ERK, downregulated cyclin D1, 
CDK4, and CDK6 in ALCL 
cells[388], heat-shock protein 
antagonist, induced cell cycle 
inhibition and apoptosis by 
inhibiting NF-kappaB, AP-1 and 
PI3K/Akt pathways[376]) 
U0126 (MEK1/2 inhibitor) 17-AAG synergizes 
with U0126 in 









Activated ERK promotes ALCL cell survival. HSP90 
is abundantly expressed in ALCL cells. 17-AAG 
produced its effect on ALCL cells by inhibiting 
Hsp90/FLT3 which dephosphorylated ERK [388]. 
Such an action is complemented by U0126‘s inhibition 
of MEK1/2 which inhibited ERK[388] 
ABT-737(Bcl-2 family proteins 
Bcl-2, Bcl-xL inhibitor[794]) 
Dexamethasone (down-
regulatied Bcl-2 and Bcl-
xL[795]) 





ABT-738‘s inhibition of Bcl-2 and Bcl-xL[794] is 
complemented by dexamethasone ‗s down-regulation 
of Bcl-2 and Bcl-xL[795] 
Azithromycin (hindered bacterial 
protein synthesis by binding to 50S 
component of 70S ribosomal 
subunit[431]) 
Ceftazidime (blocked 
penicillin-binding proteins and 









Hindered protein synthesis by azithromycin[431] 
reduces penicillin-binding proteins to complement 







effect in HER-2 
positive breast 
cancer cell lines[797] 
Combination 
Index 
Bortezomib's inhibition of NF-kappaB[796] is 
complemented by herceptin's inhibition of HER-2 
receptor[797] that subsequently blocks EGF-induced 
NF-kappaB activation[798] 
Gleevec (selective inhibitor of c-
Abl, p210bcr-abl, c-Kit, and 
PDGF-R tyrosine 
kinases[779,780]) 
Histone deacetylase inhibitor 
(promoted histone acetylation 
and chromatin structure 
relaxation[764]; down-
regulated Bcr-abl, c-Myc and 
HDAC3[765]) 
Synergistically 
induced apoptosis in 
STI571-resistant 
K562 and 
LAMA 84 cells[799] 
Combination 
index 
Gleevec 's pro-apoptotic inhibition of Abl[780,800]  
may be partially complemented by Histone deacetylase 
inhibitor's down-regulation of Bcr-abl[765] 
Rapamycin or deforolimus  (mTOR 
inhibitor[775];targeted transcription 
3-BrOP (inhibited glycolysis 





mTOR inhibition by rapamycin further compromised 
the ability of cells to uptake glucose when the 
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factor yy1 to down-regulate 
mitochondrial transcriptional 
regulators PGC-1alpha, oestrogen-
related receptor alpha and nuclear 
respiratory factors[801] (18046414) 
key enzyme in the glycolytic 
pathway[802]) 
metabolism in cancer 
cells[802] 
glycolytic pathway is inhibited by 3-BrOP[802], which 
is partly due to the down-regulation of nuclear 
respiratory factors by 3-BrOP[801] that down-
regulated glycolytic and mitochondrial oxidative 
proteins[803] 
Triclosan (E.coli fabI inhibitor, 
antimicrobial activity[348]) 
Antisense drug Ec106fabI 
targeting mRNA of E.coli 
fabI[348] 
Some combinations 
of protein inhibitor 
and antisense drug of 










Joint inhibition and reduction of bacterial protein 
Celecoxib (COX-2 inhibitor, 
inactivated protein kinase Akt to 
stop its suppression of apoptosis, it 
also inhibited ER Ca2+ 
ATPase[397]) 
Emodin (tyrosine kinase 
inhibitor [398], down-
regulated protein kinase Akt 
via inhibition of components 
of the PI3K pathway to reduce 
AKT suppression of 
apoptosis[399]) 
Synergistically 







In addition to its antitumor activity via tyrosine kinase 
inhibition, emodin down-regulated Akt[399] to 
complement celecoxib‘s inactivation of Akt[397] to 
reduce Akt‘s suppression of apoptosis 
Different targets of 
the related pathways 
that regulate the 
same process 
17-DMAG (Inhibited Hsp90, which 
prevented stabilization of "client" 
cancer targets such as mutated p53, 
Raf-1, ErbB2, and other signaling 
proteins[804], thereby induced 
apoptosis and growth arrest in 
certain carcinoma cells[805]. 
Attenuated STAT3 and phospho-
ERK level[806] 
Arsenic trioxide (inhibited 
thioredoxin reductase leading 
to apoptosis, which is the basis 
for its anticancer activity[807], 
down-regulated constitutive 
STAT3 activity in AML 
cells[804] 






activity and inducing 





Isobologram Both drugs complement each other‘s activity by 
inducing apoptosis via Hsp90[804] and thioredoxin 
reductase inhibition[807]. Moreover, both drugs 
downregulated the constitutive STAT3[804,806], 
which are overexpressed in 50% of AML cases. 
Aplidin (induced apoptosis by 
activating and clustering death 
receptors FasL[434],  activating  
JNK, EGFR, Src, and 
Cytarabine (DNA binder[437], 
inhibited synthesome 
associated DNA polymerase 
alpha activity[438], inhibited 
Aplidin synergizes 
with cytarabine in 
exhibiting anticancer 





Both drugs complement each other‘s activity by 
inducing apoptosis via each of the two major cascades 
of apoptosis pathway, aplidin activated and clusterd 
death receptors of FasL [434] which subsequently 
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p38MAPK[435], inhibited VEGF 
release and secretion[436]) 
RNA synthesis and DNA 
repair that lead to increased 
cellular stress and reduced 
survival protein Mcl-l which 
subsequently activate caspase 
and apoptosis [439]) 
and lymphoma 
models in vitro and 
in vivo[440] 
activates the receptor-mediated extrinsic cascade[441], 
cytarabine increased cellular stress and reduced 
survival protein Mcl-1[439] which subsequently 
triggers the mitochondrial intrinsic cascade[441]. 
Different targets of 
the same pathway 
that regulate the 
same target 
Paclitaxel (stabilized microtubules 
via alpha-tubulin acetylation[395], 
distorted mitosis to trigger 
apoptosis [415] and induce p53 and 
CDK inhibitors[416]) 
Lonafarnib (farnesyl 
transferase inhibitor, inhibited 
Ras farnesylation, microtubule 
associated alpha-tubulin 
deacetylase[394], and P-
gp[808], metabolized by 






Thin plate spline 
method 
Both drugs complement each other‘s microtubule 
stabilization effects through enhanced acetylation 
activity of alpha-tubulin by paclitaxel[395] and 
reduced deacetylation activity of alpha-tubulin 
deacetylase by lonafarnib[394] 
Paclitaxel (stabilized microtubules 
via alpha-tubulin acetylation[395], 
distorted mitosis to trigger 
apoptosis[415] and induce p53 and 
CDK inhibitors[416]) 











Both drugs complement each other‘s microtubule 
stabilization effects through enhanced acetylation 
activity of alpha-tubulin by paclitaxel[395] and 
reduced deacetylation activity of alpha-tubulin 
deacetylase by tubacin[442] 
Paclitaxel (stabilized microtubules 
via alpha-tubulin acetylation[395], 
distorted mitosis to trigger 
apoptosis[415] and induce p53 and 
CDK inhibitors[416]) 
Trichostatin (histone 
deacetylase inhibitor, inhibited 
microtubule associated alpha-
tubulin deacetylase activity 
[394], acetylated core 
histones at PTEN promoter 
thereby induced PTEN 
transcription leading to 
enhanced apoptosis[811], 
induced cyclin-dependent 
kinase inhibitor p21[812] 
thereby induced G1 arrest and 












These drugs complement each other by two actions. 
One jointly promotes apoptosis by triggering it via 
aberrant mitosis (paclitaxel)[415] and by enhancing it 
via upregulating PTEN (trichostatin)[811]. The other 
involves microtubule stabilization by enhanced 
acetylation activity of alpha-tubulin (paclitaxel)[395] 
and reduced deacetylation activity of alpha-tubulin 
deacetylase (trichostatin [394] 
Different targets of 5-AZA-2‘-deoxycytidine (DNA Fluorouracil (metabolite Synergistic effect of  5-AZA-2‘-deoxycytidine inhibition of DNA 
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related pathways that 
regulate the same 
target 
methyltransferase -1 and -3B 
inhibitor, stopped silencing of the 
pro-apoptotic BI [387]) 
inhibited thymidylate synthase 
that stopped DNA 
synthesis[550], stabilized and 
activated P53 by blocking 







methyltransferase -1 and -3B stopped silencing of 
tumor suppressor gene, pro-apoptotic BIK, in cancer 
cells[387]. Fluorouracil stabilized and activated P53 
[551], activation of P53 upregulated BIK[815] which 
complements 5-AZA-2‘-deoxycytidine‘ un-silencing 
of BIK 
5-AZA-2‘-deoxycytidine (DNA 
methyltransferase -1 and -3B 
inhibitor, stopped silencing of the 
pro-apoptotic BIK[387]) 
Depsipeptide (histone 
deacetylase inhibitor, induced 




Valeriote & Lin‘s 
comparative 
analysis method 
5-AZA-2‘-deoxycytidine inhibition of DNA 
methyltransferase -1 and -3B stopped silencing of 
tumor suppressor gene, pro-apoptotic BIK, in cancer 
cells to complement depsipeptide‘s induction of the 
same gene[387] 
Gefitinib (EGFR tyrosine kinase 
inhibitor, induced cyclin-dependent 
kinase inhibitors p27 and p21, 
decreased MMP-2 and MMP-9 
enzyme activity[422]) 
ST1926 (activated MAP 
kinases p38 and JNK, released 









Gefitinib 's inhibition of EGFR is complemented by 
ST1926's activation of MAP kinases p38[443] that 
subsequently mediates internalization of EGFR[445], 
and by ST1926's activation of caspase proteolytic 
cascade[443] 
Different targets of 
related pathways 
Fluorouracil (metabolite inhibited 
thymidylate synthase that stopped 
DNA synthesis[550], stabilized and 
activated P53 by blocking MDM2 
feedback inhibition through 
ribosomal proteins[551]) 
RPR-115135 (farnesyl 






Joint tumor suppressive (via fluorouracil stabilization 
of P53[551]) and antiproliferative (via RPR-115135 
inhibition of Ras farnestlation[817]) actions 
CP55940 (cannabinoid agonist, 
elicited analgesic effects in acute 
and chronic pain states via spinal 
and supraspinal pathways[391]) 
Dexmedetomidine (alpha2 
adrenoceptor agonist, activated 









Cannabinoid agonist modulated spinal and supraspinal 
pathways[391] that regulate pain[390] , 
dexmedetomidine promoted sleepiness[454] that 
sustains reduction in spike activity of spinoreticular 
tract neurons[389] 
     
Dipropofol (inhibited bacterial 




transpeptidation reactions in 
polymerization of bacterial 
cell wall peptidoglycan, 






Hindered protein synthesis by dipropofol[819] might 
reduce cell-wall synthesis proteins and thus 
complement vancomycin‘s inhibition of cell wall 
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biosynthesis[820]) 
Tipifarnib (farnesyl transferase 
inhibitor, inhibited Ras 
farnesylation, upregulated death 
receptor 5, a p53 target gene and 
receptor of TRAIL[821], inhibited 
P-gp[822]) 
Zoledronic acid (activated 
caspase 3 and fragmented 
PARP to induce apoptosis, 
reduced Ras activity and 
antagonized its stimulation by 
EGF[823]) 





Joint anti-growth activities via tipifarnib inhibition of 
Ras farnesylation[821] and zoledronic acid reduction 
of Ras activity[823], joint apoptosis activities via 
tipifarnib upregulation of death receptor 5[821] and 
zoledronic acid activation of caspase 3[823], 
upregulation of death receptor helps to activate 
capspases[824]) 
Paclitaxel (stabilized microtubules 
via alpha-tubulin acetylation[395] 
distorted mitosis to trigger 
apoptosis[415] and induce p53 and 
CDK inhibitors[416], activated 
caspase-10,  caspases-8, -6, and -3, 
leading to apoptosis[417], 
activated ERK[418] which in turn 
activates CDK2[419], activated 
p38 MAP kinase and p53[420]) 







Use of both drugs promoted complementary apoptosis 
activities via triple actions of surviving down-
regulation by NU6140[421], microtubule 
stabilization[395] and caspase activation[417] by 
paclitaxel. Paclitaxel‘s promotion of apoptosis may be 
partially offset by its counteractive pro-growth 
activation of ERK [418] and CDK2[419], which 




Iloprost (prostacyclin receptor 
agonist leading to vascular 
relaxation[447], activated 
phospholipase C [448] that 
promoted VEGF-induced skin 
vasorelaxation [449], self-
regulated endothelial cell 
adhesion molecules[450]) 




Dose effect curve 
surpassed that of 
individual drug 
alone combined 
Sildenafil produced vasodilation activity by inhibiting 
phosphodiresterase-5[446], iloprost produced 
vasodilation activity by agonizing prostacyclin 
receptor[447] and by activating phospholipase 
C[448]. Targeting of multiple vasodilatation 
regulation pathways  NO/cGMP[452], MaxiK channel 
-mediated relaxation[453], and phospholipase C[448] 
contribute to the synergistic actions. 
Different target 
subtypes of related 
pathways 
Dexmedetomidine (alpha2A 
receptor agonist, produced 
antinociceptive effect via an 
endogenous sleep-promoting 
pathway[454]) 
ST-91 (agonist of alpha2 
receptor of other subtypes, 
produced antinociceptive 
effect via upraspinal receptors 
and at both spinal and 
brainstem levels of the 







ST-91 modulated spinal and supraspinal 
pathways[455] that regulate pain[390] , 
dexmedetomidine promoted sleepiness[454] that 
sustains reduction in spike activity of spinoreticular 
tract neurons[389] 
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Same target 
(different states) 
Mycophenolate mofetil (inosine 
monophosphate dehydrogenase 
inhibitor, drug metabolite 
mycophenolic acid binds to the site 




dehydrogenase inhibitor, drug 
metabolite mizoribine 
monophosphate binds to the 
enzyme in transition state 
having a new 
conformation[457]) 
Mild synergistic 







Simultaneous inhibition of enzyme reactant-state and 
transition state have the advantage of covering more 
conformational space for the inhibitors to better 





Paclitaxel (stabilized microtubules 
via alpha-tubulin acetylation[395], 
distorted mitosis to trigger 
apoptosis[415] and induce p53 and 
CDK inhibitors[416]) 
Discodermolide (stabilized 
microtubule dynamics and 
enhanced microtubule polymer 
mass[459] resulting in 
aberrant mitosis that triggers 
apoptosis [415] and induced 
p53 and CDK 
inhibitors[416], retained 
antiproliferative activity 
against carcinoma cells 






Explanation 1: Binding sites of both drugs 
overlapping, certain mutations resistant to one drug are 
ineffective against the other, thereby covering more 
diverse range of mutant types[60,340,462]. 
Explanation 2: One drug binds and induces 
conformational change in tubulin that increases the 
binding affinity of the other[60,463]. Explanation 3: 
These drugs may differentially bind to or affect 
different tubulin subtypes, microtubule architectures, 
or microtubule regulators, thereby covering more 




Paclitaxel (stabilized microtubules 
via alpha-tubulin acetylation[395], 
distorted mitosis to trigger 
apoptosis[415] and induce p53 and 
CDK inhibitors[416]) 
Peloruside A (binds at a 
different site from that of 
paclitaxel, stabilized 
microtubules via binding to a 
unique site on the tubulin 
alpha, beta heterodimer[465]) 
Peloruside A 
synergizes with 
paclitaxel to enhance 
the antimitotic action 
of the drugs[465] 
Berenbaum‘s 
combination index 
Explanation 1: Binding sites of both drugs 
overlapping, certain mutations resistant to one drug are 
ineffective against the other, thereby covering more 
diverse range of mutant types[60,340,462]. 
Explanation 2: One drug binds and induces 
conformational change in tubulin that increases the 
binding affinity of the other[60,463]. Explanation 3: 
These drugs may differentially bind to or affect 
different tubulin subtypes, microtubule architectures, 
or microtubule regulators, thereby covering more 
diverse range of microtubule dynamics[57,60,435,463] 
Paclitaxel (external DNA binder 
with partial helix stabilization 
without altering B-form, binds to 
A-T, G-C bases and the backbone 
PO(2) groups[392], interacted 
Trabectedin (formed DNA 
adduct at the central G in 
minor groove of pyrimidine-
G-G and purine-G-C triplets 






Both drugs enhance each other‘s effect by two actions: 
(1) binding to different sites of DNA at mutually 
compatible conformation, thereby complement each 
other on their blocking of DNA polymerase and 
transcription processes[385,392], (2) these bindings 
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with DNA topoisomerase I[825]) hamper strand separation and 
stall replication and 
transcription forks[385], 
induced topoisomerase I 
mediated protein-linked DNA 
breaks[826], traped protein 
from the nucleotide-excision 
repair system resulting in 
DNA damage[827], induced 
transient p53 elevation[828], 
and it is a P-gp 
substrate[829]) 
facilitated interaction with DNA topoisomerase 
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Appendix  Table S3 Literature reported pharmacodynamically synergistic drug combinations due to facilitating actions, in which synergy has 





Drug A (mechanism of actions 
related to synergy) 
Drug B (mechanism of actions 











binding protein 2A and thus 
bacterial cell wall 
synthesis[466]) 







Most penicilling-binding proteins are associated 
with membrane[468], membrane disruption by 
daptomyci [467] likely hinders the functions of 
penicilling-binding proteins and further expose 
them to ampicillin binding 
Gentamicin (targeted bacterial 
ribosome, caused misreading of 
the genetic code and inhibited 
translocation, thereby disrupted 
protein synthesis[401]) 
Vancomycin (inhibited bacterial 
cell wall peptidoglycan 
synthesis[402], altered 
permeability of cell membrane 
and selectively inhibited 








Vancomycin altered membrane 
permeability[403] thereby enhanced gentamicin 
penetration into bacterial cells and its 
bioavailability 
Daptomycin (disrupted bacterial 
membrane function without 
penetrating into the 
cytoplasm[831], depolarized 
membrane[832], and inhibited 
lipoteichoic acid synthesis[833]) 
Rifampicin (interfered with 
bacterial nucleic acid synthesis 








Depolarization of bacterial membrane by 
daptomycin[832] enhanced rifamapicin 





regulate the same 
target  
 
BQ-123 (Endothelin A receptor 
antagonist, mediated 
vasodilatation[405]) 
Enalapril (angiotensin converting 
enzyme inhibitor, up-regulated 
Endothelin B[406], vasodilation 
is mediated by both ACE 






blind, crossover studies 
Enalapril up-regulated ETB as well as inhibited 
ACE leading to vasodilation[406,407] , BQ-123 
antagonism of ETA caused vasodilation[405] 
and displaced endogenous ET-1 from ETA onto 
upregulated ETB to enhance its activity by 
effectively increasing ETB agonist 
concentration[404] 
Candesartan-cilexetil 
(angiotensin AT1 receptor 
antagonist[469] ) 
Ramipril (angiotensin converting 
enzyme inhibitor[470], reduced 






leftwards compared to 
hypothetic additive 
curve 
Candesartan-cilexetil reduced systolic blood 
pressure by antagonizing angiotensin AT1 
receptor[469], ramipril reduced systolic blood 
pressure by inhibiting angiotensin converting 
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enzyme[470], ramipril inhibited AT1 receptor 
agonist formation[471] thereby facilitating the 
action of candesartan-cilexetil by reducing AT1 
agonist-antagonist competition 
Same target Saquinavir (HIV protease 
inhibitor[836], Pgp 
substrate[837]) 
Lopinavir (HIV protease 
inhibitor (9835517), inhibited 
Pgp in CACO-2 cells[837]) 
Synergistic inhibition of 
HIV1 replication in MT4 
cells[837] 
Combination indices As a Pgp substrate, HIV protease inhibitor 
saquinavir may be removed by Pgp mediated drug 
efflux, making it less available for HIV protease 
inhibition[837]. Inhibition of Pgp by another HIV 
protease inhibitor lopinavir facilitates the 
therapeutic action of saquinavir by blocking its 
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Appendix  Table S4 Literature reported pharmacodynamically additive drug combinations, in which additive action has been determined by well 
established synergy/additive analysis methods and its molecular mechanism has been revealed 
Action type Combination target 
relationship 
Drug A (mechanism of 
action related to additive 
effect) 
Drug B (mechanism of action 











Different targets of 
the same pathways 
that regulate the 
same target 
 
Citicoline (increased BCL-2 
expression[838], regulated 
Bcl-2 antiapoptotic pathway 
for neuron cell survival [839]. 
Bcl-2 interacted with IP(3) 
receptor Ca(2+) channels on 
ER, regulating their opening in 
response to IP(3) and thus 
inhibiting IP(3)-mediated 
Ca(2+) signals that induce 
apoptosis[840]) 
Nimodipine (L-type voltage 
sensitive calcium channel 
blocker [838], reduced Ca(2+) 






infarct  volume 
Citicoline upregulated Bcl-2[838], 
thereby enhanced inhibition of IP(3)-
mediated Ca(2+) signals which reduced 
apoptosis[840].Nimodipine reduced 
Ca(2+) influx to rescue cortical neurons 
from apoptosis[841].  
CP55940 (cannabinoid 










actions in some 
cases and 
synergistic 




Both produced therapeutic actions via 
coupling to postsynaptic GIRK2 
potassium channels[843,845] 
CP55940 (cannabinoid 
antagonist[842], coupling to 
postsynaptic GIRK2 
potassium channels[843]) 
Morphine (mu opioid receptor 
agonist[846], coupling to 




actions in some 
cases and 
synergistic 




Both via their coupling to postsynaptic 
GIRK2 potassium channel [843,847] 
Diazoxide (ATP-sensitive K+ 
channel activator[481], 
enhanced ATPase activity of 
channel regulatory subunits 
sulphonylurea 
Sodium nitroprusside (activated 
ATP-sensitive K+ 
channel[481], acted as the 






& dose effect data 
analysis 
Diazoxide enhanced ATPase activity of 
channel regulatory subunits[482], 
Sodium nitroprusside opened the channel 
by acting as the donor of nitric 
oxide[848]. 
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receptors[482]) channel[848]) 
Diazoxide (ATP-sensitive K+ 
channel opener[481], 
enhanced ATPase activity of 





channel[481], activated channel 
via a cGMP-dependent protein 





& dose effect data 
analysis 
Diazoxide enhanced ATPase activity of 
channel regulatory subunits[482], 
Dibutyryl-cGMP activated channel via a 
cGMP-dependent protein kinase 
[483,484] 




soluble guanylate cyclase 
inhibitor[753] 












Both acted redundantly at the  heme 
polymerization pathway 
Retinoic acid (activated and 
up-regulated retinoic acid 
receptor beta, a tumor 
suppressor that promote 
apoptosis[850]) 
Trichostatin A (histone 
deacetylase inhibitor, 
reactivated retinoic acid 
receptor beta mRNA 
expression[851]) 
Additive 




& dose effect data 
analysis 
Retinoic acid activated and up-regulated 
the target[850], Trichostatin A up-
regulated the target[851] 
Same target 
(different sites with 
direct contact with 
agonist site) 
Propofol (interacted with 
GABA A receptor, acting on 
at TM3 segment of the beta2 
subunit[486]) 
Sevoflurane (interacted with 
GABA A receptor at Ser270 of 











Propofol binds to TM3 segment of the 
beta2 subunit[486], Sevoflurane binds to 
Ser270 of the alpha1 subunit[487]. As 
agonist binding site is located between 
alpha1 and beta2 subunits[489], both 
drugs likely hinder agonist activity, 
thereby producing mutually substitutable 
actions. 




binding protein 2A and thus 
bacterial cell wall 
synthesis)[466] 
Imipenem (inhibited penicillin-
binding protein -1A, -1B, -2, -4 









Both acted at the same active site of 
penicillin-binding protein 2A[491] but at 
relatively high MICs of ≥32g/ml [466]. 
The relatively high MICs make it less 
likely for both drugs to saturate target 
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Different targets of 
unrelated pathways 
Anidulafungin (inhibitor of 
beta-(1,3)-dglucan synthase, 
an essential component of 
fungal cell wall)[852] 
Amphotericin B (formed ion 









Anidulafungin disrupted cell wall 
formation during reproductive 
cycle[852], Amphotericin B disrupted 
membranes of mature fungi[495]. They 
act at different stages and different sites in 
non-interfering manner. 
Artemisinin (interfered with 
parasite transport proteins 
PfATP6, disrupted parasite 
mitochondrial function, 
modulated host immune 
function)[492] 
Curcumin (generated ROS and 
down-regulated PfGCN5 
histone acetyltransferase 
activity, producing cytotoxicity 







Artemisinin blocked calcium transport to 
endoplasmic reticulum[492], Curcumin 
induced DNA damage and histone 
hypoacetylation[261]. They act at 







Trabectedin (formed covalent 
guanine adduct at specific sites 
in DNA minor grove[476], 







Both bind to DNA in non-interfering 
manner, one preferred AT regions[475], 
the other alkylated guanines[476]. 
Recent progresses in designing dual 
platinum- intercalator conjugates[477] 
suggested that it is possible for both drugs 
to act without hindering each other‘s 
binding mode 
Independent 
actions at dosages 
significantly 
lower than MICs, 
complementary 
actions at higher 
dosages 
 




bacterial protein synthesis by 
binding to 50S component of 
70S ribosomal subunit[431]) 
Imipenem (inhibited penicillin-
binding protein -1A, -1B, -2, -4 









Azithromycin hindered bacterial protein 
synthesis[431] at MIC of 
0.12g/ml[494]. Imipenem blocked 
bacterial cell wall formation[490] at MICs 
of ≥32g/ml[466]. At dosages 
significantly lower than MICs for both 
drugs, azithromycin‘s reduction of 
penicillin-binding proteins[490] may be 
insufficient for imipenem to saturate these 
proteins, allowing its unhindered 
inhibition of these proteins[490], thereby 
these actions proceed in non-interfering 
manner 
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Appendix  Table S5 Literature reported pharmacodynamically antagonistic drug combinations in 2000-2006, in which antagonism has been 
determined by established methods and its molecular mechanism has been revealed. The antagonism of the listed drug combinations is due to 




Drug A (mechanism of 
action related to 
antagonism) 
Drug B (mechanism of 








Possible mechanism of antagonism of interfering 
actions 
Different targets of 
related pathways that 




induced cell cycle 
inhibition and apoptosis 
by inhibiting NF-





Cytarabine (DNA binder 
[437], inhibited 
synthesome associated 
DNA polymerase alpha 
activity[438]) 
17-AAG antagonized 
the cytotoxic activity 
of cytarabine[437] 
Median dose effect 
analysis 
(Calcusym) 
17-AAG altered the condition necessary for cytarabine to 
produce its activity. It induced G1 arrest, which 
subsequently prevented cytarabine incorporation into 
cellular DN[437] 
Amphotericin B (formed 




ergosterol, a component 









Amphotericin B can form ion channels more easily in the 
presence of ergosterol [495], ravuconazole inhibition of 
ergosterol synthesis[496] can therefore reduce the activity 
of amphotericin B in forming ion channels[495] 
Same target 4-HPR (Reduced ERK 
activity to inhibit 
prostate cancer 
cells[854], activated JNK 








(Reduced ERK activity 
to inhibit prostate cancer 
cells[854], activated 









Sodium butyrate and 
4-HPR administered 
together antagonize 
effects of each other 
on prostate 
cancer[854] 
Isobologram Co-administration of 4-HPR and sodium butyrate possibly 
affected each other‘s actions in suppressing IκBα 
phosphorylation, thereby reduced their inhibitory effects 
on NF-κB activation and antiapoptotic gene expression. 
NF-κB activation also downregulated JNK 
phosphorylation leading to inhibition of apoptosis in 
prostate cells[854]. 
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Adenosine receptor antagonist binding may be associated 
with non-unique binding site conformations [479]. 
Aminophylline binding may lock the receptor into a unique 
conformation that hinder theophylline binding, thereby 
producing antagonistic effect 
 
Appendix  Table S6 Literature reported pharmacokinetically potentiative drug combinations, in which potentiative effect has been determined by 
established methods and its molecular mechanism has been revealed 
 
Biochemical class of 
potentiative effect  
Drug A (therapeutic or toxic effects 
and mechanism of actions) 
Drug B (mechanism of action related 
to potentiative effect) 
Reported potentiative effect [Ref] Possible mechanism of potentiative 
actions 
Positive regulation 
of drug transport or 
permeation 
AZT (anti-HIV, HIV-1 reverse 
transcriptase inhibitor) 
1,8-Cineole (formed hydrogen bonds 
with lipid head groups of stratum 
corneum lipids[502]) 
Enhanced cross-skin permeation of 
AZT[503] 
Enabled drug transport across skin 
possibly by disrupting absorption 
barrier via binding to lipid head 
groups 
Ciprofloxacin (antibacterial, inhibited 
DNA gyrase, an enzyme specific and 
essential for all bacteria) 
Gatifloxacin (inhibited efflux pump of 
ciprofloxacin[856]) 
Synergistic antibacterial action against 
pseudomonas aeruginosa via efflux pump 
inhibition[856] 
Avoided drug excretion by inhibiting 
efflux pump of ciprofloxacin  
Doxorubicin (anticancer by DNA 
intercalation) 
HPMA copolymer (formed conjugate 
with anthracycline[857]) 
Polymer anthracycline conjugation 
enabled bypass of multi-drug 
resistance[857] 
Enabled drug absorption by avoiding 
its efflux via drug-polymer conjugate 
formation 
Fexofenadine (nonsedating 
antihistamine, H1-antagonist, renal 
uptake by hOAT3 transporter) 
Probenecid (inhibited hOAT3 
transporter uptake of 
fexofenadine[858]) 
Increased plasma concentration of 
fexofenadine due to inhibition of its renal 
elimination[859] 
Avoided drug excretion by inhibiting 
hOAT3 transporter uptake of 
fexofenadine 
Levodopa (dopaminergic agent in 
Parkinson's disease) 
Fatty acid synthesis inhibitor (selective 
inhibition of fatty acid synthesis delays 
barrier recovery rates after barrier 
perturbation of drugs[860]) 
Enhanced transcutaneous delivery of 
levodopa[860-862] 
Delayed recovering of drug transport 
barrier by inhibiting the synthesis of 
barrier components 
Low molecular weight heparin 
(antithrombotic, antithrombin binder 
to inhibit activated coagulation 
factors) 
Chitosan (absorption enhancer, 
reversibly interacted with components 
of tight junctions, leading to widening 
of paracellular routes and increased 
permeability of peptide drugs across 
Oral drug absorption enhancement[499] Disrupted drug absorption barrier 
across mucosal epithelia via 
interaction with barrier components 
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mucosal epithelia[499]) 
Low molecular weight heparin 
(antithrombotic, antithrombin binder 
to inhibit activated coagulation 
factors) 
Sodium caprate (absorption enhancer, 
released calcium from intracellular 
stores via activation of phospholipase C 
in plasma membrane, which induced 
contraction of calmodulin-dependent 
actin microfilament, followed by 
dilatation of the paracellular route[863]) 
Sodium caprate acts as a relatively safe 
and efficient absorption enhancer of low 
molecular weight heparin[863-865] 
Disrupted drug absorption barrier at 




Fluorouracil (anticancer, metabolized 
by thymidine phosphorylase and 
others, metabolite inhibited 
thymidylate synthase that stopped 
DNA synthesis[550], 
metabolite stabilized P53 due to RNA-
directed effects) 
Sorivudine (antiviral, metabolized into 
(E)-5-(2-Bromovinyl)uracil by 
thymidine phosphorylase, which 
subsequently inactivates this enzyme by 
irreversible binding[866]) 
Enhanced toxic activity of  fluorouracil by 
elevating its plasma concentrations[866] 
Enhanced level of drug in plasma by 
metabolism and uptake inhibition 
Cerivastatin (cholesterol-lowering, 
HMG-CoA reductase inhibitor) 
Gemfibrozil (inhibited CYP2C8 
mediated metabolism of statins, 
inhibited OATP2 mediated uptake of 
cerivastatin[504]) 
Increased plasma concentration of statins 
by inhibiting their metabolism and 
uptake[504-506] 
Enhanced level of drug in plasma by 
metabolism and uptake inhibition 
Cyclosporine (immunosuppressive via 
calcineurin antagonism, induced 
nephrotoxicity by decreasing renal 
blood flow, generating reactive free 
radicals, and inducing 
vasoconstriction and apoptosis) 
Sirolimus (increased cyclosporine 
concentrations in whole blood and, 
particularly, in kidney[867]) 
Exacerbated renal dysfunction by 
cyclosporine[867] 
Enhanced level of drug in tissue of 
toxic action 
HSV thymidine kinase gene and 
ganciclovir (anticancer gene therapy 
drug combination) 
Ponicidin (significantly accumulated 
the phosphorylated metabolites of 
ganciclovir and suppressed the 
extracellular release of 
ganciclovir[868]) 
Potentiated ganciclovir cytotoxicity[868] Enhanced level of prodrug metabolite 
Methamphetamine (psychomotor 
stimulant by targeting biogenic amine 
transporters) 
D-chlorpheniramine (increased plasma 





Enhanced level of drug in tissue of 
therapeutic action 
HSV thymidine kinase gene and 
ganciclovir (anticancer gene therapy 
Scopadulciol (stimulated HSV 
thymidine kinase activity, increased 
Improved efficacy of cancer gene therapy 
via enhanced activity and increased level 
Enhanced level of prodrug metabolite 
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drug combination) levels of ganciclovir metabolite[871]) of prodrug metabolite[871] 
Rosuvastatin (decreased levels of 
atherogenic lipoproteins in patients 
with or at high risk of cardiovascular 
disease, HMG-CoA inhibitor) 
Cyclosporine (Inhibited OATP-C 
mediated uptake, rosuvastatin is a 
substrate of this process[872]) 
Significantly increased systemic exposure 
of rosuvastatin[872] 
Enhanced level of drug by inhibiting 
drug uptake 
Rosuvastatin (decreased levels of 
atherogenic lipoproteins in patients 
with or at high risk of cardiovascular 
disease, HMG-CoA inhibitor) 
Gemfibrozil (Inhibited OATP2 
mediated uptake, rosuvastatin is a 
substrate of this process[873]) 
Increased plasma concentrations of 
rosuvastatin[874] 




Fluorouracil (anticancer, metabolized 
by thymidine phosphorylase and 
others [875], metabolite inhibited 
thymidylate synthase that stopped 
DNA synthesis[550], 
metabolite stabilized P53 due to RNA-
directed effects[876]) 
2'-deoxyinosine (modulator that 
enhances thymidine phosphorylase 
activity[500]) 
Enhanced antitumor activity of 
fluorouracil in human colorectal cell lines 
and colon tumor xenografts[500] 
Enhanced metabolism of prodrug into 
active metabolite 
Doxorubicin (anticancer by DNA 
intercalation, converted to 
doxorubicinol by NADPH-dependent 
aldo/keto or carbonyl reductases 
[507], which produced cardiotoxicity 
by mediating transition from 
reversible to irreversible damage) 
Paclitaxel (stimulated enzymatic 
activity of NADPH-dependent 
aldo/keto or carbonyl reductases[507]) 
Enhanced cardiotoxicity by increasing 
metabolism of doxorubicin into toxic 
metabolit[507] 
Enhanced metabolism of drug into 
toxic metabolite 
Tirapazamine and cisplatin 
(Tirapazamine produced anti-cancer 
effect and potentiated cisplatin 
anticancer activities when metabolized 
by P450R into toxic free radical[877], 
cisplatin is a DNA adduct) 
Adenoviral delivery of human P450R 
genes (enhanced tirapazamine 
metabolizing enzyme expression and 
metabolism of prodrug into active 
metabolite[877]) 
Targeted gene prodrug therapy increased 
efficacy of tirapazamine[877] 
Enhanced metabolism of prodrug into 
active metabolite 
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Appendix  Table S7 Literature reported pharmacokinetically reductive drug combinations, in which reductive effect has been determined by 
established methods and its molecular mechanism has been revealed. 
 
Biochemical class of 
reductive effect  
Drug A (therapeutic or toxic effects 
and mechanism of actions) 
Drug B (mechanism of action related to 
reductive effect) 
Reported reductive effect [Ref] Possible mechanism of 
reductive actions 
Drug transport and 
permeation  
Amphotericin B (antileishmanial, 
formed aggregate with 
miltefosine[508]) 
Miltefosine (antileishmanial, formed 
aggregate with amphotericin B[508]) 
Reduced miltefosine-induced paracellular 
permeability enhancement in Caco-2 cell 
monolayers, inhibited uptake of both 
drugs, decreased transepithelial transport 
of both drugs[509] 
Reduced drug permeability and 
transport  
Gamma-hydroxybutyrate (drug of 
abuse, increased dopamine 
concentration, MCT1 transporter 
mediated its disposition and renal 
reabsorption[878]) 
Luteolin (exhibited MCT1 transporter 
mediated uptake of gamma-
hydroxybutyrate[879]) 
Significantly increased renal and total 
clearances of gamma-
hydroxybutyrate[878] 
Enhanced drug excretion 
Drug distribution 
and localization  
Cisplatin (DNA inter- and intra- 
strand adduct) 
Procainamide hydrochloride (formed 
cisplatin-procainamide complex[511]) 
Reduced cisplatin-induced hepatotoxicity 
via formation of less toxic platinum 
complex, leading to inactivation of 
cisplatin or its highly toxic metabolites and 
to a different subcellular distribution of 
platinum[511] 
Reduced level of toxic drug by 
formation of less toxic complex 
and rearrangement of its 
subcellular distribution 
Drug metabolism  Warfarin (anticoagulant and 
antithrombotic, affected coagulation 
proteins that act sequentially to 
produce thrombin, metabolized by 
CYP3A4[512]) 
Quinidine (stimulated CYP3A4 mediated 
metabolism of warfarin[513]) 
Reduced anticoagulanet effect of warfarin 
by stimulating its metabolism[513] 
Enhanced metabolism of active 
drug into inactive metabolite 
Diclofenac (anti-inflammatory, 
metabolized into 5-hydroxylated by 
cytochrome P450 CYP3A4[880]) 
Quinidine (stimulated CYP3A4 mediated 
metabolism of diclofenac[880]) 
Increased diclofenac clearance and 
reduced its plasma concentration by 
enhanced metabolism[880] 
Reduced level of drug by 
enhanced metabolism 
Mycophenolate mofetil 
(immunosuppressive, a prodrug whose 
metabolite mycophenolic acid is a 
potent and reversible uncompetitive 
inhibitor of inosine monophosphate 
dehydrogenase, metabolized by 
Rifampin (induced expression of 
gastrointestinal uridine diphosphate-
glucuronosyltransferases[882]) 
Drug interaction leads to underexposure 
and loss of clinical efficacy of 
mycophenolate mofetil by induction of 
renal, hepatic, and gastrointestinal uridine 
diphosphate-glucuronosyltransferases and 
organic anion transporters[882] 
Reduced level of drug by 
enhanced metabolism 
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gastrointestinal uridine diphosphate-
glucuronosyltransferases[881]) 
Valproic acid (antiepileptic, increased 
gabaergic transmission, reduced 
release and/or effects of excitatory 
amino acids, blocked voltage-gated 
sodium channels, modulated 
dopaminergic and serotoninergic 
transmission, metabolized into 
valproic acid glucuronide[883]) 
Carbapenem antibiotics (inhibited the 
hydrolytic enzyme involved in the 
hydrolysis of valproic acid glucuronide to 
valproic acid, resulting in a decrease of 
plasma concentration of valproic 
acid[859]) 
Caused seizures in epileptic patients due to 
lowered plasma levels of valproic 
acid[859,884]  
Reduced level of drug in plasma 
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Appendix  Table S8 Drug related sensitizing/resistant mutations of EGFR and cancer related activating mutations of EGFR, PIK3CA, RAS, and 
BRAF, and inactivation mutations of PTEN.  
Disease Type of Mutation 
Percentage of 85 NSCLC 
Cell-lines or 40 Breast 
Cancer Cell-lines with 
This Type of Mutation 
Specific Mutations (Number of NSCLC or  Breast 
Cancer Cell-lines with This Mutation)  
NSCLC 





E746_A750del (4) / E746_A750del, T751A(1) /  
E746_T751del, I ins(1)  /  L747_E749del, A750P(1) /  
L747_S752del, P753S(1) / L858R(2) 




2.4% T790M (2) 




1.2% G776VC (1) 
Activating mutation of KRAS
[886]
 32.9% 
G12A (1)  /  G12C (9) /  G12D (3) / G12R (1) / G12S (1) /  
G12V (4) /  G13C (2) /  G13D (4) /  Q61H (2) /  Q61K (1)  
Activating mutation of NRAS
[886]
 5.9% Q61K (3) /  Q61L (1) /  Q61R (1) 
Activating mutation of BRAF 
[887]
 7.1% G466V(1) /  G469A(3) /  L597V(1) /  V600E(1) 
Activating mutation PIK3CA [888,889] 4.7% E542K (1) /  E545K (2) /   H1047R(1) 
Inactivating mutation PTEN
[890]





C420R(2) /  E542K(2) / E545K(2) / H1047L(1) /  
H1047R(6)   / P539 (1) 
Inactivating mutation PTEN
[891]
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Appendix  Table S9 Cancer related and drug related specific mutations in 85 NSCLC and 40 breast cancer cell-lines.  
Cell-lines Disease Mutated Gene[591,592] Type of Mutation  
Mutation Details 
Amino Acid Nucleotide 
A427 NSCLC KRAS Activating mutation G12D 35G>A 
A549 NSCLC KRAS Activating mutation G12S 34G>A 
Calu1 NSCLC KRAS Activating mutation G12C 34G>T 
Calu3 NSCLC ND    
Calu6 NSCLC KRAS Activating mutation Q61K 181C>A 
Colo699 NSCLC ND *    
DV90 NSCLC KRAS Activating mutation G13D 38G>A 
EKVX NSCLC ND    
H1155 NSCLC KRAS Activating mutation Q61H 183A>T 
H1155 NSCLC PTEN Inactivating mutation R233* 697C>T 
H1299 NSCLC NRAS Activating mutation Q61K 181C>A 
H1355 NSCLC KRAS Activating mutation G13C 37G>T 
H1355 NSCLC BRAF Activating mutation G469A 1406G>C 
H1395 NSCLC BRAF Activating mutation G469A 1406G>C 
H1437 NSCLC ND    
H1563 NSCLC PIK3CA* Activating mutation E542K 1624G>A 
H1568 NSCLC ND    
H157 NSCLC KRAS Activating mutation G12R 34G>C 
H157 NSCLC PTEN Inactivating mutation G251C 751G>T 
H157 NSCLC PTEN Inactivating mutation H61R 182A>G 
H1648 NSCLC ND    
H1650 NSCLC EGFR EGFR sensitizing mutation E746_A750del 2235_2249del15 
H1666 NSCLC BRAF Activating mutation G466V 1397G>T 
H1734 NSCLC KRAS Activating mutation G13C 37G>T 
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H1755 NSCLC BRAF Activating mutation G469A 1406G>C 
H1770 NSCLC ND    
H1781 NSCLC ERBB2* 
gefitinib and erlotinib resistant 
mutation 
G776VC  
H1792 NSCLC KRAS Activating mutation G12C 34G>T 
H1819 NSCLC ND    
H1838 NSCLC ND     
H1915 NSCLC ND*    
H1944 NSCLC KRAS* Activating mutation G13D 38G>A 
H1975 NSCLC EGFR EGFR-I sensitizing mutation  L858R 2573T>G 
H1975 NSCLC EGFR EGFR-I resistant mutation T790M 2369C>T 
H1993 NSCLC ND    
H2009 NSCLC KRAS Activating mutation G12A 35G>C 
H2030 NSCLC KRAS Activating mutation G12C 34G>T 
H2052 NSCLC ND    
H2077 NSCLC ND*    
H2087 NSCLC BRAF Activating mutation L597V 1789C>G 
H2087 NSCLC NRAS Activating mutation Q61K 181C>A 
H2110 NSCLC ND    
H2122 NSCLC KRAS Activating mutation G12C 34G>T 
H2126 NSCLC ND    
H2172 NSCLC ND*    
H2228 NSCLC ND    
H23 NSCLC KRAS Activating mutation G12C 34G>T 
H23 NSCLC PTEN Inactivating mutation R233* 697C>T 
H2347 NSCLC NRAS Activating mutation Q61R 182A>G 
H2444 NSCLC KRAS* Activating mutation G12V  
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H28 NSCLC ND    
H2882 NSCLC ND    
H2887 NSCLC KRAS* Activating mutation G12V  
H3122 NSCLC ND    
H322 NSCLC ND    
H3255 NSCLC EGFR EGFR-I sensitizing mutation L858R 34G>T 
H358 NSCLC KRAS Activating mutation G12C 34G>T 
H441 NSCLC KRAS Activating mutation G12V 35G>T 
H460 NSCLC PIK3CA Activating mutation E545K 1633G>A 
H460 NSCLC KRAS Activating mutation Q61H 183A>T 
H520 NSCLC ND    
H522 NSCLC ND    
H596 NSCLC PIK3CA Activating mutation E545K 1633G>A 
H647 NSCLC KRAS Activating mutation G13D 38G>A 
H661 NSCLC ND    
H820 NSCLC EGFR* EGFR-I sensitizing mutation E746_T751del, I ins  
H820 NSCLC EGFR* EGFR-I resistnat mutation T790M 2369C>T 
HCC1171 NSCLC KRAS* Activating mutation G12C  
HCC1195 NSCLC NRAS* Activating mutation Q61L  
HCC1359 NSCLC ND*    
HCC15 NSCLC NRAS* Activating mutation Q61K  
HCC1833 NSCLC ND*    
HCC193 NSCLC ND*    
HCC2279 NSCLC EGFR* EGFR-I sensitizing mutation E746_A750del 2235_2249del15 
HCC2429 NSCLC ND*    
HCC2450 NSCLC PIK3CK* Activating mutation H1047R 3140A>G 
HCC2935 NSCLC EGFR* EGFR-I sensitizing mutation E746_A750del, T751A  
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HCC364 NSCLC BRAF Activating mutation V600E 1799T>A 
HCC366 NSCLC ND*    
HCC4006 NSCLC EGFR* EGFR-I sensitizing mutation L747_E749del, A750P  
HCC44 NSCLC KRAS* Activating mutation G12C  
HCC461 NSCLC KRAS* Activating mutation G12D  
HCC515 NSCLC KRAS* Activating mutation G13D  
HCC78 NSCLC ND*    
HCC827 NSCLC EGFR* EGFR-I sensitizing mutation E746_A750del 2235_2249del15 
HCC95 NSCLC ND*    
HOP62 NSCLC KRAS Activating mutation G12C 34G>T 
HOP92 NSCLC ND    
LCLC103H NSCLC ND    
LCLC97TM NSCLC KRAS Activating mutation G12V 35G>T 
LouNH91 NSCLC EGFR* EGFR-I sensitizing mutation L747_S752del, P753S  
PC9 NSCLC EGFR* EGFR-I sensitizing mutation E746_A750del 2235_2249del15 
SKLU1 NSCLC KRAS* Activating mutation G12D 35G>A 
AU565 Breast cancer ND    
BT20 Breast cancer PIK3CA Activating mutation P539R 1616C>G 
BT20 Breast cancer PIK3CA Activating mutation H1047R 3140A>G  
BT474 Breast cancer ND    
BT549 Breast cancer PTEN Inactivating mutation V275fs*1 823delG 
CAL-51 Breast cancer PIK3CA Activating mutation E542K 1624G>A 
CAMA1 Breast cancer PTEN Inactivating mutation D92H 274G>C 
EFM19 Breast cancer PIK3CA Activating mutation H1047L 3140A>T 
EFM19 Breast cancer PIK3CA* Activating mutation H1047R 3140A>G 
EFM192A Breast cancer PIK3CA* Activating mutation C420R  
HCC1143 Breast cancer ND    
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HCC1395 Breast cancer ND    
HCC1419 Breast cancer ND    
HCC1954 Breast cancer PIK3CA* Activating mutation H1047R 3140A>G 
HCC70 Breast cancer ND    
HS578T Breast cancer HRAS Activating mutation G12D c35G>A 
JIMT-1 Breast cancer PIK3CA
#
 Activating mutation C420R  
KPL1 Breast cancer ND*    
MCF7 Breast cancer PIK3CA Activating mutation E545K c633G>A 
MDA-MB-157 Breast cancer ND    
MDA-MB-175VII Breast cancer ND    
MDA-MB-231 Breast cancer BRAF  Activating mutation G464V 1391G>T   
MDA-MB-231 Breast cancer KRAS Activating mutation G13D 38G>A 
MDA-MB-361 Breast cancer PIK3CA Activating mutation E545K 1633G>A 
MDA-MB-361 Breast cancer PIK3CA Activating mutation K567R 1700A>G 
MDA-MB-415 Breast cancer PTEN Inactivating mutation C136Y 407G>A 
MDA-MB-435s Breast cancer BRAF Activating mutation V600E 1799T>A 
MDA-MB-436 Breast cancer ND    
MDA-MB-453 Breast cancer PTEN Inactivating mutation E307K 919G>A 
MDA-MB-453 Breast cancer PIK3CA Activating mutation H1047R 3140A>G 
MDA-MB-468 Breast cancer PTEN Inactivating mutation A72fsX5 253+1G>T 
SK-BR-3 Breast cancer ND    
T47D Breast cancer PIK3CA Activating mutation H1047R 3140A>G 
UACC812 Breast cancer ND*    
UACC893 Breast cancer PIK3CA Activating mutation H1047R 3140A>G 
ZR-75-1 Breast cancer ND    
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ZR-75-30 Breast cancer ND    
* Mutation was only reported in Ref [592]; # PIK3CA mutation of JIMT-1  was reported by Ref  [892]                                                                                                                                                                   
Abbreviations:   ND, no sensitizing/resistant/activating mutation was detected according to COSMIC database and Ref 4.                                                                                                                                                                                 
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Reported Potency (IC50) of 
Gefitinib Inhibition (µM) 
Sensitivity of Cell-




Reported Potency (IC50/ED50) 
of Erlotinib Inhibition (µM) 
Sensitivity of Cell-




Reported Potency (ED50) of 
Lapatinib Inhibition (µM) 
Ref [594] Ref [593] Ref [594] Ref [590] Ref [590] 
A427    R  1.24 R 9.4406 
A549 R 25  R 60 10 R 10 
Calu1 R  41 R  10 R 10 
Calu3 S 0.78  - 1.29 0.7 S 0.1679 
Calu6 R  34 R  9.65 R 2.7542 
Colo699    R  4.26 R 5.8884 
DV90    R  3.95 R 1.4125 
EKVX    R  10 R 10 
H1155 R 183  R 8.63    
H1299 R 26.4  R 41.9 10 R 10 
H1355 R 325  R 27 3.31 R 5.6885 
H1395 R 71  R 10.5 5.05 R 6.6834 
H1437 R 62  R 12.5 10 R 10 
H1563    R  10 R 10 
H1568    R  1.08 R 2.541 
H157 R 115  R 128 10 R 10 
H1648 R 36.7  R 34 7.77 S 0.9441 
H1650 R 11.7  R 15 2.13 R 3.8905 
H1666 R 180  R 13 3.31 S 0.5957 
H1734    R  3.79 R 4.3652 
H1755    R  7.5 R 10 
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H1770 R 160  R 111 10   
H1781 R 19  R 44 2.54 R 2.9174 
H1792    R  10 R 10 
H1819 R 19  R 6.3 3.92 S 0.7328 
H1838    R  3.47 R 10 
H1915    R  10 R 10 
H1944    R  1.83 R 10 
H1975 R 25  R 33 10 R 10 
H1993 R 17.9  R 5.2 8.06 R 4.3152 
H2009 R 33.2  R 25.8 10 R 10 
H2030    R  4.95 R 5.0119 
H2052    R  8.98 R 10 
H2077    R  10 R 10 
H2087 R 18.4  R 9.9 10 R 10 
H2110    R  4.5 R 2.7861 
H2122 R 35  R 76.8 10 R 10 
H2126 R 21.4  R 13 10 R 10 
H2172    R  10 R 8.9125 
H2228    R  10 R 10 
H23    R  10 R 5.6234 
H2347 R 60  R 5.2 10 R 5.9566 
H2444    R  4.22 R 7.6736 
H28    R  10 R 1.6032 
H2882 R 19.2  R 66 10 R 5.1286 
H2887 R 110  R 101 10 R 10 
H3122    R  10 R 10 
H322 R 120  R 56 2.21 R 2.4831 
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H322M    R  1.29 S 0.4416 
H3255 S 0.089  S 0.129 0.02 S 0.309 
H358 R 12.5  R 6.2 1.11 R 1.6032 
H441 R 15.7  R 7.1 3.61 R 10 
H460 R 16.9  R 72 10 R 3.3113 
H520 R 13.6  R  10 R 6.8391 
H522    R  5.83 R 8.7096 
H596    R  1.2 R 10 
H647    R  10 R 10 
H661    R  10 R 10 
H820 R 3  R 7.1 10 R 10 
HCC1171 R 127  R 160 10 R 10 
HCC1195 R 27.6  R 175 10 NA  
HCC1359 R 65  R 88 10 R 10 
HCC15 R 52  R 100 10 R 10 
HCC1833    R  10 R 2.6915 
HCC193 R 21.1  R 20.5 10 R 1.7378 
HCC2279 S 0.0479  S 0.093 0.01 R 10 
HCC2429    R  10 R 5.9566 
HCC2450    R  10 R 10 
HCC2935 S 0.11  S 0.163 0.07 S 0.2344 
HCC364    R  4.19 R 10 
HCC366 R 30  R 11 0.99 R 10 
HCC4006 S 0.23  S 0.124 0.04 S 0.537 
HCC44 R 57.8  R 28 10 R 10 
HCC461 R 13.9  R 16 9.04 R 10 
HCC515 R 120  R 154 1.85 R 9.5499 
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HCC78 R 81  R 21.2 10 R 4.1687 
HCC827 S 0.04  S 0.0388 0.02 S 0.7943 
HCC95 R 24  R 18.4 10 R 3.2359 
HOP62    R  10 R 5.4325 
HOP92    R  10 R 10 
LCLC103H    R  10 R 10 
LCLC97TM    R  5.26 R 7.3282 
LouNH91    R  3.05 R 5.1286 
PC9 S 0.0309  S  0.02 R 1.4962 
SKLU1    R  10 R 10 
* A cell-line with IC50≤ 1 µmol/L for gefitinib, erlotinib, and lapatinib was considered to be sensitive (S) to a given drug[583],  otherwise it was considered as resistant (R) to 
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Appendix  Table S11 Sensitivity data of breast cancer cell-lines treated with trastuzumab and lapatinib  
Breast Cancer 
Cell-lines 





Reported Potency of Trastuzumab Inhibition 
(%25 growth inhibition of cancer cell at 10µg/ml 
or ED50 ≤1µg/ml) 
Sensitivity of Cell-




Reported Potency(IC50) of  Lapatinib 
Inhibition (µM) 
Ref  [599] Ref  [600] Ref  [601] Ref  [598] Ref  [602]  Ref  [604] Ref  [603] 
BT20 R   R  R 9.8   
BT474 S S S S S S 0.022 0.025  
BT549 R  R   R  6.35  
CAL51      R 1.2   
CAMA1 R  R   R 8.3   
EFM19      R 4.6   
EFM192A R    R R 1.1   
HCC1143 R   R      
HCC1395 R   R      
HCC1419 S S S       
HCC1954 R R R       
HCC70 R  R       
Hs578T      R  5.11  
JIMT-1 R R    R   >1.5 
KPL1      R 5.4   
MCF7 R R R R  R 7.7 4.82  
MDA-MB-157      R 6.3   
MDA-MB-175VII      S 0.012   
MDA-MB-231 R  R R  R 18.6 7.01  
MDA-MB-361 R  R  R R 0.99   
MDA-MB-415 R  R       
MDA-MB-435s R  R R  R 8.5   
MDA-MB-436 R   R      
MDA-MB-453 S  S   - 3.9 0.079  
MDA-MB-468 R   R  R 4.7 2.32  
SK-BR-3 S S S   S 0.037 0.032  
T47D R  R R  R 1.9 4.83  
UACC812 S  S   S 0.01   
UACC893 R  R   S 0.433   
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ZR75-1 -  R S  R 9.9 3.01  
ZR75-30 S S S       
# A cell-line with IC50≤ 1 µmol/L for  lapatinib or %25 growth inhibition of cancer cells at 10µg/ml for Trastuzumab was considered to be sensitive (S) to a given drug[583],  
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ras mutation status 
Smoking 4 
AD2 Cluster 1 65.6 F 1 1 0 91.8 alive BD Poor + - 48 
AD5 Cluster 1 62 F 1 2 0 108.2 alive BA Well - + positive 
L01 Cluster 1 76.7 M 1 2 0 47 alive BD/CC Poor - - 100 
L06 Cluster 1 57.9 F 1 1 0 91.9 alive BD Poor - + NA 
L26 Cluster 1 61.4 M 1 2 0 17.7 alive BD Poor - + 90 
L33 Cluster 1 53.5 F 3 4 0 29.4 alive BD Moderate - - 23 
L43 Cluster 1 50.6 F 1 2 0 78.5 alive BD Moderate - - 57 
L56 Cluster 1 60.2 M 1 1 0 61.8 alive BD/CC Moderate + - 90 
L62 Cluster 1 52.3 F 3 3 2 52.4 alive BD Moderate - - none 
L83 Cluster 1 62 F 1 2 0 30.6 alive BA/mucinous Well - - none 
L91 Cluster 1 63.7 M 3 2 2 6.1 alive BD/mucinous Poor - - 30 
L92 Cluster 1 55.4 M 3 4 0 8.5 alive BD Poor - - 50 
AD10 Cluster 1 65 M 1 1 0 84.1 death BD Moderate - NA 60 
L04 Cluster 1 51.7 M 1 2 0 45.8 death BD Poor - - 50 
L13 Cluster 1 67.1 M 1 1 0 79.5 death BD Moderate + + 25 
L19 Cluster 1 56.5 M 3 3 2 9.6 death BD Moderate - + 40 
L34 Cluster 1 77.2 M 3 1 2 14.9 death BD Moderate + - 45 
L36 Cluster 1 69.7 M 3 1 2 7.2 death BD/PA Moderate - + 25 
L37 Cluster 1 64.4 M 3 1 2 2.6 death BD Poor - + 84 
L41 Cluster 1 73.1 F 1 2 0 8.4 death BD/CC Poor - + 26 
L54 Cluster 1 45.8 F 3 3 1 4 death BD Poor + + 75 
L40 Cluster 1 54.9 F 3 1 2 20.1 death BD Moderate - - 7.5 
L80 Cluster 1 68.2 F 1 2 0 10.1 death BD/mucinous Moderate + + 50 
L61 Cluster 1 63.1 F 1 2 0 20.6 death BD Moderate - - 30 
L95 Cluster 1 72 F 3 2 2 5.4 death BD Poor - + 50 
L96 Cluster 1 64 F 3 3 1 21.2 death BD Moderate - + 50 
AD7 Cluster 2 56 M 1 1 0 68.1 alive BD Moderate + - 80 
L02 Cluster 2 63.2 M 1 1 0 39.1 alive BD Poor - - 27 
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L09 Cluster 2 48.2 F 1 1 0 98.7 alive BD Moderate - + none 
L101 Cluster 2 46.3 F 1 1 0 40 alive B/A/mucinous Well - - NA 
L103 Cluster 2 84.6 F 1 1 0 30.8 alive B/A Well - - none 
L104 Cluster 2 68.5 F 1 1 0 24.4 alive B/A Well - - 5 
L105 Cluster 2 74.2 F 1 1 0 28.3 alive B/A with PA Well - + 75 
L108 Cluster 2 61 F 1 1 0 19.5 alive B/A Well - + 100 
L111 Cluster 2 54.9 F 1 1 0 1.5 alive B/A Well - + 40 
L12 Cluster 2 44.6 F 1 1 0 85.2 alive BD Moderate - - 15 
L18 Cluster 2 82.5 F 1 1 0 48.2 alive BD Well - - none 
L23 Cluster 2 62.2 M 3 2 2 15.1 alive BD/PA Moderate - + 20 
L25 Cluster 2 62.6 F 1 2 0 14.5 alive BD Well - + 50 
L27 Cluster 2 70 M 1 1 0 21.1 alive BD Poor + - 60 
L38 Cluster 2 78.5 F 3 4 2 10 alive BD Poor + + 2 
L42 Cluster 2 76 F 1 1 0 63.4 alive BD Well - - 40 
L46 Cluster 2 60.4 M 1 2 0 82.4 alive BD Poor - + 160 
L47 Cluster 2 60 M 1 2 0 60.5 alive BD Moderate - + 27 
L48 Cluster 2 42.8 M 1 1 0 77.8 alive BD Moderate - - 60 
L52 Cluster 2 67.3 M 1 1 0 65.4 alive BA Well - - 30 
L57 Cluster 2 73.6 F 1 2 0 54.8 alive BD/PA Moderate - + 50 
L65 Cluster 2 59.6 M 1 1 0 52.9 alive BD Moderate - - 60 
L78 Cluster 2 75.6 F 1 1 0 36.5 alive BD Moderate - + 108 
L82 Cluster 2 69.2 F 1 1 0 34.1 alive BA/BD Well - - 40 
L85 Cluster 2 60.2 M 1 1 0 26.8 alive BD/mucinous Moderate - + 60 
L97 Cluster 2 63.6 F 1 1 0 4.9 alive B/A Well - + 34 
L50 Cluster 2 72.1 M 1 1 0 19 death BD/PA Moderate + + 100 
AD3 Cluster 3 59.5 F 1 2 0 93.7 alive BD Moderate - - positive 
AD8 Cluster 3 75 M 1 2 0 34.2 alive BD Moderate - - 14 
L05 Cluster 3 54.6 F 1 1 0 110.6 alive BD/CC Moderate - - 29 
L08 Cluster 3 59.9 F 1 1 0 107.9 alive BD Moderate - + 80 
L102 Cluster 3 74.6 F 1 1 0 40 alive BD Moderate - - 50 
L106 Cluster 3 82.8 F 1 1 0 25.3 alive B/A Well - - none 
L107 Cluster 3 59.4 F 1 1 0 13 alive BD well/mod. - + none 
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L17 Cluster 3 40.9 F 1 2 0 83.7 alive BD/PA Moderate - + 15 
L22 Cluster 3 65.6 M 1 1 0 12.5 alive BD Moderate + - 90 
L30 Cluster 3 51.8 F 1 1 0 20.2 alive BD Moderate + - 20 
L31 Cluster 3 62.1 F 1 1 0 25.2 alive BA/mucinous Well - - 20 
L49 Cluster 3 65.8 F 1 1 0 70.7 alive BD Moderate - + 20 
L59 Cluster 3 71.5 F 3 2 2 54.6 alive BD/PA Moderate - + 25 
L64 Cluster 3 65.4 M 1 2 0 48.1 alive BD Moderate + - 12 
L76 Cluster 3 46.2 M 1 1 0 87.7 alive BD Poor - + 50 
L81 Cluster 3 58.4 M 1 1 0 36 alive BA Well - - 90 
L84 Cluster 3 66.8 F 1 2 0 32.2 alive BD Poor - - 15 
L86 Cluster 3 62.7 F 1 1 0 10.1 alive B/A Well - - 45 
L87 Cluster 3 66.3 M 1 1 0 10.4 alive BD Moderate + - 18 
L88 Cluster 3 52.9 F 1 1 0 8.3 alive BD Poor + + 60 
L89 Cluster 3 58.8 M 3 2 2 12.2 alive BD Moderate NA + 48 
L99 Cluster 3 73.8 M 1 2 0 4.5 alive B/A/mucinous Well - + 55 
L100 Cluster 3 72.9 F 1 1 0 43.8 censored B/A Well - - 2.5 
L24 Cluster 3 84.5 F 1 1 0 1.6 censored BD Poor - - 75 
AD6 Cluster 3 66.2 M 1 2 0 34.6 death BA Well - + NA 
L11 Cluster 3 68.2 F 1 2 0 34.7 death BA Well - + none 
L20 Cluster 3 79.8 M 1 2 0 19.9 death BA Well - - 30 
L35 Cluster 3 64.4 M 3 2 2 28.2 death BD Moderate + + 4 
L45 Cluster 3 74.9 F 1 1 0 29.6 death BD Poor - + 30 
L53 Cluster 3 58.5 F 3 2 2 16.6 death BD/PA Moderate - - none 
L79 Cluster 3 49 F 1 2 0 8.7 death BD Poor - - 60 
L90 Cluster 3 63.8 F 1 1 0 5.8 death BD/PA Moderate - - 100 
L94 Cluster 3 72 M 3 3 2 2.4 death BD/mucinous Moderate - - 50 
 
1These clusters are obtained from hierarchical cluster analysis of the 86 samples and 21 survival marker genes share by 10 signatures 
2This is patient's survival time from operation date to death or last follow up as of May 2001 
3BD: bronchial derived; BA: bronchial alveolar; CC: clear cell; PA: papillary; Note that some tumors contained a mixture of two histological types 
4Patient smoking history in packs per year 
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Clinical Path (type 
diameter features) 3 
Path II4 Site of elapse/ metastasis Smoking5 
AD111 Cluster 3 76 F T1NxMx IA 72.4 1 ad 2.0 m-p   40 
AD115 Cluster 2 70 F T2N1M0 IIB 21.9 3 ad 6.5 m adm/adw lung, LN 75 
AD118 Cluster 3 69 M T1N0Mx IA 49.6 3 ad 2.5 m adm lung, LN 25 
AD120 Cluster 3 68 M T2N0Mx IB 38.9 3 ad 8.0 m adm bone 54 
AD122 Cluster 1 73 F T2N1Mx IIB 33.9 3 ad 5.0 m adm lung 0 
AD123 Cluster 1 60 M T3N0Mx IIB 74 1 ad 5.0 m adm,pap  126 
AD127 Cluster 3 65 F T1N2Mx IIIA 8.2 3 ad 1.8 p adp LN 69 
AD130 Cluster 1 75 M T2N1Mx IIB 7.1 d ad 15.0 BAC BAC  100 
AD136 Cluster 1 66 F T2N0Mx IB 31.4 1 ad 4.0 m adm  100 
AD159 Cluster 1 71 M T2N1Mx IIB 19.7 d ad 5.5 m-p adw,acinar  80 
AD162 Cluster 3 75 F T2N0Mx IB 41.7 1 ad 3.5 m admod,acinar  60 
AD164 Cluster 1 68 M T3N0Mx IIB 15 3 ad 4.5 p adpoor, acinar LN 80 








bone, myocardium 21.6 




AD173 Cluster 1 57 F T2N1Mx IIB 22.3 d ad 5.0 m-p admod,acinar  27 
AD179 Cluster 2 85 M T2N0Mx IB 24.3 3 ad 5.6 m w/BAC adw//adw,acinar lung, bone 24.75 
AD187 Cluster 1 69 M T1N0Mx IA 86.3 3 ad 1.8 p adp lung 120 
AD183 Cluster 2 75 F T1N0Mx IA 42.2 2 ad 2.0 m BAC adw//adw,acinar  22.5 
AD188 Cluster 1 74 F T2NxMx IB 21.6 d ad 2.7  BAC adw,acinar  116 
AD201 Cluster 1 46 M T1N2 IIIA 12.3 3 ad 1.5 m  lung, bone 90 
AD203 Cluster 3 60 F T1N0Mx IA 106.1 1 ad 2.2 m-p   0 
AD207 Cluster 3 64 F T2 IB 66.8 4 ad 3.5 w BAC ad m  0 
AD212 Cluster 3 55 F T2N0M0 IB 59 1 ad 3.0 m-p   54 
AD213 Cluster 2 69 M T1Nx IA 48.8 d ad 2.5 m   111 
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AD225 Cluster 1 88 M T2NxMx IB 2.6 4 ad 3.5 m   72 
AD226 Cluster 1 56 F T1N0Mx IA 60.5 1 ad 2.0 m   18 
AD228 Cluster 1 60 F T2N0 IB 41.2 3 ad 3.0 m  brain 75 
AD230 Cluster 3 56 M T1N0 IA 56.7 1 ad 2.5 p adp  60 




AD236 Cluster 1 53 F T2N0Mx IB 14.2 3 ad 5.5 m-p  lung, brain 40 
AD239 Cluster 3 60 M T2N0M0 IB 58.5 1 ad 2.9 m w/BAC BAC  40 
AD240 Cluster 1 77 F T1N0M0 IA 43.5 1 ad 2.0 m-w   5 





AD247 Cluster 3 49 M T1N0 IA 71.1 1 ad 2.0 m   32 
AD249 Cluster 1 67 M T1Nx IA 31 4 ad 1.2 m   45 
AD250 Cluster 3 61 F T1Nx IA 91 2 ad 2.0 w w/BAC adm lung 10 
AD252 Cluster 2 66 F T1N0 IA 16.5 3 ad 1.4  LN, CSF, brain 50 
AD255 Cluster 3 79 M T2N0 IB 44.8 1 ad 3.5 m   50 
AD258 Cluster 1 67 M T2Nx IB 12.3 3 ad 4.5 p  bone 54 
AD259 Cluster 2 58 M T3N0 IIB 20.5 d ad 5.0   45 




AD261 Cluster 2 66 F T1N0 IA 57.6 1 ad 2.7 w w/BAC   75 
AD262 Cluster 2 63 F T4N1Mx IIIB 16.6 4 ad 2.0 m-p   10 
AD266 Cluster 2 65 F T1N0 IA 41.9 3 ad 2.5 w w/BAC adm lung, bone, liver 0 
AD267 Cluster 3 61 M T2N0M0 IB 56 1 ad 2.8 m-p   120 
AD268 Cluster 3 50 F T2N0M0 IB 50.1 1 ad 3.5 p   10 
AD276 Cluster 2 68 M T2N2 IIIA 4.5 3 ad 2.1 m-p  pleura, brain 140 
AD277 Cluster 3 72 F T1Nx IA 8.2 3 ad 3.0 m  liver, ?bone 27 
AD283 Cluster 3 78 M T1N0 IA 47.2 3 ad 2.5 m w/pap  lung, LN, bone, groin 20 
AD287 Cluster 3 36 F T4Nx IIIB 7.4 d ad 4.0 p adp  10 
AD296 Cluster 1 63 M T1N1 IIA 9.3 3 ad 2.4 m-p w/pap  liver 88 
AD299 Cluster 1 78 F T1N0M0 IA 37.9 3 ad 2.2 m-p  lung 50 
AD301 Cluster 1 59 F T2N0M0 IB 7.8 3 ad 4.0 p  brain 40 
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AD302 Cluster 3 65 F T2N3Mx IIIB 57.8 3 ad 3.7 w BAC adm w/BAC lung 0 
AD304 Cluster 2 71 F T2N0 IB 8.2 3 ad 5.0 p  lung, liver, spleen 35 
AD308 Cluster 3 62 M T2N0 IB 79 2 ad 4.0 m  brain 66 
AD309 Cluster 1 77 F T2N0 IB 37.6 3 ad 3.4 w adw lung 0 
AD311 Cluster 1 63 F T2N0 IB 50.5 1 ad 5.0 m ok 50%  13 
AD313 Cluster 1 74 F T1N0 IA 25.3 3 ad 1.5 m-p adp LN 90 
AD317 Cluster 3 41 F T2Nx IB 99.1 1 ad 3.5 m pap   7 
AD318 Cluster 1 54 M T2N0M0 IB 83 1 ad 4.0 muc adm  100 
AD323 Cluster 1 56 F T2N1 IIB 6.8 d ad 4.0 p   39 
AD327 Cluster 1 50 F T2N0 IB 81.9 1 ad 6.5 m   27 
AD330 Cluster 3 50 F T1N1 IIA 7.3 3 ad 2.4 m  brain 40 
AD331 Cluster 3 59 M T1N0M0 IA 52.9 1 ad 2.0 m   45 
AD332 Cluster 1 52 M TxN0 I 6 3 ad m  
pleura, liver, colon, 
?adrenal, ?pancreas 
75 
AD335 Cluster 2 40 F T3N0 IIB 46.9 1 ad 4.5 m   20 
AD336 Cluster 3 71 M T2N0Mx IB 21.1 4 ad 1.7 m   0 
AD338 Cluster 3 55 F T2NxMx IB 75.4 1 ad 5.0 w BAC 
(1) ad w/BAC 
or ( 2)BAC 
 15 
AD346 Cluster 2 65 F T1N0 IA 17.3 1 ad 2.5 m   50 
AD347 Cluster 1 65 F T2N0Mx IB 0.5 1 ad 3.5 m BAC adm  20 
AD351 Cluster 2 43 F T2N1 IIA 24.3 3 ad 5.5 m  lung, LN 0 
AD353 Cluster 3 69 M T2N0Mx IB 13.7 1 ad 3.5 m BAC adw w/bac  30 
AD356 Cluster 2 72 M T2N0 IB 49.2 1 ad 4.0 w BAC   50 
AD361 Cluster 1 54 F T2N IB 6.4 4 ad 4.5 p   0 
AD362 Cluster 3 56 M T2N0 IB 71.5 d ad 6.5 BAC BAC muc  40 
AD366 Cluster 2 71 M T2N2 IIIA 9.4 3 ad 6.2 m-p w/pap  lung 23 
AD367 Cluster 1 55 F T2N0 IB 76.1 2 ad 6.5 m-p  brain 25 
AD368 Cluster 3 33 F T2N0 IB 62.6 1 ad 6.0 m-p w/muc   32 
AD374 Cluster 1 51 M T2N0 IB 8.8 3 ad 11.0 p  
lung, pleura, pericardium, 
diaphragm 
100 
AD375 Cluster 2 47 F T2N0 IB 23.4 d ad 7.2 p adm  13 
AD379 Cluster 2 65 M T2N1 IIB 35.4 2 ad 5.5 w/clear  lung, adrenal, brain 80 
                                                                                                                              Appendices  
                                                                                                                                                                
                                                                                                                              270                                                                                                                                                                                                                                                                                                                                                                                                                          
AD382 Cluster 2 51 F T2N2Mx IIIA 30.1 3 ad 5.0 p  brain 31 
1These clusters are obtained from hierarchical cluster analysis of the 84 samples and 21 survival marker genes we selected.  
2Patient status at last followup or death (1= alive; 2=alive with recurrence; 3= dead with recurrence; 4= dead without evidence of recurrence; d= dead, disease status unknown) 
3,4diameter (cm) subtype (BAC = bronchioloalveolar carcinoma). type (ad = adenocarcinoma ) differentiation (p, m-p, m, m-w, w) /w= with 
5Smoking: patient smoking history (self-reported) in pack/year 
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Appendix  Table S15 List of 10 derived lung adenocarcinoma prognosis marker gene 





included this gene 





















ADFP(X97324) 10 1 46 35 28 19 22 15 18 3 13 
CXCL3(X53800) 10 2 37 24 7 23 3 14 4 6 19 
PLD1(U38545) 10 5 7 2 31 41 17 8 9 11 3 
SLC2A1(K03195) 10 6 3 12 3 3 8 13 12 2 11 
SPRR1B (M19888) 10 7 10 29 11 10 7 9 10 5 12 
GALNT4 (Y08564) 10 8 23 25 27 11 32 25 14 1 28 
LDHB(X13794) 10 10 11 1 1 15 16 11 8 15 1 
FXYD3(U28249) 10 11 6 7 29 14 52 18 42 22 5 
REG1A(J05412) 10 13 8 9 23 9 15 16 45 14 6 
CHRNA2 (U62431) 10 14 24 26 30 8 46 28 40 27 27 
SERPINE1 (J03764) 10 18 30 16 22 12 2 1 31 4 15 
FUT3(U27326) 10 19 14 19 21 2 28 10 15 30 21 
PRKACB (M34181) 10 20 5 5 15 6 1 3 1 33 4 
TUBA4A(X06956) 10 21 1 14 25 13 53 49 29 26 14 
VEGF(M27281) 10 22 33 8 26 30 14 26 19 23 32 
RPS3(X55715) 10 25 2 10 2 5 39 55 13 17 36 
ANXA8(X16662) 10 28 32 18 12 21 20 4 22 18 26 
VDR(J03258) 10 32 39 33 6 4 30 2 11 16 37 
CXCR7(U67784) 10 33 47 30 24 43 41 37 27 39 29 
POLD3(D26018) 10 35 25 15 18 1 11 50 2 31 8 
BSG(X64364) 10 36 38 39 17 33 48 27 3 20 33 
CYP24(L13286) 9 23 13 34 20 22 23  41 19 25 
HLA-G (HG273-HT273) 9 30 27 11  25 19 34 32 24 31 
WNT10B (U81787) 9 39 35 28  39 36 29 25 38 41 
GARS(U09510) 9 41 26 31  31 26 19 46 44 20 
SPRR2A(M21302) 9  21 13 34 40 21 21 34 47 18 
NULL (HG2175-HT2245) 9  49 37 5 44 34 56 35 53 16 
CD58(Y00636) 8 16 12 3 14 17 6  44  34 
KRT14(J00124) 8   20 9 34 25 12 23 12 22 
E48(X82693) 7 9 15   20 33 22 5 48  
FADD(X84709) 7 12  6  35 51 17  8 9 
STX1A(L37792) 7 15 18 22  46 5  6  24 
ENO2(X51956) 7 24 4   32 38 32  45 47 
SPRR2A(L05188) 7 29 41   7 45 44 48 28  
FEZ2(U69140) 7 38  23   42 30 26 9 17 
KRT18(X12876) 7 43 42 41  26 44 6 43   
ALDH2(X05409) 7  19  10 45 4 20 21  23 
UCN(U43177) 6 4  36 13 18 9    10 
SCYB5(L37036) 6 31 16  33 42 31   29  
AIP-1(U23435) 6 37  42  28 18   32 7 
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NULL(U92014) 6 42 17   27  39  36 42 
NULL(L43579) 6 47 54    35 5 24 37  
CEBPA(U34070) 6   17  24 12  47 25 30 
KIAA0138 (D50928) 5 34 29  19  37    2 
TFF1(X52003) 5 40 34   37 24   43  
KRT19(Y00503) 5 49   4  40 54 20   
RPS26(X69654) 4 17 28    49   21  
S100A2(Y07755) 4 26 51     40  34  
GS3686 (AB000115) 4 46 36      49 41  
EMP1(Y07909) 4  9   38 27  38   
HPCAL1(D16227) 4  43  8   33 36   
LCN2(S75256) 4   38    41 37  44 
PEX7(U88871) 4   4  29    40 43 
EFNB2(U81262) 3 44       30  40 
ALDH8(U37519) 3 45 52      17   
EPS8(U12535) 3  20    50   51  
NDRG1(D87953) 3  22     48   46 
CSTB(U46692) 3  40     45  10  
PSPH(Y10275) 3  44 27    23    
CYBA(M21186) 3      29 7 7   
CNN3(S80562) 3       57 39 49  
VIPR1(X77777) 3   40     50  35 
NULL(U49020) 2 51       16   
ALDH7(U10868) 2  45    10     
AXL (HG162-HT3165) 2  53       35  
TYRO3(U02566) 2   32  36      
P2RX5(U49395) 2    32 16      
GRO1(X54489) 2        28 42  
ERBB3(M34309) 2       51  7  
BM-002(Z70222) 2    16  13     
LAMB3(U17760) 2   21       39 
INHA(X04445) 2       38  46  
TAX1BP2 (U25801) 1 3          
IGHM(V00563) 1 27          
SPRR2A(X53065) 1 48          
NP(K02574) 1 50          
P63(X69910) 1  31         
AP3B1(U91931) 1  48         
C6(X72177) 1  50         
HFL1(M65292) 1          38 
PRKCN (HG2707-HT2803) 1       24    
SHB(X75342) 1         13  
EIF5A(S72024) 1        33   
FCGR3B(J04162) 1       47    
GRIN1 (HG4188-HT4458) 1      47     
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SLC2A3(M20681) 1          45 
CA9(X66839) 1       42    
FLJ20746 (U61836) 1      43     
PPBP(M54995) 1       52    
TUBA4A (HG2259-
HT2348) 
1      54     
EMS1(M98343) 1       53    
IGF2(M17863) 1       36    
CHAT (HG4051-HT4321) 1       31    
LAMC2(U31201) 1         50  
BMP2(M22489) 1       43    
KIAA0111 (D21853) 1         52  
TNFAIP6 (M31165) 1       35    
NULL (HG415-HT415) 1       46    
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